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Preface
The cover of this thesis shows the famous painting “The anatomy lesson of dr. 
Nicolaes Tulp” by Rembrandt van Rijn. The painting, which was made in 1632, portrays 
dr. Nicolaes Tulp giving a public anatomy lesson to the Dutch Guild of Surgeons. 
According to genealogical sources recovered from my grandfather’s archives, I may 
have a distant relation to one of the portrayed men. Unfortunately, that relation is 
not to dr. Tulp, but to the subject of dissection. His name was Adriaen Adriaenszn ‘t 
Kint and he was executed for theft prior to the dissection. By serving as the subject of 
dissection, he indirectly contributed to the scientific body of knowledge. Almost 400 
years later, this thesis summarizes my own contributions to the medical sciences. 
Thus, this thesis marks the progression across generations, closing the circle from 
criminal to doctor.
Erik F. Blom
Utrecht, the Netherlands, May 2020
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Etiology of lung cancer
Throughout life, the genetic material inside cells is continuously damaged as a 
result of both endogenous and environmental factors (including exposure to certain 
chemical substances). Usually, such mutations are recognized, and the damaged 
cells are repaired or removed. Other cells reproduce to replace them. This process 
is regulated by complex molecular mechanisms. If mutations occur in the genetic 
material responsible for these regulatory mechanisms, a cell may start to behave 
abnormally.1-3 In particular, such a cell may proliferate and divide abnormally, and 
spread or invade to other parts of the body. This is known as a malignant tumor, or 
cancer.4 Usually, several mutations are necessary to develop cancer.2,5 
For cancer originating from the lungs, tobacco smoking is by far the most 
important risk factor,6,7 accounting for up to 90% of cases.8-11 Tobacco smoke damages 
cells in the lungs and contains at least 15 chemicals that have been proven to cause 
cancer in humans.9,12 The relative risk of lung cancer has been estimated to be up to 20 
times higher in smokers compared to lifelong non-smokers.9 The risk of lung cancer 
increases as a function of the intensity and duration of smoking.9,11,13 Accumulated 
smoking behavior can be expressed as a function of smoking intensity and duration 
in terms of pack-years. A pack-year is defined as the equivalent of having smoked 20 
cigarettes (i.e. one pack) per day for one year. It should be noted that the increased 
risk for lung cancer extends to those exposed to secondhand smoke, although to a 
much lesser degree. It has been estimated that non-smokers living with a smoker 
have a 20-30% increased risk of lung cancer.14  
Other independent risk factors include chronic obstructive pulmonary 
disease,15,16 a positive family history for lung cancer,17  and exposure to occupational 
or environmental factors such as air pollution,2,18 industrial chemicals,2 asbestos,2,19 
and radon.2,20 This thesis focuses on the United States, in which these factors play a 
relatively modest role compared to tobacco smoking. However, in other geographical 
areas, factors such as indoor air pollution due to cooking on coal burning stoves may 
play a larger role.21,22
Pathology
Two main types of lung cancer can be distinguished: non-small cell lung cancer and 
small cell lung cancer. Small cell lung cancer, which accounts for approximately 13% 
of cases,23,24 is strongly associated with tobacco smoking, and is clinically the most 
aggressive type of lung cancer.2 This type of lung cancer tends to develop in the central 
airways and grow and spread quickly.25
Non-small cell lung cancer is a clinically more diverse disease, but can be 
predominantly further classified as adenocarcinoma or squamous cell carcinoma. 
Adenocarcinomas, which account for approximately 50% of all lung cancer cases,24 
originate in glandular cells.2,25 This type of lung cancer is more often located 
peripherally in the lungs.2,25 Although adenocarcinomas are related to smoking, they 
are also the most common subtype of lung cancer among never-smokers.25 Squamous 
cell carcinomas arise from the epithelial cells that line the airways.2 This type of 
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non-small cell lung cancer accounts for approximately 23% of all lung cancer cases.24 
Squamous cell carcinomas are closely related to smoking exposure, and are more often 
located centrally in the lungs.2,25 In this thesis, the remaining histological subtypes are 
grouped together in the common category other non-small cell lung cancer.
Epidemiology
Incidence and mortality in the United States
As smoking is the main risk factor for lung cancer, the number of new cases in the 
population (i.e. incidence) and the number of persons dying from lung cancer (i.e. 
disease-specific mortality) depend on patterns of smoking behavior.
Although the causal relationship between smoking and lung cancer has been 
established since the 1950s,6,7 it was the 1964 Surgeon General’s report that raised 
awareness among the general public of the dangers of tobacco smoking.26 As a result, 
the percentage of the population that smokes (i.e. smoking prevalence) among men 
in the United States is much lower for those born in more recent years (see Figure 
1).27 This is due to lower rates of smoking initiation and higher rates of smoking 
cessation. Patterns in women are similar to those in men, but lag because women 
started smoking later. Across the entire US population, cigarette smoking prevalence 
has decreased by approximately two thirds since 1965, from approximately 40% in 
196510  to 13.7% in 2018.28
As the risk of lung cancer builds up with age and continued exposure to smoke, 
there is a lag time of 20 to 30 years between changes in smoking prevalence in the 
population and changes in lung cancer mortality. Therefore, the peak in smoking 
prevalence among men in the 1960s resulted in a peak in lung cancer mortality of 
over 50 deaths per 100,000 men in 1990.29 Following the drop in smoking prevalence 
after the 1960s, lung cancer mortality dropped to approximately 30 deaths per 100,000 
men around 2010.29 Nevertheless, lung cancer remains an important health issue to 
date. It is still the second most common form of cancer in the United States for both 
males and females, with an estimated 228,150 new cases in 2019.30 The lifetime chance 
of developing lung cancer is approximately 1 in 15 for men and 1 in 17 for women.23 In 
2019, an estimated 142,670 persons died of lung cancer, which is more than of colon, 
breast, and prostate cancer together.23,30 Lung cancer mainly (but not exclusively) 
occurs in elderly persons; the mean age at diagnosis is 70 years.23
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Figure 1: Smoking prevalence among males in the United States by calendar year and birth 
year. Reprinted from Am J Prev Med, 46(2), Holford TR et al., Patterns of birth cohort-specific 
smoking histories, 1965-2009, pages e31-7, Copyright (2014), with permission from Elsevier.
Stage at diagnosis
The extent to which cancer has spread at the time of diagnosis is called the stage. 
The American Joint Committee on Cancer developed a widely adopted staging system 
based on the size of the primary tumor, the presence of spread to regional lymph 
nodes, and the presence of spread to distant sites in the body. In this thesis, the 7th 
edition of this staging system is used, which was in effect from 2010-2017.31 This system 
distinguishes 7 stages of malignant lung cancer: IA, IB, IIA, IIB, IIIA, IIIB, and IV. For 
clinical purposes, these stages are grouped into wider categories.
Non-small cell lung cancer stages IA to IIB comprise tumors that have not 
invaded any clinically significant anatomical structures, such as the heart or great 
vessels. Also, there is no spread or limited spread to regional lymph nodes, and there 
is no metastasis to distant sites. Therefore, these stages are generally referred to 
as early-stage or localized non-small cell lung cancer. This stage group comprises 
approximately 19% of non-small cell lung cancer cases.24 
Stages IIIA-IIIB non-small cell lung cancer are a clinically diverse group of patients. 
The tumor may or may not have spread to important anatomical structures, and 
spread to regional lymph nodes may be either limited or more extensive. However, 
these stages show no metastasis to distant sites. Stages IIIA-IIIB are commonly 
referred to as locally advanced or regional non-small cell lung cancer. This stage 
group comprises approximately 24% of cases.24
If distant metastasis is present (e.g. in the adrenal glands, brain, or bones), non-
small cell lung cancer is categorized as stage IV, regardless of the tumor size or lymph 
node involvement. This stage group is commonly referred to as advanced or distant 
non-small cell lung cancer, and comprises the majority of cases (approximately 55%). 
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For small cell lung cancer, metastatic disease (stage IV) is referred to as extensive 
disease. This stage group comprises approximately 75% of cases,24 which reflects the 
aggressive nature of this type of lung cancer. All other small cell lung cancer stages 
are referred to as limited disease, which is relatively uncommon.  
Survival
The time that a person remains alive after receiving the diagnosis of cancer is called 
the overall survival. As stated earlier, lung cancer is an aggressive disease. Therefore, 
overall survival is generally short. However, overall survival strongly depends on 
the stage at diagnosis (see Figure 2). For stage IA, the median overall survival time 
is 58 months.32 For stage IV, median overall survival time is only 6 months.32 The 
corresponding percentage of patients that are alive five years after they were diagnosed 
with lung cancer is 52% for stage IA and 4% for stage IV.  
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Figure 2: Overall survival by clinical stage at diagnosis 
 
Reprinted from J Thor Oncol, 2(8), Groome PA et al., The IASLC Lung Cancer Staging Project: Validation of the 
Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming 
(Seventh) Edition of the TNM Classification of Malignant Tumours, pages 694-705, Copyright (2007), with 
permission from Elsevier. 
 
Treatment 
The overall survival statistics reflect the available treatment options, which are better when the type 
of lung cancer is less aggressive, and when the stage at diagnosis is limited. As such, the minimal 
recommended treatment for lung cancer differs by lung cancer type (i.e. non-small cell lung or versus 
small cell lung cancer) and stage at diagnosis.33,34 
The most important curative treatment option for lung cancer is the surgical removal of (part 
of) the affected lung. This is only feasible if the disease has not spread too far, and if the patient is fit 
enough to live with the reduced lung volume. Therefore, surgical treatment is recommended for early-
stage non-small cell lung cancer, as well as for a small subgroup of patients with locally advanced non-
small cell lung cancer or limited disease small cell lung cancer.33,34  However, when surgical treatment 
for locally advanced non-small cell lung cancer or limited disease small cell lung cancer is deemed 
feasible, an additional treatment with chemotherapy is recommended to improve the chance of 
complete removal of the tumor.33,34 Chemotherapy is administered systemically, and can therefore 
reach tumor cells that have potentially spread from the primary tumor.  
If surgical treatment for these stage groups is technically not feasible, or when the patient is 
not fit enough, other treatments are recommended. For early-stage non-small cell lung cancer, the 
recommended alternative to surgery is stereotactic body radiation therapy.33 This type of treatment 
provides a high dose of radiation to a small target.35,36 Therefore, stereotactic body radiation therapy 
can cure small tumors, while limiting damage to surrounding tissue. For inoperable patients with 
Figure 2: Overall survival by clinical stage at diagnosis. Reprin ed from J Thor Oncol, 2(8), 
Groome PA et al., The IASLC Lung Cancer Staging Project: Validation of the Proposals for 
Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming 
(Seventh) Edition of the TNM Classification of Malignant Tumours, pages 694-705, Copyright 
(2007), with permission from Elsevier.
Treatment
The overall survival statistics reflect the available treatment options, which are 
better when the type of lung cancer is less aggressive, and when the stage at diagnosis 
is limited. As such, the minimal recommended treatment for lung cancer differs by 
lung cancer type (i.e. non-small cell lung or versus small cell lung cancer) and stage 
at diagnosis.33,34
The most important cur tive treatment option for l ng cancer is the surgical 
removal of (part of) the affected lung. This i  only feasib e if the disease has not spread 
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too far, and if the patient is fit enough to live with the reduced lung volume. Therefore, 
surgical treatment is recommended for early-stage non-small cell lung cancer, as well 
as for a small subgroup of patients with locally advanced non-small cell lung cancer 
or limited disease small cell lung cancer.33,34  However, when surgical treatment for 
locally advanced non-small cell lung cancer or limited disease small cell lung cancer 
is deemed feasible, an additional treatment with chemotherapy is recommended 
to improve the chance of complete removal of the tumor.33,34 Chemotherapy is 
administered systemically, and can therefore reach tumor cells that have potentially 
spread from the primary tumor. 
If surgical treatment for these stage groups is technically not feasible, or when the 
patient is not fit enough, other treatments are recommended. For early-stage non-
small cell lung cancer, the recommended alternative to surgery is stereotactic body 
radiation therapy.33 This type of treatment provides a high dose of radiation to a small 
target.35,36 Therefore, stereotactic body radiation therapy can cure small tumors, while 
limiting damage to surrounding tissue. For inoperable patients with locally advanced 
non-small cell lung cancer or limited disease small cell lung cancer, stereotactic body 
radiation therapy is not feasible because the disease is too widespread. Instead, a 
combination of conventional radiotherapy and chemotherapy is recommended.33,34 
Finally, when distant metastasis is present, curative treatment is not possible. 
Nevertheless, guidelines recommend that chemotherapy should always be provided.33,34 
In some cases, metastases of the brain and bones may require additional treatment 
with radiotherapy to reduce symptoms.33,34 Very recently, two new classes of drugs 
have been introduced. One class of drugs, called targeted therapy, targets specific 
molecular pathways in tumor cells. The second class of drugs, called immunotherapy, 
prompts the patient’s immune system to recognize and attack tumor cells. Although 
non-curative, these drugs may prolong survival in select patients.37-39 Currently, their 
use is limited to metastatic disease, although this may extend to earlier stages in the 
future. However, the recommendations for these treatments are so recent that they 
are not considered in this thesis. For example, in October 2016 pembrolizumab was 
the first immunotherapy agent approved by the US Food and Drug Administration 
for the first-line treatment of certain advanced lung cancer cases.
Primary prevention (smoking cessation)
As tobacco smoking is the main risk factor for lung cancer, preventing individuals 
from starting to smoke and encouraging current smokers to quit is potentially the 
most effective method to prevent lung cancer.10 
Examples of tobacco control policies are increased taxes on tobacco products and 
the introduction of smoke free indoor air policies.10 It has been estimated that nearly 
800,000 lung cancer deaths have been averted in the United States between 1975-
2000 due to such tobacco control policies.40 However, this number represents only 
about a third of the 2.5 million lung cancer deaths that could have been avoided if 
tobacco control would have been immediate and complete.40 Another study projected 
that, despite continuing current tobacco control policies since the 1965 Surgeon 
General’s report, 50,000 persons will still die of lung cancer in the United States in 
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2065.41 Therefore, despite the successes of tobacco control, lung cancer will remain an 
important public health issue in the foreseeable future.
Secondary prevention (screening)
Principles of screening
According to the World Health Organization, screening is defined as “the identification 
of unrecognized disease in an apparently healthy, asymptomatic population […]”.42 In 
the case of cancer, a tumor may exist for a period of time before it progresses and 
causes symptoms (see Figure 3). During this period, which is called the preclinical 
phase, a screening test may provide an early diagnosis. The time with which screening 
may advance the diagnosis is called the lead time. If early diagnosis allows for more 
favorable treatment options, death may be postponed.
However, early diagnosis does not always change the time of death, for example if 
treatment was not successful. In that case, overall survival after the diagnosis of lung 
cancer is longer, while the patient does not live any longer. This is known as lead time 
bias. To account for lead time bias, the benefit of screening in a screened population 
compared to a non-screened population is generally either expressed as the number 
of life-years gained due to postponing death, or as the difference in the number of 
persons that died due to the disease within a specified period of follow-up (i.e. disease-
specific mortality reduction).
Generally, the quality of life of cancer patients is poor.43 Therefore, it is also 
important to account for changes in quality of life due to early diagnosis and 
treatment. This is done by weighing the number of life-years gained due to screening 
by a factor that measures quality of life, a so called health state utility value. The 
resulting outcome is a quality-adjusted life year.
Time
Birth
Time of 
death 
with 
screening
Disease 
onset 
Lead time
No detectable 
disease
Preclinical (screen detectable) 
disease
Benefit 
due to 
screening
Survival 
without 
screening
Time of 
death 
without 
screening
Diagnosis 
through 
screen test
Clinical 
diagnosis 
(symptoms)
Survival with screening
Figure 3: Principles of screening.
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In some cases, a screen-detected cancer would have never caused symptoms if screen-
ing had not occurred. This is referred to as overdiagnosis, and is considered the main 
harm of cancer screening. Overdiagnosis can lead to unnecessary treatment and anx-
iety, and can happen for two reasons. First, a screen-detected cancer may progress 
very slowly, or not at all, and may therefore never have reached the size at which 
it would cause symptoms if screening had not occurred (as indicated by the green 
arrows in Figure 4). The tendency of screening to detect slower growing tumors is 
called length bias. Second, a person with a progressive screen-detected cancer may die 
of other causes before the cancer would have progressed to a size at which it causes 
symptoms (as indicated by the red arrow in Figure 4). This is especially likely when 
screening patients with a limited life expectancy, such as elderly persons with comor-
bidities. Another harm of screening is a false positive screening result, in which case 
unnecessary invasive diagnostic procedures such as biopsies may occur. 
Figure 4: Principles of overdiagnosis. Adapted with permission from the U.S. National cancer 
Institute: https://prevention.cancer.gov/news-and-events/infographics/what-cancer-overdiag-
nosis.
Current evidence for lung cancer screening
Most lung cancer cases are diagnosed at an advanced stage, with limited treatment 
options. Therefore, lung cancer screening has been investigated since the 1960s. Several 
studies investigated the benefits of screening with chest radiography, but found no 
mortality benefit.44-48  
After low-dose computed tomography technology was introduced, several new 
lung cancer screening studies were initiated. The single-arm International Early Lung 
Cancer Action Project (I-ELCAP) showed that up to 85% of screen-detected lung cancer 
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were found in stage I.49 However, the mortality benefit due to early detection could not 
be assessed due to the lack of a control group.
In 2002, the US-based National Lung Screening Trial (NLST) was initiated, which 
randomized 53,454 participants to receive either three annual low-dose computed 
tomography scans or three annual chest radiography screens.50 Those included were 
current or former smokers (quit less than 15 years ago) aged 55-74, with a smoking 
history of at least 30 pack-years. The NLST found a statistically significant 20% 
reduction in lung cancer mortality, as well as a statistically significant reduction in 
all-cause mortality of 6.7%.51 
Whereas the control group in the NLST received three annual chest radiography 
screens, seven smaller European randomized controlled trials compared low-dose 
computed tomography screening to usual care. The inclusion criteria and screening 
protocol differed across studies (see Table 1).50,52-58 The Dutch-Belgian randomized lung 
cancer screening trial (NELSON), which randomized 15,822 high-risk individuals,52 
showed a statistically significant 24% reduction in lung cancer mortality after a 
minimum of 10 years of follow-up.59 Thus far, the other European trials did not find 
a statistically significant reduction in lung cancer mortality,54,60-62 although it should 
be noted that these studies were not powered to find such a difference. Nevertheless, 
pooling of data across these trials may provide additional evidence.
Role of microsimulation modeling
Although the published and ongoing randomized trials are important sources 
of evidence, results are not necessarily representative for members of the general 
population. For example, the main risk factor for lung cancer (i.e. smoking behavior) 
is decreasing.27 Also, it is impossible to compare many different screening policies in 
randomized controlled trials. For example, only a single set of screening eligibility 
criteria was assessed in each lung cancer screening trial, while other criteria may 
be more effective or efficient.63,64 In addition, only several screening rounds were 
assessed, whereas a screening program in the general population considers continued 
screening. Microsimulation models use existing data sources to extrapolate the 
effects of screening to such situations. Therefore, such models can provide valuable 
information to policy makers.63,65 
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Table 1: Overview of study protocols of low-dose computed tomography screening studies.
Study N Ages Smoking 
history
Smoking 
cessation
Control Screening 
Interval
Number 
of 
screens
NLST50 53,454 55-74 ≥30 pack-years <15 years 3 annual 
chest ra-
diography 
screens
Annual 3
NELSON52 15,822 50-75 ≥15 cigarettes 
per day for ≥25 
years or ≥10 
cigarettes per 
day for ≥30 
years
≤10 years Usual care Depending 
on round: 
1, 2, or 2,5 
years
4
DLCST53 4,104 50-70 ≥20 pack-years ≤10 years Usual care Annual 5
MILD54 4,099 ≥49 ≥20 pack-years ≤10 years Usual care Annual or
biennial
5 
(annual) 
or 3 
(biennial)
UKLS55 4,055 50-75 Predicted 
5-year risk of 
lung cancer 
diagnosis ≥5%
- Usual care Single screen 1
LUSI56 4,052 50-69 ≥15 cigarettes 
per day for ≥25 
years or ≥10 
cigarettes per 
day for ≥30 
years
≤10 years Usual care Annual 4
ITA-
LUNG57
3,206 55-69 ≥20 pack-years ≤10 years Usual care Annual 4
DANTE58 2,472 60-74 ≥20 pack-years ≤10 years Usual care Annual 5
Lung cancer screening recommendations
In 2013, the United States Preventive Task Force recommended annual screening 
between ages 55-80 of current smokers and former smokers that quit less than 
15 years ago, and that accumulated a smoking history of at least 30 pack-years.66 
This recommendation was partly based on modeling efforts.63 Also, the Centers for 
Medicare & Medicaid Services issued a decision memo approving reimbursement of 
lung cancer screening.67 Nevertheless, lung cancer screening uptake in the United 
States has remained low.68,69 In Europe, many countries are planning for a possible 
implementation of lung cancer screening.70 In the meantime, many questions remain, 
some of which are answered in this thesis.
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Research questions and outline of this thesis
This thesis aims to answer two main research questions:
- Research question I: How does the implementation of lung cancer screening 
affect the demand for different treatment modalities?
- Research question II: What are the benefits and harms of population-based lung 
cancer screening programs?
The first research question is discussed in chapters 1 to 3. Although the benefits of 
early detection of lung cancer due to screening have been established in randomized 
controlled trials,51,59 successful implementation in the general population depends on 
optimal treatment of cases detected at an early stage. Chapters 1 and 2 investigate 
which treatments lung cancer patients in the United States currently receive. Chapter 
1 investigates whether treatments received by lung cancer patients in the United 
States are in concordance with clinical practice guidelines. Also, chapter 1 identifies 
which groups of patients are less likely to receive the recommended treatment. 
Chapter 2 investigates the uptake of the new treatment modalities minimally invasive 
surgery and stereotactic body radiation therapy among early-stage non-small cell 
lung cancer patients. Finally, the implementation of a population-based lung cancer 
screening program will shift the stage at which lung cancer is diagnosed towards 
early stages. Chapter 3 investigates how current lung cancer treatment patterns will 
change as a result of that shift. This information is used to project the future demand 
for the different treatment modalities used in lung cancer care.
The second research question is dealt with in chapters 3 to 6. Population-
based screening programs are different from randomized trials. First, the screened 
population is dynamic, with new persons becoming eligible for screening each year. 
Second, screening occurs far beyond the 1-5 rounds offered in the randomized trials. 
The benefits and harms of population-based lung cancer screening programs have 
been previously assessed for a single cohort of the general U.S. population.63 However, 
it is unclear how the decreasing smoking prevalence across different birth cohorts27 
affects these benefits and harms. Therefore, chapter 4 projects how overdiagnosis, 
which is considered the main harm of lung cancer screening, will change over time 
in a population-based lung cancer screening program in the United States. When 
assessing the benefits of a population-based cancer screening, it is important to 
consider the generally poor quality of life of cancer patients.71 Such an adjustment can 
be done by using health state utility values. Therefore, Chapter 5 provides an overview 
of the literature on health state utility values for lung cancer. Also, pooled values are 
calculated. In Chapter 6, we use the identified health state utility values to assess the 
benefits and harms of a population-based lung cancer screening program among 
screening-eligible individuals. To account for age and cohort effects, the benefits and 
harms of continued screening from the year 2020 are assessed for persons at different 
ages. The key benefits and harms are summarized in a clinical decision aid which 
can be used to facilitate shared decision making between clinicians and potentially 
screening-eligible individuals.
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Abstract
Rationale
The level of adherence to lung cancer treatment guidelines in the United States is 
unclear. In addition, it is unclear whether previously identified disparities by racial or 
ethnic group and by age persist across all clinical subgroups.
Objectives
To assess the level of adherence to the minimal lung cancer treatment recommend-
ed by the National Comprehensive Cancer Network guidelines (guideline-concordant 
treatment) in the United States, and to assess the persistence of disparities by racial 
or ethnic group and by age across all clinical subgroups.
Methods
We evaluated whether 441,812 lung cancer cases in the National Cancer Database di-
agnosed between 2010 and 2014 received guideline-concordant treatment. Logistic 
regression models were used to assess possible disparities in receiving guideline-con-
cordant treatment by racial or ethnic group and by age across all clinical subgroups, 
and whether these persist after adjusting for patient, tumor, and health care provider 
characteristics. 
Results
Overall, 62.1% of subjects received guideline-concordant treatment (range across clinical 
subgroups: 50.4-76.3%). However, 21.6% received no treatment (range: 10.3-31.4%) and 
16.3% received less intensive treatment than recommended (range: 6.4-21.6%). Among 
the most common less intensive treatments for all subgroups was “conventionally 
fractionated radiotherapy only” (range: 2.5-16.0%), as was “chemotherapy only” 
for nonmetastatic subgroups (range: 1.2-13.7%), and “conventionally fractionated 
radiotherapy and chemotherapy” for localized non-small-cell lung cancer (5.9%). 
Guideline-concordant treatment was less likely with increasing age, despite adjusting 
for relevant covariates (age ≥80 yr compared with <50 yr: adjusted odds ratio = 0.12, 95% 
confidence interval = 0.12-0.13). This disparity was present in all clinical subgroups. In 
addition, non-Hispanic black patients were less likely to receive guideline-concordant 
treatment than non-Hispanic white patients (adjusted odds ratio = 0.78, 95% confidence 
interval = 0.76-0.80). This disparity was present in all clinical subgroups, although 
statistically nonsignificant for extensive disease small-cell lung cancer.
Conclusions
Between 2010 and 2014, many patients with lung cancer in the United States received 
no treatment or less intensive treatment than recommended. Particularly, elderly 
patients with lung cancer and non-Hispanic black patients are less likely to receive 
guideline-concordant treatment. Patterns of care among those receiving less intensive 
treatment than recommended suggest room for improved uptake of treatments such 
as stereotactic body radiation therapy for subjects with localized non-small-cell lung 
cancer. 
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Introduction
An estimated 142,670 persons will die of lung cancer in the United States in 2019, 
making it the leading cause of cancer-related deaths.1 Reflecting the large burden to 
society, lung cancer treatment is an important topic of medical research. A recent 
bibliometric analysis identified a total of 32,161 studies published on lung cancer 
between 2004 and 2013, of which 36% focused on treatments.2 Clinical practice 
guidelines, which can be considered the basis for measures of quality of care, compile 
the available evidence and expert consensus.3
However, literature indicates that the minimal treatment recommended in these 
guidelines (i.e., guideline-concordant treatment) may not be provided to all patients 
with lung cancer in the United States.4 Furthermore, there is evidence that specific 
subgroups are less likely than others to receive guideline-concordant treatment. For 
example, the proportion of cases that receive guideline-concordant treatment is 
lower for more advanced stages.4 Also, disparities by racial or ethnic group have been 
described. For example, black patients are less likely to receive surgical treatment 
for localized non-small-cell lung cancer (L-NSCLC; stages I-II) than white patients.5-10 
In addition, elderly patients with lung cancer are less likely to receive guideline-
concordant treatment, despite controlling for comorbidity.4,9,10 However, comparability 
and generalizability of the available literature are limited because often only one 
specific subset of clinical cases is examined,5,11 relatively small sample sizes are used,8,10 
different methodologies are applied,5,7 or the data cover different timespans.5,7 Thus, it 
is unclear whether disparities in receiving guideline-concordant treatment by racial 
or ethnic group and by age persist, and whether these are similar across clinical 
subgroups of lung cancer in the United States.
Therefore, the first aim of this study was to assess the level of adherence to 
predefined, stage-specific guideline-concordant treatment for each clinical subgroup 
of patients with lung cancer in a large U.S. dataset. The second aim was to assess 
whether previously identified disparities in receiving guideline-concordant treatment 
by racial or ethnic group and by age persist across all clinical subgroups of lung 
cancer. Some of the results of this study have been previously reported in the form 
of an abstract.12
Methods
Data
We used the U.S. National Cancer Database (NCDB) to extract a cohort of 441,812 
patients diagnosed with lung cancer between 2010 and 2014 (see Figure E1 in the 
online supplement). The NCDB, established in 1989, is a nationwide, facility-based, 
comprehensive clinical surveillance resource oncology dataset that currently captures 
70% of all newly diagnosed malignancies in the United States annually, from more 
than 1,500 affiliated facilities. The NCDB records the first course of treatment, defined 
as all methods of treatment recorded in the treatment plan and administered to the 
patient before disease progression or recurrence. Analysis of individual-level NCDB 
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data was performed on site at the University of Michigan Medical School. 
To assess the generalizability of the NCDB data to the general U.S. population, 
we compared baseline characteristics to a cohort of patients with lung cancer from 
the population-based Surveillance, Epidemiology, and End Results (SEER) dataset.13 
A detailed version of the methods, including the rationale for case selection, data 
cleaning, and the analysis of the SEER dataset, is available online (see supplemental 
methods and Tables E1 and E2). This study was deemed exempt by the Institutional 
Review Board of the University of Michigan.
Definition of guideline-concordant treatment
Two main lung cancer types can be distinguished: NSCLC and small-cell lung cancer 
(SCLC), with the majority presenting as NSCLC. Because SCLC is clinically more aggressive 
than NSCLC, clinical guidelines provide specific treatment recommendations for 
clinical subgroups of lung cancer type and stage at diagnosis. For each of these clinical 
subgroups, we assessed whether guideline-concordant treatment was received, defined 
as the minimal first course treatment these patients should receive according to the 
National Comprehensive Cancer Network guidelines.14,15
Although surgery is still recommended as the primary minimal treatment for 
L-NSCLC (stages I-II), stereotactic body radiation therapy (SBRT) is now recommended 
as an alternative treatment to surgery for patients with L-NSCLC.14 SBRT delivers 
high-dose radiation to a specific target in only a few fractions and provides local 
tumor control rates of up to 90% with moderate toxicity.16,17 Therefore, both surgery 
and SBRT were considered guideline-concordant treatment for L-NSCLC. The 
minimal recommended treatment for locally advanced NSCLC (LA-NSCLC; stage III) 
and limited-disease SCLC (LD-SCLC; stages I-III) depends on operability.14,15 If operable, 
the minimal recommendation is surgery combined with chemotherapy. However, 
the majority of patients with LA-NSCLC and those with LD-SCLC are inoperable, in 
which case the minimal recommendation is a combination of radiotherapy and 
chemotherapy. Therefore, both treatment combinations were considered guideline-
concordant for LA-NSCLC and LD-SCLC. For advanced NSCLC (A-NSCLC; stage IV) and 
extensive disease SCLC (ED-SCLC; stage IV), the minimally recommended treatment 
is chemotherapy.14,15 As we assessed the minimal recommended treatment for each 
clinical subgroup, additional treatments were allowed beside guideline-concordant 
treatment (e.g., radiotherapy for bone metastases beside chemotherapy in A-NSCLC). A 
summary of the treatment combinations that were considered guideline-concordant 
for each clinical subgroup can be found in Table E3.
Because the most frequently used SBRT schemes in the United States comprise 
a total dose of 45 Gray or more over 1-5 fractions18-20 and the U.S. billing code for 
SBRT includes a maximum of 5 fractions,14 SBRT was defined as thoracic radiotherapy 
with a total radiation dose of 45 Gray or more delivered in 5 fractions or less. There 
were no restrictions on radiation dose or fractionation for stages other than L-NSCLC. 
Chemotherapy included the use of targeted therapies. We were not able to separately 
assess the use of immunotherapy agents in these data, because their use was not 
recommended in the evaluated time-period (see supplemental methods).
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Statistical analysis
For each clinical subgroup, we assessed the proportion of cases that received guideline-
concordant treatment, less intensive treatment than recommended (defined as 
treatment that was not guideline-concordant), and no treatment. We used clinical 
stage at diagnosis for creating clinical subgroups because pathological stage can only 
be known after the outcome of interest (initial treatment) has occurred. For the 
groups of patients who received guideline-concordant treatment and less intensive 
treatment than recommended, we separately assessed which mutually exclusive 
combinations of surgery, SBRT, conventionally fractionated radiotherapy (CRT; defined 
as all radiotherapy other than SBRT), chemotherapy (including targeted therapy), 
and other treatment (including immunotherapy and experimental treatments) were 
received.
To identify whether previously identified disparities in receiving guideline-
concordant treatment by racial or ethnic group and by age persist, we fitted a logistic 
regression model with receipt of guideline-concordant treatment as binary outcome 
and racial or ethnic group and age as independent variables. We further adjusted 
this model for several covariates that could be associated with racial or ethnic 
group and age, and also affect receiving guideline-concordant treatment. Based on 
previous literature, we included sex,9 health insurance status21 Charlson comorbidity 
score,22 facility type,11 and stage at diagnosis.4 We further included histology, because 
squamous cell carcinomas are often located centrally,23 potentially making them 
more difficult to surgically resect. Finally, we included hospital volume, because it is 
a well-established indicator of quality of care.24 The derivation and composition of 
these variables is detailed in the supplemental methods.
To identify whether disparities by racial or ethnic group and by age extend across 
all clinical subgroups, we also fitted a separate model for each clinical subgroup. For 
clinical subgroups with multiple guideline-concordant treatment combinations, we 
fitted a separate model for each treatment combination. For example, two separate 
models were fitted for L-NSCLC: one with SBRT as binary outcome and one with 
surgery as binary outcome. These models were adjusted for the same covariates as 
the overall model.
All analyses were performed using R software version 3.4.1.25 The base-R glm 
function was used to fit the logistic regression models. We used multiple imputation 
to address missing data, using three imputations.26 Multicollinearity was assessed by 
calculating generalized variance inflation factors.27
Results
Patient characteristics
Baseline characteristics of the 441,812 included patients are shown in Table 1. When 
comparing these with lung cancer cases in the population-based SEER registry, we 
found only very small differences in sex, age, racial or ethnic group, health insurance 
status, histology, and stage at diagnosis (Table E4).
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Table 1: Characteristics of patients in the National Cancer Database diagnosed with non-small 
cell lung cancer or small cell lung cancer in the years 2010–2014.
Overall
(N = 441,812) 
NSCLC 
(n  =  375,832)
SCLC 
(n = 65,980)
Patient characteristics
Sex, n (%) Male 228,519 (51.7) 196,454 (52.3) 32,065 (48.6) 
Female 213,293 (48.3) 179,378 (47.7) 33,915 (51.4) 
Age at diagnosis, n (%) <50 yr 22,328 (5.1) 19,224 (5.1) 3,104 (4.7) 
50-54 yr 33,619 (7.6) 27,968 (7.4) 5,651 (8.6) 
55-59 yr 50,955 (11.5) 42,054 (11.2) 8,901 (13.5) 
60-64 yr 62,839 (14.2) 51,902 (13.8) 10,937 (16.6) 
65-69 yr 75,298 (17.0) 62,838 (16.7) 12,460 (18.9) 
70-74 yr 71,798 (16.3) 60,983 (16.2) 10,815 (16.4) 
75-79 yr 58,053 (13.1) 50,616 (13.5) 7,437 (11.3) 
≥80 yr 66,922 (15.1) 60,247 (16.0) 6,675 (10.1) 
Racial or ethnic 
group, n (%)
Non-Hispanic white 349,842 (79.2) 294,833 (78.4) 55,009 (83.4) 
Non-Hispanic black 48,060 (10.9) 42,799 (11.4) 5,261 (8.0) 
Non-Hispanic Asian 9,483 (2.1) 8,741 (2.3) 742 (1.1) 
Hispanic 12,081 (2.7) 10,587 (2.8) 1,494 (2.3) 
Other 2,806 (0.6) 2,441 (0.6) 365 (0.6) 
Unknown 19,540 (4.4) 16,431 (4.4) 3,109 (4.7) 
Health insurance 
status, n (%)
Private 117,168 (26.5) 99,666 (26.5) 17,502 (26.5) 
Medicare 256,740 (58.1) 219,916 (58.5) 36,824 (55.8) 
Medicaid 34,278 (7.8) 28,118 (7.5) 6,160 (9.3) 
Other government 
insurance
7,023 (1.6) 5,928 (1.6) 1,095 (1.7) 
No insurance 18,112 (4.1) 15,009 (4.0) 3,103 (4.7) 
Unknown 8,491 (1.9) 7,195 (1.9) 1,296 (2.0) 
Charlson comorbidity 
score, n (%)
0 24,6887 (55.9) 211,483 (56.3) 35,404 (53.7) 
1 130,577 (29.6) 110,304 (29.3) 20,273 (30.7) 
≥2 64,348 (14.6) 54,045 (14.4) 10,303 (15.6) 
Health care provider 
characteristics
Facility type, n (%) Academic 140,344 (31.8) 121,914 (32.4) 18,430 (27.9) 
Nonacademic 298,618 (67.6) 251,260 (66.9) 47,358 (71.8) 
Unknown 2,850 (0.6) 2,658 (0.7) 192 (0.3) 
Hospital volume,  
median (IQR) 
524 (302-861) 533 (304-871) 500 (288-837)
table continues
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Overall
(N = 441,812) 
NSCLC 
(n  =  375,832)
SCLC 
(n = 65,980)
Tumor 
characteristics 
Histology*, n (%) Adenocarcinoma 192,943 (43.7) 192,943 (51.3) -
Squamous cell 98,848 (22.4) 98,848 (26.3) -
Other non-small cell 84,041 (19.0) 84,041 (22.4) -
Small cell 65,980 (14.9) - 65,980 (100.0) 
Clinical stage at 
diagnosis, n (%)
IA 62,694 (14.2) 61,123 (16.3) 1,571 (2.4) 
IB 26,984 (6.1) 26,049 (6.9) 935 (1.4) 
IIA 17,456 (4.0) 15,898 (4.2) 1,558 (2.4) 
IIB 15,199 (3.4) 14,300 (3.8) 899 (1.4) 
IIIA 57,989 (13.1) 48,881 (13.0) 9,108 (13.8) 
IIIB 34,088 (7.7) 26,941 (7.2) 7,147 (10.8) 
IV 227,402 (51.5) 182,640 (48.6) 44,762 (67.8) 
Abbreviations: NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer; yr = year; 
IQR = interquartile range.
* NSCLC is subdivided into three distinct histology categories, whereas SCLC is considered a 
separate disease category.
Adherence to guideline-concordant treatment
The proportion of cases that received guideline-concordant treatment within each 
clinical subgroup was stable between 2010 and 2014 (Figure E2). As shown in Table 
2, 62.1% of all cases diagnosed between 2010 and 2014 received guideline-concordant 
treatment (range = 50.4% in A-NSCLC to 76.3% in L-NSCLC). However, 16.3% received 
less intensive treatment than recommended (range = 6.4% in ED-SCLC to 21.6% in LA-
NSCLC), and 21.6% received no treatment (range = 10.3% in L-NSCLC to 31.4% in A-NSCLC).
Table 2: Receipt of guideline-concordant treatment among lung cancer patients by clinical 
subgroup.
Clinical Subgroup n Guideline-
Concordant 
Treatment*
n (%) 
Less Intensive 
Treatment Than 
Recommended†
n (%)
No Treatment
n (%)
Overall 441,812 274,338 (62.1) 72,155 (16.3) 95,319 (21.6)
L-NSCLC 117,370 89,503 (76.3) 15,741 (13.4) 12,126 (10.3)
LA-NSCLC 75,822 45,774 (60.4) 16,412 (21.6) 13,636 (18.0)
A-NSCLC 182,640 92,119 (50.4) 33,227 (18.2) 57,294 (31.4)
LD-SCLC 21,218 14,765 (69.6) 3,927 (18.5) 2,526 (11.9)
ED-SCLC 44,762 32,177 (71.9) 2,848 (6.4) 9,737 (21.8)
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Abbreviations: L-NSCLC = localized non-small-cell lung cancer (stages I-II); LA-NSCLC = locally 
advanced non-small-cell lung cancer (stage III); A-NSCLC = advanced non-small-cell lung 
cancer (stage IV); LD-SCLC = limited-disease small-cell lung cancer (stages I-III); ED-SCLC = 
extensive disease small-cell lung cancer (stage IV).
* Guideline-concordant treatment was defined as the minimal treatment patients should 
receive according to the National Comprehensive Cancer Network guidelines. Hence, 
additional treatment was allowed beside guideline-concordant treatment. We considered 
guideline-concordant treatment to be either surgery or stereotactic body radiation therapy 
for L-NSCLC; either radiotherapy and chemotherapy or surgery and chemotherapy for LA-
NSCLC; chemotherapy for A-NSCLC; either radiotherapy and chemotherapy or surgery and 
chemotherapy for patients with LD-SCLC; and chemotherapy for patients with ED-SCLC. 
† Less intensive treatment than recommended was defined as treatment that was not guideline-
concordant.
Patterns of care among patients that received guideline-concordant 
treatment
Among L-NSCLC cases that received guideline-concordant treatment, “surgery 
only” was received most frequently (49.1%), followed by “surgery and chemotherapy” 
(11.4%), and “SBRT only” (10.0%) (Table 3). In every other clinical subgroup, “CRT and 
chemotherapy” was most common (range = 25.9% in A-NSCLC to 63.5% in LD-SCLC). 
Among subjects with LA-NSCLC and LD-SCLC, “surgery, CRT, and chemotherapy” was 
also used (7.4% and 2.6%, respectively), as was “surgery and chemotherapy” (4.4% and 
2.4%, respectively). Among subjects with A-NSCLC and ED-SCLC, “chemotherapy only” 
was common (19.5% and 35.0%, respectively).
Table 3: Patterns of care among patients with lung cancer by clinical subgroup.
 
Clinical Subgroup Treatment Received* n (%)
L-NSCLC Guideline-concordant treatment
  Surgery only 57,605 (49.1)
  Surgery and chemotherapy 13,359 (11.4)
  SBRT only 11,740 (10.0)
  Surgery, CRT, and chemotherapy 4,405 (3.8)
  Surgery and CRT 1,562 (1.3)
Less intensive treatment than recommended
  CRT only 7,129 (6.1)
  CRT and chemotherapy 6,953 (5.9)
  Chemotherapy only 1,465 (1.2)
LA-NSCLC Guideline-concordant treatment
  CRT and chemotherapy 36,108 (47.6)
  Surgery, CRT, and chemotherapy 5,580 (7.4)
  Surgery and chemotherapy 3,335 (4.4)
table continues
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Clinical Subgroup Treatment Received* n (%)
Less intensive treatment than recommended
  CRT only 6,577 (8.7)
  Chemotherapy only 6,008 (7.9)
  Surgery only 2,676 (3.5)
A- NSCLC Guideline-concordant treatment
  CRT and chemotherapy 47,370 (25.9)
  Chemotherapy only 35,620 (19.5)
  CRT, chemotherapy, and other  treatment 2,970 (1.6)
  Chemotherapy and other treatment 2,715 (1.5)
Less intensive treatment than recommended
  CRT only 29,219 (16.0)
LD-SCLC Guideline-concordant treatment
  CRT and chemotherapy 13,477 (63.5)
  Surgery, CRT, and chemotherapy 545 (2.6)
  Surgery and chemotherapy 514 (2.4)
Less intensive treatment than recommended
  Chemotherapy only 2,917 (13.7)
  CRT only 534 (2.5)
  Surgery only 340 (1.6)
ED-SCLC Guideline-concordant treatment
  CRT and chemotherapy 15,671 (35.0)
  Chemotherapy only 15,658 (35.0)
Less intensive treatment than recommended
  CRT only 2,597 (5.8)
Abbreviations: L-NSCLC = localized non-small-cell lung cancer (stages I-II); LA-NSCLC = locally 
advanced non-small-cell lung cancer (stage III); A-NSCLC = advanced non-small-cell lung cancer 
(stage IV); LD-SCLC = limited-disease small-cell lung cancer (stage I-III); ED-SCLC = extensive 
disease small-cell lung cancer (stage IV); SBRT = stereotactic body radiation therapy, defined as 
thoracic radiotherapy with a dose of ≥45 Gray in ≤5 fractions; CRT = conventionally fractionated 
radiotherapy, defined as all radiotherapy other than Stereotactic Body Radiation Therapy. 
* All mutually exclusive combinations of treatment modalities (i.e., all combinations of 
surgery, SBRT, CRT, chemotherapy, and other treatment) were assessed. However, for each 
clinical subgroup, only those treatment combinations that were more prevalent than 1% are 
reported in this table. 
Patterns of care among patients that received less intensive treatment 
than recommended
“CRT only” was among the most commonly received less-intensive-than-recommended 
therapies for each clinical subgroup, as was “chemotherapy only” for subgroups other 
than A-NSCLC and ED-SCLC (Table 3). Most common among L-NSCLC were “CRT 
only” (6.1%), “CRT and chemotherapy” (5.9%), and “chemotherapy only” (1.2%). Among 
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subjects with LA-NSCLC and LD-SCLC, the most commonly received less-intensive-
than-recommended treatments were “CRT only” (8.7% and 2.5%, respectively) and 
“chemotherapy only” (7.9% and 13.7%, respectively). “CRT only” was the most common 
among metastatic subgroups A-NSCLC (16.0%) and ED-SCLC (5.8%).
Disparities in receiving guideline-concordant treatment
As can be seen in Table 4, the odds of receiving guideline-concordant treatment 
decreased with advancing age (for those aged ≥80 yr compared with those aged <50 
yr: odds ratio [OR] = 0.14; 95% confidence interval [CI] = 0.13-0.14). This association 
remained present after adjusting for covariates (for those aged ≥80 yr compared with 
those aged <50 yr: adjusted odds ratio [aOR] = 0.12; 95%CI = 0.12-0.13). In addition, the 
association between age and receiving guideline-concordant treatment was consistent 
across clinical subgroups, with a notable exception in L-NSCLC (Table E5). In L-NSCLC, 
advancing age was associated with a decreased odds of receiving surgery (for those 
aged ≥80 yr compared with those aged <50 yr: aOR = 0.06; 95%CI = 0.05-0.06). However, 
the odds of receiving SBRT for L-NSCLC increased with advancing age (for those aged 
≥80 yr compared with those aged <50 yr: aOR = 18.39; 95%CI = 14.09-23.99). 
Compared with non-Hispanic white patients, non-Hispanic black patients (OR 
= 0.82; 95%CI = 0.81-0.84) and Hispanic patients (OR=0.87, 95%CI=0.84-0.90) were less 
likely to receive guideline-concordant treatment. This association remained present 
after adjusting for covariates (non-Hispanic black patients: aOR = 0.78; 95%CI = 0.76-
0.0.80; Hispanic patients: aOR = 0.94; 95%CI = 0.90-0.98). On the other hand, non-
Hispanic Asian patients were more likely to receive guideline-concordant treatment 
after adjusting for covariates (aOR = 1.09; 95%CI = 1.04-1.15). However, results for non-
Hispanic Asian patients and Hispanic patients varied within clinical subgroups (table 
E5). For example, within the subgroup of L-NSCLC, both non-Hispanic Asian patients 
and Hispanic patients were more likely to receive surgery than non-Hispanic white 
patients (non-Hispanic Asian patients: aOR = 1.23; 95%CI = 1.10 - 1.37; Hispanic patients: 
aOR = 1.24; 95%CI = 1.13-1.36), but less likely to receive SBRT (non-Hispanic Asian 
patients: aOR = 0.51; 95%CI = 0.43-0.62; Hispanic patients: aOR = 0.47; 95%CI = 0.40-0.56). 
In addition, non-Hispanic Asian patients with A-NSCLC were more likely to receive 
chemotherapy (aOR = 1.25; 95%CI = 1.18-1.34).
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Discussion 
To our knowledge, this study is the first to investigate adherence to guideline-
concordant treatment as well as disparities by racial or ethnic group and by age in a 
uniform manner for all clinical subgroups of lung cancer including SCLC. 
Adherence to guideline-concordant treatment
We show that overall, the level of adherence to guideline-concordant treatment among 
patients with lung cancer in the United States is only 62.1%, and varies across clinical 
subgroups. The rate of guideline-concordant treatment was highest for L-NSCLC. This 
makes sense as treatment for L-NSCLC is potentially curative and therefore offers the 
most obvious benefits. The rate of guideline-concordant treatment was lowest for 
A-NSCLC. 
A possible explanation for this finding could be a lack of referral to medical 
oncologists among patients with A-NSCLC. A recent study reported that only 54% of 
stage IIIB-IV NSCLC cases triaged at the British Columbia Cancer Agency were assessed 
by a medical oncologist.28 Another study found that one of the most common reasons 
for not referring patients to a medical oncologist or prescribing chemotherapy was 
the patient’s preference against treatment.29 Some patients with incurable disease 
fear that chemotherapy side-effects may negatively affect their quality of life.30 
Perhaps this could influence their willingness to accept chemotherapy. However, 
chemotherapy for advanced disease has been shown to improve quality of life, 
symptom control, and survival compared with best supportive care.31 Therefore, 
discussing a patient’s possible fears of chemotherapy and the potential health 
benefits could be an important step toward increasing the uptake of chemotherapy.  
Compared with our results, Wang and colleagues4 reported even lower rates of 
guideline-concordant treatment among 20,511 NSCLC cases diagnosed between 2003 
and 2008. In their study, the proportion that received guideline-concordant treatment 
was 51% among subjects with L-NSCLC, 35% among subjects with LA-NSCLC, and 27% 
among subjects with A-NSCLC. The difference compared with our study is likely due 
to patient selection, as Wang and colleagues included only veterans aged 65 years or 
older. 
Within the group that received guideline-concordant treatment, our data show 
that most L-NSCLC cases received surgery, whereas SBRT and other modalities were 
used much less frequently. In contrast, most cases in the potentially operable clinical 
subgroups LA-NSCLC and LD-SCLC did not receive surgery as guideline-concordant 
treatment. 
In our data, 16.3% of cases received less intensive treatment than recommended. 
The patterns of care among these cases provide important clues toward improvements 
in clinical care. For example, the frequent use of “CRT only”, “CRT and chemotherapy”, 
and “chemotherapy only” among L-NSCLC suggests that the uptake of SBRT among 
inoperable cases may still be lagging. Among subjects with LA-NSCLC and those with LD-
SCLC the most common forms of less-intensive-than-recommended treatment were 
“CRT only” and “chemotherapy only”. These findings suggest room for improvement 
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in the uptake of multimodality treatments such as “CRT and chemotherapy” and 
“surgery and chemotherapy”, for these subgroups. The frequent use of “CRT only” 
among A-NSCLC and ED-SCLC subgroups suggests room for an increased uptake of 
chemotherapy among these metastatic subgroups.
Finally, 21.6% of cases in our study received no treatment. This is consistent with 
findings in a smaller study among 6,662 lung cancer cases in the Kaiser Permanente 
Southern California tumor registry diagnosed between 2008 and 2013.22 In that study, 
rates of nontreatment ranged from 9% among stage 0-II (compared with 10.3% among 
L-NSCLC in our study) to 34% among stage IV (compared with 31.4% among A-NSCLC 
in our study). 
Disparities in receiving guideline-concordant treatment
In our study, advancing age was strongly associated with the odds of receiving 
guideline-concordant treatment across all clinical subgroups. These findings are in 
line with the conclusions of an earlier study.4 This association persisted after adjusting 
for factors that could influence fitness for surgery, such as comorbidity, histology, and 
stage, as well as health care provider characteristics. Other studies also reported a 
lower likelihood of lung cancer surgery among older patients, although these findings 
cannot be directly compared with ours due to the use of different age groups and 
methods.9,10,32 Although we confirm the lower likelihood of receiving surgery for elderly 
L-NSCLC cases, we also show that the likelihood of receiving SBRT strongly increases 
with advancing age. These results indicate that SBRT is indeed used as an alternative 
guideline-concordant treatment for L-NSCLC cases that have contraindications for 
surgery. However, especially in other clinical subgroups, efforts should be made to 
ensure that elderly patients receive the minimal recommended treatment.
Racial or ethnic group was also associated with the odds of receiving guideline-
concordant treatment in both the adjusted and unadjusted analyses. Earlier research 
among U.S. patients with lung cancer had already shown that black patients are 
less likely to receive surgery for L-NSCLC5-10,33 and chemotherapy for A-NSCLC.33,34 Our 
current study shows that disparities by racial or ethnic group persist and extend to 
every clinical subgroup of NSCLC. Furthermore, we show that Hispanic patients are 
also less likely to receive guideline-concordant treatment in general, but more likely 
to receive surgery for L-NSCLC. In an earlier study, McCann and colleagues35 offer a 
possible explanation for racial disparities. They reported that, although surgery was 
offered to black and white patients with lung cancer at the same rate, black patients 
declined surgery more often. Their study showed no statistically significant difference 
in insurance between the groups, and results were corrected for preoperative 
pulmonary function, tumor stage, and comorbidity. Furthermore, Lin and colleagues36 
reported that negative surgical beliefs, fatalism, and mistrust among racial minorities 
can partly explain why black patients are less likely to receive guideline-concordant 
treatment. More research is needed to identify the underlying reasons for such beliefs 
and mistrust and to test strategies to overcome any barriers to delivery of guideline-
concordant treatment.
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Strengths and limitations
A major strength of this study is the very large sample size, combined with the extensive 
treatment data available in the NCDB. The linked SEER-Medicare database, which 
also contains detailed treatment variables, may be biased toward older individuals as 
it mainly includes patients aged 65 years or older. In contrast, the NCDB data used for 
our study included patients with lung cancer aged 18 years or older. 
There are several potential limitations to our study. The first is the hospital-based 
nature of the data, which captures only cases diagnosed and treated in Commission 
on Cancer-affiliated hospitals. However, these hospitals together treat 70% of incident 
cancer cases in the United States. Furthermore, we compared baseline characteristics 
to a cohort of patients captured by the smaller, but population-based, SEER database 
and found only small differences. Therefore, our results are likely generalizable to the 
U.S. population.
Second, our data include only the first course of treatment. Nevertheless, we 
were able to define guideline-concordant treatment as the minimal recommended 
treatment. Although the focus of this article was therefore the issue of receiving 
less intensive treatment than recommended, we acknowledge that receiving more 
intensive treatment than recommended could potentially also be an issue. However, 
for most clinical subgroups the NCDB data does not contain sufficient clinical 
variables to assess whether each possible combination of surgery, radiotherapy, 
chemotherapy, and other treatment was more intensive than recommended. For 
example, radiotherapy is not recommended as a minimal treatment for A-NSCLC, 
but may still be prescribed as symptomatic treatment for painful bone metastases. 
Nevertheless, we were able to assess that 10.4% of stage I NSCLC cases received 
adjuvant or neoadjuvant chemotherapy, which could provide an indication of the 
extent to which overtreatment occurs. In addition, 2.9% of A-NSCLC cases received 
surgery. Future studies should focus more in depth on the severity and consequences 
of receiving more intensive treatment than recommended for lung cancer. 
Third, the data did not include several clinical variables that may affect the 
choice of treatment. Smoking cessation after the diagnosis of lung cancer has been 
associated with reduced all-cause mortality37 and a reduced risk of hospital death and 
pulmonary complications after surgery.38 Therefore, active smokers may have been 
less likely to receive surgery. However, guidelines state that surgery should not be 
denied to patients only due to smoking.14 Pulmonary function and performance score 
may have also influenced the likelihood of receiving surgery.39 Although our correction 
for comorbidities may have partially accounted for these factors, the Charlson score 
is an aggregate measure that does not account for all possible comorbidities. Another 
factor that we could not fully account for using the NCDB data is socioeconomic 
status, although we were able to include insurance status. We addressed the absence 
of these clinical variables by assessing multiple guideline-concordant treatments for 
some clinical subgroups. For instance, both SBRT and surgery were regarded guideline-
concordant treatments for L-NSCLC. However, this carries the implicit assumption 
that, when the nonsurgical treatment was given, the patient was indeed medically 
inoperable.  
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Fourth, we used the official cut-off of 5 fractions in our definition of SBRT, whereas 
some institutions use schemes with up to 10 fractions.19 However, using a cut-off of 
10 fractions would only increase the use of SBRT among L-NSCLC in our dataset from 
10.4 to 10.9%.  
Fifth, hospital-based data, such as those from the NCDB, could potentially be 
clustered by hospital. However, in an exploratory analysis using the data before 
multiple imputation, incorporating clustering by hospital identification had a 
negligible effect on the estimates of the overall regression model (data not shown). 
Given that the effect of clustering by hospital is therefore likely small, we did not 
incorporate clustering by hospital in our final models.
Finally, we were not able to take patient preferences into account. Hence, we 
cannot draw firm conclusions on the underlying causes of the identified disparities 
by racial or ethnic group and by age. 
Conclusions
We show that many patients with lung cancer in the United States do not receive 
guideline-concordant treatment. Efforts should be made to decrease the proportion 
of cases that receive no treatment or less intensive treatment than recommended. 
Specifically, patterns of care among those receiving less intensive treatment than 
recommended suggest room for an improved uptake of SBRT among L-NSCLC, 
multimodality therapy among LA-NSCLC and LD-SCLC subgroups, and chemotherapy 
among those with metastatic disease (A-NSCLC and ED-SCLC). Furthermore, we 
show that elderly patients and non-Hispanic black patients are less likely to receive 
guideline-concordant treatment across most clinical subgroups of lung cancer, despite 
adjusting for relevant patient, tumor, and health care provider characteristics. This 
knowledge may be used to target interventions for improving the rate of lung cancer 
cases that receive guideline-concordant treatment and to reduce disparities.
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Data
We used the National Cancer Database (NCDB) to extract a cohort of patients diagnosed 
with lung cancer between 2010-2014. The NCDB, established in 1989, is a nationwide, 
facility-based, comprehensive clinical surveillance resource oncology data set that 
currently captures 70% of all newly diagnosed malignancies in the United States 
annually, from more than 1500 affiliated facilities. The NCDB records the first course 
of treatment, defined as all methods of treatment recorded in the treatment plan 
and administered to the patient before disease progression or recurrence. Analysis 
of individual-level NCDB data was performed on site at the University of Michigan 
Medical School. This study was deemed exempt by the Institutional Review Board of 
the University of Michigan.
Case selection
Only cases with International Classification of Diseases for Oncology 3rd edition (ICD-
0-3) malignant behavior code were selected.1 Stages 0, occult, and unknown were 
excluded as guidelines provide no treatment recommendations for these patients. 
We further removed cases without a known stage subcategory (e.g. stage I rather than 
IA) because these do not provide sufficient detail. We selected only those cases staged 
using the American Joint Committee on Cancer (AJCC) 7th edition Cancer Staging 
Manual, which was effective from 2010-2017.2 In accordance with NCDB instructions, 
we further excluded the following: cases with a history of multiple primary tumors of 
which lung cancer wasn’t the first; cases with a date of diagnosis before the reporting 
facility’s reference date (i.e. the date from which the facility guarantees the accuracy 
of data); and cases that did not receive any treatment at the reporting facility. Also, 
we excluded cases with unknown treatment. Finally, we selected only cases with less 
than four months (122 days) between diagnosis and onset of therapy because the 
NCDB uses the principle that initial treatment must begin within four months of the 
date of initial diagnosis.
Data cleaning
Baseline characteristics
Baseline characteristics of included patients were derived and included sex, age at 
diagnosis, racial or ethnic group, insurance status, Charlson comorbidity score, tumor 
histology, clinical stage at diagnosis, treating facility type, and treating hospital 
volume. The derivation of these variables is detailed below.
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Deriving sex
The standard coding of sex was used.
Deriving age at diagnosis
Age at diagnosis was collapsed into categories under 50, 80 or over, and 5-year intervals 
in between.  
Deriving racial or ethnic group
Available Race codes were recoded to categories White, Black, Asian, Other (and 
Unknown) using definitions from the Census 2000 Technical Documentation3 as 
shown in Table E1. The variable for Spanish/Hispanic origin was collapsed into 
categories Non-Hispanic, Hispanic and Unknown. Cases in which the only evidence of 
the person’s Hispanic origin was surname or maiden name were explicitly assigned 
the category Unknown. Cases with Hispanic origin could be of any Race. Therefore, 
recoded variables Race and Spanish/Hispanic origin were combined into a new 
variable with categories non-Hispanic White, non-Hispanic Black, non-Hispanic 
Asian, Hispanic, Other, and unknown.
Deriving insurance status
The standard coding of insurance status was used. According to the NCDB codebook, 
the first recorded payer or insurer was used if multiple forms of insurance are recorded 
on the patient’s admission page.
Deriving Charlson comorbidity score
The Charlson comorbidity score is the sum of the scores for each of the comorbid 
conditions as mapped from the Charlson Comorbidity Score Mapping Table in the 
online NCDB Data Dictionary.4 Individual comorbidities were not available in the 
data. The Charlson score in the NCDB is only available aggregated into scores 0, 1 and 
2 or higher. A Charlson score of 0 does not mean that no comorbidities are present, 
but that none of the comorbidities from the mapping table were present. 
Deriving tumor histology
ICD-0-3 morphological codes were assigned to categories adenocarcinoma (including 
bronchioalveolar carcinoma and large cell carcinoma), squamous cell carcinoma, 
other non-small cell and small cell lung cancer (SCLC), as shown in Table E2. The 
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classification was based on an earlier publication.5 In accordance with the ICD-0-3 
coding manual, morphological codes that were not listed in that classification or 
that were accompanied by a lung cancer-specific site code despite not being typically 
associated with lung cancer were not discarded but were assigned the histological 
category other.1
Deriving stage at diagnosis
We used clinical stage at diagnosis because pathological stage is only available after 
the outcome of interest (initial treatment) has taken place. As is customary in clinical 
guidelines, clinical stage for SCLC was collapsed to limited disease SCLC (LD-SCLC; 
stages I-III) and extensive disease SCLC (ED-SCLC; stage IV). For the analysis of NSCLC 
cases, we collapsed stages IA, IB, and II into localized NSCLC (L-NSCLC), stages IIIA 
and IIIB into locally advanced NSCLC (LA-NSCLC), and stage IV into advanced NSCLC 
(A-NSCLC).
Deriving facility type
Treating facility type was derived by combining Commission on Cancer accreditation 
categories into academic (includes Academic Comprehensive Cancer Programs and 
National Cancer Institute-designated Comprehensive Cancer Centers) and non-
academic (all other reported program types). Commission on Cancer programs 
categories are based on type of facility, program structure, services provided, and the 
volume of patients. Key characteristics of the category “Academic Comprehensive 
Cancer Program” are the annual accession of at least 500 newly diagnosed cancer 
cases, the availability of a full range of diagnostic and therapeutic services, the 
participation in research, and the participation in postgraduate medical education 
in at least four programs including internal medicine and surgery.6  The category 
National Cancer Institute-Designated Comprehensive Cancer Center Program only 
requires the availability of a full range of diagnostic and treatment facilities.6
Deriving hospital volume
Hospital volume was calculated by determining how many lung cancer cases (both 
NSCLC and SCLC) were treated at the reporting (and therefore treating) facility, using 
the unique facility identifier. Hospital volume was aggregated in quartiles and used as 
a categorical variable.
Extracting a cohort from the Surveillance, Epidemiology, and End Results 
dataset
Applying a case selection process similar to that of the studied NCDB cohort, we 
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extracted a cohort from the Surveillance, Epidemiology, and End Results (SEER) 18 
Registries Research Data + Hurricane Katrina Impacted Louisiana Cases November 
2016 data submission using proprietary SEER*Stat software.7 First, only cases with 
ICD-0-3 topography codes for lung cancer (C340 - C343, C348 and C349) and malignant 
behavior code were selected. We only selected cases staged using the AJCC 7th Edition 
Cancer Staging Manual.2 Stages 0 and occult and cases with unspecified substage (i.e. 
stage I rather than IA) were excluded. For full comparability of baseline characteristics 
between the NCDB and the SEER database, we did not exclude cases with an unknown 
stage in this comparison.  Only cases with “one primary only” or “1st of 2 or more 
primaries” were selected. Finally, only cases with known age diagnosed in years 2010 
through 2014 were selected.  
To assess the generalizability of NCDB data to the general US population, we 
compared baseline characteristics of the cohort from the SEER database to the 
cohort of lung cancer patients from the NCDB database. Where possible, ICD-
0-3 morphological codes were assigned to histology categories using the same 
classification that we used for the NCDB cohort, as shown in Table E2. The following 
histologies were available in the NCDB cohort, but not in the SEER cohort: 8143, 8572, 
8573 (classified as adenocarcinoma); 8005, 8040, 8080, 8090, 8094, 8120, 8154, 8160, 8210, 
8211, 8243, 8262, 8280, 8313, 8380, 8401, 8453, 8503, 8510 (classified as other non-small cell). 
The following histologies were available in the SEER cohort, but not in the NCDB 
cohort and were classified as follows: 8201, 8571 (adenocarcinoma); 8034, 8300, 8410, 
9590, 9591, 9650, 9651, 9663, 9671, 9673, 9680, 9687, 9690, 9699, 9714 (other non-small cell). 
We recoded and categorized racial or ethnic groups in the exact same way as for the 
NCDB cohort, as described elsewhere in the Supplementary Methods. As the insurance 
status variable in the SEER database is less granular than in the NCDB, we recoded 
insurance status in both datasets to categories insured (NCDB: private, Medicare, 
Medicaid, other government insurance; SEER: insured, insured with no specifics, any 
Medicaid), uninsured, and unknown. The treatment facility type variable that we 
used in the NCDB analysis is NCDB-specific and was therefore unavailable for the 
SEER database. Finally, the Charlson comorbidity score was also not available in the 
SEER database.
Constructing treatment variables
The NCDB records the first course of treatment, defined as all methods of treatment 
recorded in the treatment plan and administered to the patient before disease 
progression or recurrence. We were not able to distinguish whether multiple therapies 
were given concurrently or sequentially. Available treatment modalities in the dataset 
were surgery, radiotherapy, chemotherapy, hormone therapy, immunotherapy and 
other treatment (including experimental treatments).
The use of each of these modalities was coded in one or several variables. For 
each modality, crosstables were constructed between the available variables to 
check the internal consistency of the dataset. If possible based on these crosstables, 
unknown values were recoded (e.g. for n=43 cases, the variable RX_SUMM_SURG_PRIM_
SITE indicated that it was unknown whether surgery was given while the variable 
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REASON_FOR_NO_SURGERY indicated that surgery was not given. These were recoded 
as not having received surgery). Based on these crosstables, we constructed a set of 
binary variables to indicate whether surgery, radiotherapy, chemotherapy, hormone 
therapy, immunotherapy and other treatment were administered. 
The names of individual systemic agents are not recorded by the NCDB. The 
NCDB uses the SEER*Rx Interactive Antineoplastic Drugs Database8 to determine 
whether systemic agents are to be coded as chemotherapy, hormone therapy, 
or immunotherapy. We investigated the targeted therapy agents that are most 
commonly used in lung cancer care (i.e. EGFR-inhibitors erlotinib, afatinib and 
gefitinib and ALK-inhibitors crizotinib and ceritinib) in the SEER*Rx database and 
found that these were all coded as chemotherapy. Therefore, we were not able to 
separately report on the use of targeted agents.  
When investigating other novel treatment agents used in lung cancer care in the 
SEER*Rx database, we found that Vascular Endothelial Growth Factor (VEGF) inhibitor 
bevacizumab has been coded as immunotherapy for cases diagnosed after January 1st 
2013 only. For cases diagnosed prior to that date, bevacizumab had been coded as 
chemotherapy.  Protein Programmed Cell Death 1 (PD-1) inhibitors pembrolizumab, 
nivolumab and Protein Programmed Cell Death-Ligand 1 (PD-L1) inhibitor 
atezolizumab were coded as immunotherapy for all cases. The recommendation and 
clinical use of these agents in lung cancer therapy is very recent though, and is unlikely 
to be captured in the available dataset with cases diagnosed between 2010-2014. To our 
knowledge, there are no hormone therapy agents that have an accepted role in the 
treatment of lung cancer. As a result, hormone therapy and immunotherapy were 
aggregated with the other treatment category.
Radiotherapy was further divided into Stereotactic Body Radiotherapy (SBRT) and 
conventionally fractionated radiotherapy (CRT). SBRT delivers high-dose radiation to 
a specific target in only a few fractions and provides local tumor control rates of up 
to 90% with moderate toxicity.9,10 Since the most frequently used SBRT schemes in the 
US comprise a total dose of 45 Gray or more over 1-5 fractions11-13 and the US billing 
code for SBRT includes a maximum of 5 fractions,14 SBRT was defined as thoracic 
radiotherapy with a total radiation dose of 45 Gray or more delivered in 5 fractions or 
less. CRT was defined as all radiotherapy that was not SBRT. 
The remaining treatment variables were: surgery, SBRT, CRT, chemotherapy 
(including targeted therapies), and other treatment (including experimental 
treatments and immunotherapy). Cases that received none of these therapies were 
coded as having received no therapy. 
Definition of guideline-concordant treatment
Two main lung cancer types can be distinguished: NSCLC and SCLC, with the majority 
presenting as NSCLC. Since SCLC is clinically more aggressive than NSCLC, clinical 
treatment guidelines provide specific recommendations for clinical subgroups of lung 
cancer type and stage at diagnosis. For each of these clinical subgroups, we assessed 
whether guideline-concordant treatment was received, defined as the minimal 
first course treatment these patients should receive according to the National 
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Comprehensive Cancer Network guidelines.14,15 
While surgical treatment is still recommended as the primary minimal 
treatment for L-NSCLC, SBRT is now recommended as an alternative treatment to 
surgery for L-NSCLC patients.14 Therefore, both surgery and SBRT were considered 
guideline-concordant treatment for L-NSCLC. The minimal recommended treatment 
for LA-NSCLC and LD-SCLC depends on operability.14,15 If operable, the minimal 
recommendation is surgery combined with chemotherapy. However, the majority 
of LA-NSCLC and LD-SCLC patients are inoperable, in which case the minimal 
recommendation is a combination of radiotherapy and chemotherapy. Therefore, 
both treatment combinations were considered guideline-concordant for LA-NSCLC 
and LD-SCLC. For A-NSCLC and ED-SCLC, the minimal recommended treatment is 
chemotherapy.14,15 As we assessed the minimal recommended treatment for each 
clinical subgroup, additional treatments were allowed beside guideline-concordant 
treatment (e.g. radiotherapy for bone metastases beside chemotherapy in A-NSCLC). 
There were no restrictions on radiation dose or fractionation for stages other than 
L-NSCLC. A summary of the treatment combinations that were considered guideline-
concordant for each clinical subgroup can be found in Table E3 in the Online 
Supplement.
Statistical analysis
For each clinical subgroup, we assessed the proportion of cases that received guideline-
concordant treatment, less treatment than recommended (defined as treatment that 
was not guideline-concordant), and no treatment. We used clinical stage at diagnosis 
for creating clinical subgroups because pathological stage can only be known after 
the outcome of interest (initial treatment) has occurred. For the groups of patients 
who received guideline-concordant treatment and less intensive treatment than 
recommended, we separately assessed which mutually exclusive combinations of 
surgery, SBRT, CRT, chemotherapy (including targeted therapy) and other treatment 
(including immunotherapy and experimental treatments) were received.   
To identify whether previously identified disparities in receiving guideline-
concordant treatment by racial or ethnic group and by age persist, we fitted a logistic 
regression model with receipt of guideline-concordant treatment as binary outcome 
and racial or ethnic group and age as independent variables. We further adjusted 
this model for several covariates that could be associated with racial or ethnic 
group and age, and also affect receiving guideline-concordant treatment. Based on 
previous literature, we included sex,16 health insurance status,17 Charlson comorbidity 
score,18 facility type,19 and stage at diagnosis.20 We further included histology because 
squamous cell carcinomas are often located centrally,21 potentially making them 
more difficult to surgically resect. Finally, we included hospital volume because it is a 
well-established indicator of quality of care.22 
To identify whether disparities by racial or ethnic group and by age extend across 
all clinical subgroups, we also fitted a separate model for each clinical subgroup. For 
clinical subgroups with multiple guideline-concordant treatment combinations, we 
fitted a separate model for each treatment combination. For example, two separate 
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models were fitted for L-NSCLC; one with SBRT as binary outcome and one with 
surgery as binary outcome. These models were adjusted for the same covariates as 
the overall model.
All analyses were performed using R software version 3.4.1.23 The base-R glm() 
function was used to fit the logistic regression models. We used multiple imputation 
to address missing data, using three imputations.24 Multicollinearity was assessed by 
calculating generalized variance inflation factors.25 
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Supplementary Table E1: Recoding race categories from the National Cancer Database 
Participant User File.
Recoded race 
category
Original race categories
White White
Black Black
Asian Chinese; Japanese; Filipino; Hawaiian; Korean; Vietnamese; Laotian; 
Hmong; Kampuchean (including Khmer and Cambodian); Thai; Asian 
Indian or Pakistani NOS; Asian Indian; Pakistani; Other Asian (including 
Asian NOS and Oriental NOS)
Other American Indian, Aleutian or Eskimo; Micronesian NOS; Chamorran; 
Guamanian NOS; Polynesian NOS; Tahitian; Samoan; Tongan; Melanesian 
NOS; Fiji Islander; New Guinean; Pacific Islander NOS; Other
Supplementary Table E2: Assigning International Classification of Diseases for Oncology 3rd 
Edition histological codes to histology categories.
Histology category ICD-0-3 histological codes included
Adenocarcinoma 8140; 8141; 8143; 8200; 8230; 8260; 8310; 8323; 8480; 8481; 8490; 
8550; 8570; 8572; 8573; 8574; 8575; 8576
Bronchioalveolar carcinoma* 8250; 8251; 8252; 8253; 8254; 8255
Large cell carcinoma* 8012; 8013; 8014
Squamous Cell Carcinoma 8052; 8070; 8071; 8072; 8073; 8074; 8075; 8076; 8083; 8084
Other 8000; 8001; 8003; 8004; 8005; 8010; 8011; 8020; 8021; 8022; 8030; 
8031; 8032; 8033; 8035; 8040; 8046; 8050; 8051; 8080; 8082; 8090; 
8094; 8120; 8123; 8144; 8154; 8160; 8210; 8211; 8240; 8241; 8243; 8244; 
8245; 8246; 8247; 8249; 8262; 8280; 8290; 8313; 8320; 8333; 8341; 
8380; 8401; 8430; 8441; 8453; 8470; 8500; 8503; 8507; 8510; 8551; 
8560; 8562; 8940; 8980
Small cell lung cancer 8002; 8041; 8042; 8043; 8044; 8045
Abbreviations: ICD-0-3 = International Classification of Diseases for Oncology 3rd Edition.
* Bronchioalveolar carcinoma and large cell carcinoma were later grouped with 
adenocarcinoma.
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Supplementary Table E3: Overview of therapy that was considered guideline-concordant 
treatment for each clinical subgroup.
Clinical subgroup Guideline-concordant treatment* 
L-NSCLC (%) Surgery ± additional treatments AND/OR 
SBRT ± additional treatments  
LA-NSCLC (%) Surgery + chemotherapy ± additional treatments AND/OR
Radiotherapy (any regimen) + chemotherapy ± additional treatments
A-NSCLC (%) Chemotherapy ± additional treatments
LD-SCLC (%) Surgery + chemotherapy ± additional treatments AND/OR
Radiotherapy (any regimen) + chemotherapy ± additional treatments
ED-SCLC (%) Chemotherapy ± additional treatments
Abbreviations: L-NSCLC = localized non-small cell lung cancer (stages I-II); LA-NSCLC = locally-
advanced non-small cell lung cancer (stage III); A-NSCLC = advanced non-small cell lung cancer 
(stage IV); LD-SCLC = limited disease small cell lung cancer (stages I-III); ED-SCLC = extensive 
disease small cell lung cancer (stage IV); SBRT = Stereotactic Body Radiation Therapy, defined as 
thoracic radiotherapy with a dose of ≥45 Gray in ≤5 fractions. 
* Guideline-concordant treatment was defined as the minimal treatment patients should 
receive. Hence, ± sign indicates that additional treatment was allowed beside the minimal 
recommended treatment. Available treatment modalities were surgery, radiotherapy (further 
specified as Stereotactic Body Radiotherapy or conventional radiotherapy), chemotherapy 
(including targeted therapies), and other treatment (including experimental treatments and 
immunotherapy).
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of these treatment combinations was assessed in a separate model. Results are presented as 
adjusted odds ratio (95% confidence interval). 
† Hospital volume (i.e. the number of unique cases treated at the treating facility) was catego-
rized in quartiles (Q1-Q4). 
‡ NSCLC is subdivided into three distinct histology categories, while SCLC is considered a 
separate disease category.
§ As clinical subgroups are defined by stage and lung cancer type, different stages are used as 
the reference category across the different models.
All lung cancer cases in the National Cancer Database diagnosed in years 2010-2014
N = 770,754
N = 769,112
N = 698,659
Selected ICD-0-3 malignant behavior codes
(n = 1,642 excluded)
Excluded stages 0, occult, unknown, and cases without a known 
stage subcategory (e.g. stage I rather than IA) 
(n = 70,453 excluded)
Selected cases staged with AJCC 7th edition 
(n = 661 excluded)
N = 697,998
N = 540,523
N = 539,075
Excluded cases with a history of multiple primary tumors, of which 
lung cancer wasn’t the first
(n = 157,475 excluded)
Excluded cases where data completeness could not be guaranteed 
by treatment facility (reference date after date of diagnosis) 
(n = 1,448 excluded)
N = 478,062
Excluded cases diagnosed at the reporting facility that did not 
receive any treatment at that facility 
(n = 61,013 excluded)
N = 456,073
Excluded cases with unknown treatment 
(n = 21,989  excluded)
Final selection of cases
N = 441,812
Selected cases with less than 4 months (144 days) between 
diagnosis and onset of treatment  
(n =  14,261 excluded)
Supplementary Figure E1: Selection of lung cancer cases from the National Cancer Database.
Abbreviations: ICD-0-3 = International Classification of Diseases for Oncology 3rd Edition; AJCC = 
American Joint Committee on Cancer.
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Abstract
Background
We aimed to assess the uptake of minimally invasive surgery (MIS) and stereotactic 
body radiation therapy (SBRT) among early-stage (stage IA-IIB) non-small cell lung 
cancer (NSCLC) cases in the USA, and the rate of conversions from MIS to open surgery.
Materials and Methods
Data were obtained from the US National Cancer Database, a nationwide facility-
based cancer registry capturing up to 70% of incident cancer cases in the USA. We 
included cases diagnosed with early-stage (clinical stages IA-IIB) NSCLC between 
2010 and 2014. In an ecological analysis, we assessed changes in treatment by year of 
diagnosis. Among surgically treated cases, we assessed the uptake of MIS and whether 
conversion to open surgery took place. For cases that received thoracic radiotherapy, 
we assessed the uptake of SBRT.
Results
Among 117,370 selected cases, radiotherapy use increased 3.4 percentage-points 
between 2010 and 2014 (p<0.0001). Surgical treatments decreased 3.5 percentage-points 
(p<0.0001). Rates of non-treatment remained stable (range: 10.0-10.6% [p=0.4066]). 
Among surgically treated stage IA cases, uptake of MIS increased from 28.7% (95%CI: 
27.8-29.7) in 2010 to 48.6% (95%CI:47.6-49.6) in 2014 (p<0.0001), while conversions 
decreased from 17.0% (95%CI: 15.6-18.6) in 2010 to 9.1% (95%CI: 8.3-10.0) in 2014 (p<0.0001). 
MIS uptake among stages IB-IIB was lower and conversion rates were higher, but time 
trends were similar. Uptake of SBRT among stage IA receiving thoracic radiotherapy 
increased from 53.4% (95%CI:51.2-55.6) in 2010 to 73.0% (95%CI:71.4-74.6) in 2014 (p<0.0001). 
SBRT uptake among stage IB increased from 32.5% (95%CI:29.9-35.2) in 2010 to 48.2% 
(95%CI:45.6-50.8) in 2014 (p<0.0001).
Conclusion
Between 2010 and 2014, uptake of MIS and SBRT among early-stage NSCLC significantly 
increased, while the rate of conversions to open surgery significantly decreased. 
Continuing these trends may contribute to improving patient care, in particular 
with the expected increase in early-stages due to the implementation of lung cancer 
screening.
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Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide.1,2 The majority of 
lung cancer cases are non-small cell lung cancer (NSCLC).3 Currently, most NSCLC cases 
are diagnosed with metastatic disease,4 in which case curative treatment is usually 
not possible.5 However, the number of cases diagnosed with potentially curative early-
stage disease is expected to increase in upcoming years6 due to the ongoing (USA) and 
considered (EU and UK) implementation of lung cancer screening.7-9
While surgical resection is still standard of care for early-stage NSCLC, the preferred 
surgical approach has shifted from thoracotomy to minimally invasive surgery (MIS). 
MIS includes video-assisted thoracoscopic surgery (VATS) and, more recently, robotic-
assisted thoracic surgery (RATS).5 MIS is associated with less postoperative pain, shorter 
hospital stay, less pulmonary complications, and improved quality of life compared 
with thoracotomy, without compromising perioperative mortality or short-term 
survival.10-13 Although a recent analysis suggests that the uptake of VATS among 
patients with lung cancer in the US Veterans Affairs is increasing,14 the generalizability 
of these findings to early-stage NSCLC cases in the general US population remains 
unknown. In addition, the Veterans Affairs analysis did not include cases treated with 
RATS. Also, the current rate of conversions from MIS to open surgery and whether 
this rate has changed with the increased uptake of MIS is unclear.
Some patients with early-stage NSCLC are unfit for surgery due to comorbidity 
or may prefer not to undergo surgery for non-medical reasons. For those patients, 
stereotactic body radiation therapy (SBRT) is now recommended as an alternative 
standard of care.5 SBRT concentrates a high dose of radiotherapy on a small target 
volume using only a few fractions. In medically inoperable patients with early-
stage NSCLC, SBRT provides local tumor control rates of up to 90% with moderate 
toxicity.15,16 A previous analysis suggested that the uptake of SBRT in the USA could 
still be lagging.17
The degree of uptake of these therapies is topical because the effectiveness of 
the recent recommendations and plans for lung cancer screening will depend on 
optimal treatment of early-stage lung cancer. Therefore, we aimed to assess the 
uptake of MIS and SBRT among early-stage NSCLC cases in the USA, as well as the rate 
of conversions from MIS to open surgery. We hypothesized that the uptake of MIS 
and SBRT in the USA increases over time. This hypothesis was tested in an ecological 
analysis of secular trends in the facility-based US National Cancer Database (NCDB).
Methods
Data
We extracted all individual-level records from the NCDB of persons diagnosed with 
early-stage (i.e. clinical stages IA, IB, IIA, and IIB) NSCLC between 2010 and 2014. The 
NCDB, established in 1989, is a nationwide, facility-based, comprehensive clinical 
surveillance resource oncology data set that currently captures 70% of all newly 
diagnosed malignancies in the USA annually, from more than 1,500 affiliated facilities. 
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To ensure the accuracy of treatment data we excluded the following groups: non-
malignant cases; cases not staged using the American Joint Commission on Cancer 
(AJCC) seventh edition system;18 cases with a history of multiple primary tumors of 
which lung cancer was not the first; cases diagnosed before the date from which the 
reporting facility guarantees accuracy of the data; cases that were diagnosed at the 
reporting facility but received therapy elsewhere; cases with more than 4 months 
(i.e. 122 days) between diagnosis and onset of treatment, and cases for which it 
was unknown whether any treatment was received. These exclusion criteria are in 
concordance with NCDB guidelines and with a previous investigation of NCDB data 
conducted by our group.17
Statistical analysis
We assessed the proportion of cases that received surgery, radiotherapy, and no 
therapy as first course treatment by clinical stage and by year of diagnosis. Among 
surgically treated cases, we assessed whether the planned approach was MIS (which 
includes VATS and RATS), and whether conversion to open surgery took place. If a 
patient received multiple surgeries, the NCDB records the surgical approach of the 
most invasive and definitive surgical treatment. In addition, we assessed the extent 
of resection (sublobar, lobectomy or bilobectomy, pneumonectomy, or other; see 
Supplementary Methods for coding). Because the extent of disease may affect the 
technical difficulty of performing MIS, time trends in the uptake of MIS and the rate 
of conversions were assessed by clinical stage and by extent of resection.
For cases that received radiotherapy, we assessed the radiation target (thoracic vs 
non-thoracic). For cases with a thoracic radiation target, we further assessed whether 
SBRT or another radiation modality was used. In accordance with a previous report we 
defined SBRT as thoracic radiotherapy with a total radiation dose of at least 45 Gray 
over five fractions or less.17 Because the extent of disease may affect the feasibility of 
SBRT, time trends in the uptake of SBRT were assessed by clinical stage.
Trends were formally tested using χ2 trend tests. Exact binomial 95% CIs were 
calculated for proportions. All analyses were performed using R software V.3.6.1.19 This 
analysis of NCDB data was deemed exempt by the Institutional Review Board at the 
University of Michigan.
Sensitivity analyses
If the surgical approach was unknown we assumed that MIS had not taken place. 
Similarly, we assumed that SBRT was not used if the radiation modality was unknown. 
In a sensitivity analysis, we excluded those cases with missing data on either of these 
variables. 
A second sensitivity analysis assessed whether time trends in the uptake of MIS 
and SBRT differed by sex and by age.
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Patient and public involvement statement
Patients or the public were not involved in the design, or conduct, or reporting, or 
dissemination plans of our research.
Results
Patient characteristics
We identified records for 209,627 cases diagnosed with early-stage (i.e. clinical stages 
IA, IB, IIA, and IIB) NSCLC between 2010 and 2014. After exclusions, 117,370 cases were 
selected for analysis (see Figure 1). Among the selected cases, 55,248 (47.1%) were male. 
Median age at diagnosis was 70 years (IQR: 62-77 years). Clinical stage at diagnosis was 
IA for 61,123 cases (52.1%), IB for 26,049 cases (22.2%), IIA for 15,898 cases (13.5%), and IIB 
for 14,300 cases (12.2%).
General treatment patterns
Table 1 presents general treatment patterns by clinical stage at diagnosis and by 
year of diagnosis. Overall, the percentage of early-stage NSCLC cases receiving surgery 
decreased with advancing stage at diagnosis, from 72.2% (95%CI: 71.9-72.6) among 
stage IA to 48.3% (95%CI: 47.5-49.1) among stage IIB (-23.9 percentage-points; p< 0.0001). 
Conversely, the percentage receiving radiotherapy increased with advancing stage 
(from 22.4% [95%CI: 22.1-22.7] among stage IA to 44.6% [95%CI: 43.8-45.4] among stage 
IIB [+22.2 percentage-points; p< 0.0001]). Also, the percentage of cases receiving no 
treatment increased from 7.6% (95%CI: 7.4-7.9) among stage IA to 15.5% (95%CI: 15.0-16.1) 
among stage IIB (+7.9 percentage-points; p< 0.0001). 
Between 2010 and 2014, the number of early-stage NSCLC cases that received 
surgery decreased by 3.5 percentage-points (p< 0.0001), from 67.9% (95%CI: 67.3-68.5) in 
2010 to 64.4% (95%CI: 63.8-65) in 2014. The number of cases that received radiotherapy 
increased by 3.4 percentage-points (p<0.0001), from 25.6% (95%CI: 25.0-26.2) in 2010 
to 29.0 (95%CI: 28.4-29.5) in 2014. The percentage of cases that did not receive any 
treatment varied between 10.0% (95%CI: 9.7-10.4) and 10.6% (95%CI: 10.2-11.0) across 
years 2010-2014, with no particular time trend (p=0.4066).
Supporting Table 1 shows the extent of resection among surgically treated cases by 
clinical stage and year of diagnosis. Overall, 18.1% (95%CI: 17.8-18.4) received a sublobar 
resection, 77.0% (95%CI: 76.7-77.3) received a lobectomy or a bilobectomy, and 3.7% 
(95%CI: 3.6-3.8) received a pneumonectomy. Only minor changes in the distribution 
of surgical extent occurred over time. However, the percentage receiving sublobar 
resection decreased from 24.3% (95%CI: 23.9-24.7) among stage IA to 9.4% (95%CI: 8.8-
10.2) among stage IB (-14.9 percentage-points; p<0.0001). Conversely, the percentage 
receiving pneumonectomy increased with advancing stage, from 0.8% (95%CI: 0.7-0.9) 
among stage IA to 13.2% (95%CI: 12.4-14.0) among stage IIB (+12.4%; p<0.0001).
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Figure 1: Flow chart of case selection. Abbreviations: ICD-0-3 = International Classification of 
Diseases for Oncology, third edition; AJCC = American Joint Committee on Cancer.
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Table 1: Treatment patterns among early-stage non-small cell lung cancer cases by clinical 
stage at diagnosis and by year of diagnosis.
Surgery 
n (% [95% CI]) a
Radiotherapy 
n (% [95% CI])
No therapy
n (% [95% CI])
Stage
  IA 44,160 
(72.2 [71.9-72.6]) b
13,690 
(22.4 [22.1-22.7]) b
4,673 
(7.6 [7.4-7.9]) b
  IB 16,902 
(64.9 [64.3-65.5])
7,043 
(27.0 [26.5-27.6])
3,029 
(11.6 [11.2-12.0])
  IIA 9,388 
(59.1 [58.3-59.8])
5,288 
(33.3 [32.5-34.0])
2,201 
(13.8 [13.3-14.4])
  IIB 6,907 
(48.3 [47.5-49.1])
6,376 
(44.6 [43.8-45.4])
2,223 
(15.5 [15.0-16.1])
Year
  2010 15,016 
(67.9 [67.3-68.5]) b
5,659 
(25.6 [25.0-26.2]) b
2,308 
(10.4 [10.0-10.8]) c
  2011 15,194 
(67.3 [66.7-67.9])
6,044 
(26.8 [26.2-27.4])
2,287 
(10.1 [9.7-10.5])
  2012 15,385 
(65.8 [65.1-66.4])
6,465 
(27.6 [27.1-28.2])
2,487 
(10.6 [10.2-11.0])
  2013 15,827 
(64.5 [63.9-65.1])
7,062 
(28.8 [28.2-29.3])
2,562 
(10.4 [10.1-10.8])
  2014 15,935 
(64.4 [63.8-65.0])
7,167 
(29.0 [28.4-29.5])
2,482 
(10.0 [9.7-10.4])
a Patients could receive multiple treatments. Hence, the percentages receiving surgery, 
radiotherapy and no therapy do not add up to 100%.
b Statistically significant trend (p<0.0001). 
c Statistically non-significant trend (p=0.4066).
Uptake of MIS and rate of conversions
Figure 2A shows the trend in uptake of MIS by clinical stage among those treated 
surgically between 2010 and 2014. Among surgically treated stage IA cases (n=44,160), 
the uptake of MIS increased by 19.9 percentage-points, from 28.7% (95%CI: 27.8-29.7) in 
2010 to 48.6% (95%CI: 47.6-49.6) in 2014. Although the percentage receiving MIS in 2010 
was lower for stages IB-IIB than for stage IA (22.9% [95%CI: 21.5-24.3] among stage IB, 
20.0% [95%CI: 18.2-21.8] among stage IIA, 15.7% [95%CI: 13.8-17.8] among stage IIB), the 
increase over time was similar (+18.5, +15.1, and +16.8 percentage-points, respectively). 
Whereas the uptake of MIS increased over time, the rate of conversions to open 
surgery among these cases decreased. For stage IA, the rate of conversions decreased 
by 7.9 percentage-points, from 17.0% (95%CI: 15.6-18.6) in 2010 to 9.1% (95%CI: 8.3-10.0) in 
2014  (Figure 2B). The rate of conversions was higher for stages IB-IIB compared with 
stage IA in 2010, but the decreases over time were similar (range across stages: -7.0 to 
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-10.6 percentage-points). All stage-specific trends in the uptake of MIS and the rate of 
conversions to open surgery were statistically significant (p<0.0001).
Figure 2: Uptake of minimally invasive surgery among early-stage non-small cell lung cancer 
cases between 2010 and 2014 by clinical stage at diagnosis. (A) The percentage of lung cancer 
surgeries that were started as minimally invasive surgery between 2010 and 2014 by clinical 
stage at diagnosis. (B) The percentage of lung cancer surgeries which started as minimally 
invasive surgery that were converted to open surgery between 2010 and 2014, by clinical stage 
at diagnosis. 
Time trends in the uptake of MIS and the rate of conversions to open surgery by 
extent of resection are shown in Figure 3. In 2010, the uptake of MIS was highest 
among those receiving a sublobar resection (33.6% [95%CI: 31.8-35.4], followed by 
lobectomy or bilobectomy (23.6% [95%CI: 22.8-24.4]) and pneumonectomy (11.2% [95%CI: 
8.8-14.0]). Between 2010 and 2014, uptake of MIS increased for all extents of resection (for 
sublobar resection: +20.8 percentage-points [p<0.0001]; lobectomy or bilobectomy: +19.0 
percentage-points [p<0.0001]; for pneumonectomy: +8.9 percentage-points [p=0.0002]). 
In 2010, rates of conversions were highest for those receiving pneumonectomy (36.8% 
[95%CI: 25.4-49.3]), followed by those receiving lobectomy or bilobectomy (20.9% [95%CI: 
19.4-22.5]), and finally those who received a sublobar resection (11.8% [95%CI: 9.7-14.1]). 
The rate of conversions decreased over time for sublobar resections (-5.4 percentage-
points; p<0.0001) and for lobectomy or bilobectomy (-9.4 percentage-points; p<0.0001), 
but not for pneumonectomy (p=0.5813).
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Figure 3: Uptake of minimally invasive surgery among early-stage non-small cell lung cancer 
cases between 2010 and 2014 by extent of resection. (A) The percentage of lung cancer surgeries 
that were started as minimally invasive surgery between 2010 and 2014 by extent of resection. 
(B) The percentage of lung cancer surgeries which started as minimally invasive surgery that 
were converted to open surgery between 2010 and 2014, by extent of resection. Overall, only 1.3% 
of surgically treated cases received surgery of “other” extent. Therefore, time trends were not 
assessed for this category.  
Uptake of SBRT
Among early-stage NSCLC cases treated with radiotherapy, 95.5% (95%CI: 95.3-95.7) 
received thoracic radiotherapy. Figure 4 shows the uptake of SBRT among these 
cases by clinical stage. Among the 13,252 stage IA NSCLC cases that received thoracic 
radiotherapy, the use of SBRT increased from 53.4% (95%CI: 51.2-55.6) in 2010 to 73.0% 
(95%CI: 71.4-74.6) in 2014 (+19.6 percentage-points). The uptake of SBRT among the 6,729 
stage IB NSCLC cases that received thoracic radiotherapy increased by 15.7 percentage-
points, from 32.5% (95%CI: 29.9-35.2) in 2010 to 48.2% (95%CI: 45.6-50.8) in 2014. However, 
during the same period the percentage receiving SBRT remained low among the 4,962 
stage IIA cases and the 6,005 stage IIB cases that received thoracic radiotherapy. The 
uptake of SBRT among stage IIA was 5.5% (95%CI: 4.2-7.2) in 2010 and 10.5% (95%CI: 
8.7-12.6) in 2014 (+5.0 percentage-points). Among stage IIB, the uptake of SBRT was 
4.8% (95%CI: 3.7-6.2) in 2010 and 9.6% (95%CI: 8.0-11.4) in 2014 (+4.8 percentage-points). 
All stage-specific time trends in the uptake of SBRT were statistically significant 
(p<0.0001).
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Figure 4: Uptake of stereotactic body radiation therapy among early-stage non-small cell lung 
cancer cases treated with thoracic radiotherapy between 2010 and 2014 by clinical stage at 
diagnosis.
Sensitivity analyses
Data on the surgical approach or radiation modality were missing for 5,089 cases. After 
excluding those cases, the uptake of MIS and SBRT were higher, although stage-specific 
time trends remained similar (see Supporting Figures 1 and 2). For example, among 
42,773 surgically treated stage IA cases, the uptake of MIS increased by 20.6 percentage-
points, from 29.2% (95%CI: 28.2-30.2) in 2010 to 49.8% (95%CI: 48.8-50.8) in 2014 (p<0.0001). 
The rate of conversions to open surgery among these stage IA cases decreased from 
17.1 (95%CI: 15.6-18.6) in 2010 to 9.1% (95%CI: 8.3-10.0) in 2014 (-8.0 percentage-points; 
p<0.0001). Among 12,241 stage IA cases that received thoracic radiotherapy, the uptake 
of SBRT increased from 59.0% (95%CI: 56.7-61.2) in 2010 to 77.8% (95%CI: 76.3-79.3) in 2014 
(+18.8 percentage-points; p<0.0001).
The uptake of MIS and SBRT increased over time for both sexes and all age groups 
(see Supporting Figures 3-6). In addition, the rate of conversions to open surgery 
decreased over time for both sexes and all age groups. The uptake of VATS and SBRT 
were slightly higher among women than among men, whereas the rate of conversions 
was slightly lower. For example, the uptake of VATS among men in 2010 was 23.5% 
(95%CI: 22.5-24.5, compared with 26.6% among women (95%CI: 25.7-27.6). The uptake 
of SBRT was notably higher for more advanced ages (see Supporting Figure 6). For 
example, the uptake of SBRT in 2010 was 5.3% (95%CI: 2.1-10.5) among those younger 
than 50 years, compared with 38.8% (95%CI: 36.2-41.5) among those older than 80 years.
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Discussion
General treatment patterns
Patterns of care indicate that most early-stage NSCLC cases receive surgery and/or 
radiotherapy. However, whereas the percentage receiving radiotherapy increased with 
advancing stage, the percentage receiving surgery decreased with advancing stage. 
This likely reflects the increasing difficulty of performing more extensive surgical 
resections, even among those with stage IA-IIB disease.
Uptake of MIS and rate of conversions
The use of MIS among surgically treated cases increased over time, up to 48.6% among 
stage IA cases in 2014. This increasing uptake of MIS was robust across the different 
conducted sensitivity analyses. Our findings are similar to those in a recent study, 
in which 44.5% of wedge resections and lobectomies among patients with non-
metastatic lung cancer in Veterans Affairs hospitals between 2012 and 2015 were 
conducted using VATS.14 The European Thoracic Surgery Database, which collects 
data from 170 hospitals across 22 European countries, reported that the uptake of 
VATS lobectomies increased from 5.4% in 2007–2011 to 29.3% in 2012–2015.20 Thus, it 
appears that the uptake of MIS in Europe is also increasing, although its uptake may 
lag compared with the USA.20 In the UK, the uptake of MIS is similar to the USA; 
increasing from 53.4% in 2016 to 55.8% in 2017.21 Rates of conversions were similar 
in the UK (10.6% of lobectomy and bilobectomy procedures in 2017), compared with 
our US-based study (11.5% of lobectomy and bilobectomy procedures in 2014).21 The 
increasing use of MIS may particularly benefit patients with a reduced lung function 
or cardiopulmonary reserve, in whom this approach has been shown to reduce rates 
of pulmonary morbidity compared with open surgery.22 
While we confirm that the uptake of MIS is increasing, we add that the rate 
of conversions to open surgery decreased during the same period. This may reflect 
increasing experience of thoracic surgeons.23 Whereas the uptake of MIS decreased 
with advancing stage, the rate of conversions increased with advancing stage. This 
finding may be partly explained by the decreasing use of sublobar resections and the 
increasing use of pneumonectomy with advancing stage. Indeed, the uptake of MIS was 
lower for more extensive resections (e.g. pneumonectomy < (bi)lobectomy < sublobar 
resection). These observations may reflect the technical difficulty of performing more 
extensive resections by MIS.
In the USA, annual lung cancer screening has been recommended for high-risk 
individuals.7  It has been estimated that the full-scale implementation of lung cancer 
screening in the USA will shift the percentage of stage I diagnoses in the general 
population (which includes individuals that are not eligible for screening) from 22.2% 
to 30.6%.6 This will increase demand for lung cancer surgery in the USA by up to 
37.0%.6 If screening is to be effective, these cases should receive optimal treatment 
by MIS resection in a high-volume hospital.24,25 Therefore, we expect that the uptake 
of MIS in the USA will continue to increase in coming years. In Europe, lung cancer 
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screening has not yet been implemented. Nevertheless, several European countries 
have expressed the intention to start planning for the implementation of lung cancer 
screening.8 Therefore, we expect that the uptake of MIS lung resections will continue 
to increase in Europe as well.
Uptake of SBRT
Among patients with stage IA-IB NSCLC, the uptake of SBRT increased substantially 
between 2010 and 2014. This finding was robust to the different sensitivity analyses. 
The increasing uptake of SBRT may particularly benefit patients with lung cancer with 
comorbidities, which can increase the risks related to surgery. In the Netherlands, 
Palma and colleagues demonstrated that an increased use of SBRT among patients 
with stage I NSCLC led to fewer untreated elderly patients.26 In our US-based study, 
the overall percentage of early-stage patients that received radiotherapy (both SBRT 
and conventional radiotherapy) also increased (by 3.4 percentage-points). However, 
we did not find a corresponding reduction in the rate of non-treatment. Instead, we 
found that the percentage of early-stage cases that received surgery decreased by 
3.5 percentage-points. This suggests a possible shift from operable patients towards 
medically inoperable patients (e.g. due to comorbidities), which should be further 
investigated in future studies. The constant non-treatment rate of approximately 
10% suggests possibilities for a further increase in the use of radiotherapy, and in 
particular SBRT, among early-stage cases that would otherwise not receive any 
treatment.
Currently, SBRT is only recommended for medically inoperable early-stage NSCLC 
cases. However, some studies have suggested that SBRT may be feasible in medically 
operable patients,27 which could increase the future uptake of SBRT. Because lung 
cancer screening is only recommended for patients fit to undergo curative lung 
surgery,7 it’s continued implementation may not directly increase the future use of 
SBRT. However, in practice it may be difficult to assess fitness for surgery prior to 
screening. Therefore, the increase in early-stage cases due to screening may still lead 
to a further increase in the use of SBRT. Consequently, it is likely that the uptake of 
SBRT will continue to increase.
The uptake of SBRT was modest but present among stages IIA and IIB. This is 
most likely due to concerns about either lymph node involvement, tumor size, or 
size of the irradiated field. SBRT is indeed most appropriate for tumors smaller than 
5 cm (which encompasses stage I-IIA). Nevertheless, SBRT may also be used for larger 
isolated tumors (T1-3,N0,M0).5,28 
Strengths and limitations
The most important strength of this current analysis is the use of the NCDB data set, 
which captures treatment data on 70% of incident cancer cases in the USA. Although 
this database is facility-based, an earlier report found no major differences in the 
distributions of sex, age, race or ethnicity, health insurance status, histology, and 
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stage between lung cancer cases in the NCDB and the population-based Surveillance, 
Epidemiology, and End Results data set.17 Therefore, in contrast to previous reports, 
the findings of our study are likely representative for the general US population.14 
A possible limitation of our study is the lack of clinical information in the NCDB, 
such as performance status. Therefore, we could not determine whether cases were 
medically operable or not. Future research is necessary to determine whether cases 
that do not receive any treatment may have been medically eligible for surgery or 
SBRT.
A second possible limitation of using cancer registry data is that coding practices 
may change over time. However, the AJCC seventh edition staging manual was almost 
exclusively used during the study time period, which limits changes in study eligibility 
over time. In addition, no changes occurred in the coding of any of the outcome 
variables (e.g. surgical approach, surgical extent, or radiation modality).
A third limitation is that we did not assess whether the increasing use of MIS 
and SBRT affected patient outcomes. The NCDB does not include patient-reported 
outcomes, such as quality of life. In addition, we feel that a prospective randomized 
trial is the best method to provide an unbiased comparison of oncological outcomes 
across treatment modalities. Recently, the prospective VIdeo-assisted thoracoscopic 
lobectomy versus conventional Open LobEcTomy for lung cancer trial confirmed that 
that VATS lobectomy is associated with significantly lower in-hospital complications 
and a shorter length of stay than open lobectomy, without compromising oncological 
outcomes.29 Another recent prospective randomized controlled trial, which included 
inoperable stage I NSCLC cases, showed that SBRT provides superior tumor control 
compared with standard radiotherapy, without increasing toxicity.30 These studies 
indicate that the increasing uptake of MIS and SBRT in the USA will likely provide 
clinical benefit to patients with early-stage NSCLC.
Conclusions
In conclusion, patterns of care show that surgeons in the USA have been increasingly 
using MIS to treat early-stage NSCLC while the rate of conversions decreased. SBRT is 
also increasingly used. The increasing uptake of MIS and SBRT may particularly benefit 
patients with lung cancer at higher operative risk. Nevertheless, the increasing use of 
radiotherapy does not seem to coincide with a reduction in the percentage of cases 
that do not receive any treatment. Therefore, there may be room for an additional 
increase in the use of radiotherapy, and in particular SBRT, among cases that would 
otherwise receive no treatment. Continuing the increasing trends in uptake of MIS 
and SBRT may contribute to improving overall patient care, in particular with the 
expected increase in early-stage lung cancer due to the implementation of lung 
cancer screening.
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Deriving surgical extent variable
Original code 
RX_SUMM_
SURG_PRIM_SITE
Meaning Recode
0 None; no surgery of primary site; 
autopsy ONLY      
No surgery
20 Excision or resection of less than 
one lobe, NOS
Sublobar resection
21 Wedge resection Sublobar resection
22 Segmental resection, including 
lingulectomy
Sublobar resection
23 Excision, NOS Sublobar resection
24 Laser excision Sublobar resection
25 Bronchial sleeve resection ONLY Sublobar resection
30 Resection of lobe or bilobectomy, 
but less than the whole lung 
(partial pneumonectomy, NOS)
Lobectomy or bilobectomy
33 Lobectomy WITH mediastinal 
lymph node dissection
Lobectomy or bilobectomy
45 Lobe or bilobectomy extended, 
NOS
Lobectomy or bilobectomy
46 WITH chest wall Lobectomy or bilobectomy
47 WITH pericardium Lobectomy or bilobectomy
48 WITH diaphragm Lobectomy or bilobectomy
55 Pneumonectomy, NOS Pneumonectomy
56 WITH mediastinal lymph 
node dissection (radical 
pneumonectomy)
Pneumonectomy
65 Extended pneumonectomy Pneumonectomy
66 Extended pneumonectomy plus 
pleura or diaphragm
Pneumonectomy
70 Extended radical 
pneumonectomy
Pneumonectomy
12 Laser ablation or cryosurgery Other
13 Electrocautery; fulguration 
(includes use of hot forceps for 
tumor destruction)
Other
15 Local tumor destruction, NOS Other
19 Local tumor destruction or 
excision, NOS
Other
80 Resection of lung, NOS Other
90 Surgery, NOS Other
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Supporting Table 1: Extent of resection among early-stage non-small cell lung cancer cases by 
clinical stage at diagnosis and by year of diagnosis.
Sublobar
n (% [95% CI])
Lobectomy or 
bilobectomy
n (% [95% CI])
Pneumonectomy
n (% [95% CI])
Other
n (% [95% CI]) a
Stage
  IA 10727 
(24.3 [23.9-24.7]) b
32569 
(73.8 [73.3-74.2]) b
367 
(0.8 [0.7-0.9]) b
497 
(1.1 [1-1.2]) b
  IB 1903 
(11.3 [10.8-11.7])
14110 
(83.5 [82.9-84])
683 
(4 [3.7-4.3])
206 
(1.2 [1.1-1.4])
  IIA 714 
(7.6 [7.1-8.2])
7679 
(81.8 [81-82.6])
894 
(9.5 [8.9-10.1])
101 
(1.1 [0.9-1.3])
  IIB 652 
(9.4 [8.8-10.2])
5180 
(75 [74-76])
910 
(13.2 [12.4-14])
165 
(2.4 [2-2.8])
Year
  2010 2624 
(17.5 [16.9-18.1]) c
11550 
(76.9 [76.2-77.6]) e
605 
(4 [3.7-4.4]) d
237 
(1.6 [1.4-1.8]) b
  2011 2776 
(18.3 [17.7-18.9])
11611 
(76.4 [75.7-77.1])
579 
(3.8 [3.5-4.1])
228 
(1.5 [1.3-1.7])
  2012 2765 
(18 [17.4-18.6])
11851 
(77 [76.4-77.7])
595 
(3.9 [3.6-4.2])
174 
(1.1 [1-1.3])
  2013 2875 
(18.2 [17.6-18.8])
12219 
(77.2 [76.5-77.9])
562 
(3.6 [3.3-3.9])
171 
(1.1 [0.9-1.3])
  2014 2956 
(18.6 [17.9-19.2])
12307 
(77.2 [76.6-77.9]) 
513 
(3.2 [3-3.5])
159 
(1 [0.8-1.2])
Overall 13996 
(18.1 [17.8-18.4])
59538 
(77 [76.7-77.3])
2854 
(3.7 [3.6-3.8])
969 
(1.3 [1.2-1.3])
a As the percentage of surgically treated cases that received an “other” type of resection was 
low, time trends in the uptake of MIS and the rate of conversions were not further analyzed 
for this subgroup.
b Statistically significant trend (p<0.0001).
c Statistically significant trend (p=0.0370).
d Statistically significant trend (p=0.0001).
e Statistically non-significant trend (p=0.1837).
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Supporting Figure 1: Uptake of minimally invasive surgery among early-stage non-small cell 
lung cancer cases treated surgically between 2010-2014 by clinical stage at diagnosis. In this 
sensitivity analysis, cases with missing data on surgical approach or missing data on radiation 
modality were excluded. Panel A shows the percentage of lung cancer surgeries which started 
as minimally invasive surgery between 2010-2014 by clinical stage at diagnosis. Panel B shows 
the percentage of lung cancer surgeries which started as minimally invasive surgery that were 
converted to open surgery between 2010-2014, by clinical stage at diagnosis. 
Supporting Figure 2: Uptake of stereotactic body radiation therapy among early-stage non-
small cell lung cancer cases treated with thoracic radiotherapy between 2010-2014 by clinical 
stage at diagnosis. Sensitivity analysis where cases with missing data on surgical approach or 
missing data on radiation modality were excluded.
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Supporting Figure 3: Uptake of minimally invasive surgery among early-stage non-small cell 
lung cancer cases treated surgically between 2010-2014 by sex. Panel A shows the percentage 
of lung cancer surgeries that were started as minimally invasive surgery between 2010-2014 by 
sex. Panel B shows the percentage of lung cancer surgeries which started as minimally invasive 
surgery that were converted to open surgery between 2010-2014, by sex.
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Supporting Figure 4: Uptake of stereotactic body radiation therapy among early-stage non-small cell 
lung cancer cases treated with thoracic radiotherapy between 2010-2014 by sex 
 
 
 
Supporting Figure 4: Uptake of stereotactic body radiation therapy among early-stage non-
small cell lung cancer cases treated with thoracic radiotherapy between 2010-2014 by sex.
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Supporting Figure 5: Uptake of minimally invasive surgery among early-stage non-small cell lung 
cancer cases treated surgically between 2010-2014 by age 
 
 
Panel A shows the percentage of lung cancer surgeries that were started as minimally invasive surgery between 
2010-2014 by age. Panel B shows the percentage of lung cancer surgeries which started as minimally invasive 
surgery that were converted to open surgery between 2010-2014, by age. 
 
Supporting Figu  5: Uptake of minimally invasiv  surgery among early-stage non-small cell 
lung cancer cases treated surgically between 2010-2014 by age.Panel A shows the percentage of 
lung cancer surgeries that were started as minimally invasive surgery between 2010-2014 by 
age. Panel B shows the percentage of lung cancer surgeries which started as minimally invasive 
surgery that were converted to open surgery between 2010-2014, by age.
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Supporting Figure 6: Uptake of stereotactic body radiation therapy among early-stage non-
small cell lung cancer cases treated with thoracic radiotherapy between 2010-2014 by age.
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Abstract
Background
Full-scale implementation of lung cancer screening in the United States will increase 
detection of early stages. This study was aimed at assessing the capacity required for 
treating those cancers.
Methods
A well-established microsimulation model was extended with treatment data from 
the National Cancer Database. We assessed how treatment demand would change 
when implementing lung cancer screening in 2018. Three policies were assessed: 1) 
annual screening of current smokers and former smokers who quit fewer than 15 
years ago, aged 55 to 80 years, with a smoking history of at least 30 pack-years (US 
Preventive Services Task Force [USPSTF] recommendations); 2) annual screening 
of current smokers and former smokers who quit fewer than 15 years ago, aged 55 
to 77 years, with a smoking history of at least 30 pack-years (Centers for Medicare 
and Medicaid Services [CMS] recommendations); and 3) annual screening of current 
smokers and former smokers who quit fewer than 10 years ago, aged 55 to 75 years, 
with a smoking history of at least 40 pack-years (the most cost-effective policy in 
Ontario [Ontario]). The base-case screening adherence was a constant 50%. Sensitivity 
analyses assessed other adherence levels, including a linear buildup to 50% between 
2018 and 2027.
Results 
The USPSTF policy would require 37.0% more lung cancer surgeries in 2015-2040 than 
no screening, 2.2% less radiotherapy, and 5.4% less chemotherapy; 5.7% more patients 
would require any therapy. The increase in surgical demand would be 96.1% in 2018, 
46.0% in 2023, 38.3% in 2028, and 24.9% in 2040. Adherence strongly influenced results. 
By 2018, surgical demand would range from 52,619 (20% adherence) to 96,121 (80%). With 
a gradual buildup of adherence, the increase in surgical demand would be 9.6% in 2018, 
38.3% in 2023, 42.0% in 2028, and 24.4% in 2040. Results for the CMS and Ontario policies 
were similar, although the changes in comparison with no screening were smaller.
Conclusions
Full-scale implementation of lung cancer screening causes a major increase in 
surgical demand, with a peak within the first 5 years. A gradual buildup of adherence 
can spread this peak over time. Careful surgical capacity planning is essential for 
successfully implementing screening.
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Introduction
Despite decreasing incidence rates, lung cancer is still the leading cause of cancer-
related mortality in the United States.1 The National Lung Screening Trial (NLST) 
has shown that 3 annual low-dose computed tomography (LDCT) screenings for lung 
cancer can reduce lung cancer mortality by 20% in comparison with 3 annual chest 
radiography screenings.2 Since then, both the US Preventive Task Force (USPSTF)3 and 
the Centers for Medicare and Medicaid Services (CMS)4 have issued recommendations 
for LDCT screening for lung cancer. The USPSTF recommendations have been partly 
based on modeling efforts.5
The standard of care is surgery for early-stage non-small cell lung cancer (NSCLC), 
a combination of chemotherapy and radiotherapy for locally advanced NSCLC, and 
chemotherapy for advanced NSCLC.6 Consequently, early detection by lung cancer 
screening is expected to increase the demand for surgery and decrease the demand 
for radiotherapy and chemotherapy. The magnitude of this shift in treatment will 
depend on the number of screened individuals, which will decrease over time7 because 
younger birth cohorts smoke less.8
The benefits of early detection depend on the availability of adequate treatment. 
Hence, assessing the demand for treatment and planning for sufficient manpower 
are essential to successfully implementing screening. In screening programs where 
capacity (e.g., for follow-up) has been limited, program implementation has been 
done gradually to take this into account.9 Therefore, the aim of the current study was 
to project the treatment capacity required for the full-scale implementation of LDCT 
screening for lung cancer in the United States. 
Materials and methods
Simulation of lung cancer incidence rates
In this study we used the MIcrosimulation SCreening ANalysis Lung (MISCAN-
Lung) model, which simulates individual life histories in the presence and absence 
of screening to project benefits and harms of different screening policies on a 
population level. This study was deemed exempt by the Institutional Review Board 
at the University of Michigan. MISCAN-Lung has been calibrated to individual-level 
incidence and mortality data from the NLST and the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial.10,11 It accounts for differences in smoking behavior 
across birth cohorts by incorporating the National Cancer Institute’s Smoking History 
Generator.8 The model has been previously used to inform the USPSTF on the LDCT 
screening scenario with the most favorable ratio of benefits and harms for a 1950 US 
birth cohort.5 Also, it has been used to identify the most cost-effective scenario for 
Cancer Care Ontario.12 
In the current analysis, we first simulated a scenario without lung cancer 
screening. Then, we simulated 3 scenarios with screening: 1) using the USPSTF 
recommendations (i.e., annual screening of current smokers and former smokers 
who quit fewer than 15 years ago, aged 55-80 years, with a smoking history of at least 
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30 pack-years),3 2) using the CMS recommendations (i.e., stopping screening 3 years
earlier than the USPSTF scenario at the age of 77 years),4 and 3) using the most 
cost-effective policy from a recent cost-effectiveness analysis for Cancer Care Ontario 
(i.e., annual screening of current smokers and former smokers who quit fewer than 10 
years ago, aged 55-75 years, with a smoking history of at least 40 pack-years).12
The timeframe for this study was 2015-2040. We assumed that screening started 
in 2018 because the current uptake of lung cancer screening in the United States is 
low.13 We simulated the full range of birth-year cohorts from 1916 (i.e., patients aged 
99 years in 2015) through 2005 (i.e., patients aged 35 years in 2040). We assumed that 
no lung cancer occurred under the age of 35 years. We further assumed that the 
maximum age in the population was 99 years. 
Treatment capacity requirements
For each screening scenario, we adjusted the year-, sex-, age-, stage- and histology-
specific lung cancer incidence rates estimated by MISCAN-Lung to the projected 
US population by using the US Census National Population Projections.14 Therefore, 
we accounted for growth and aging of the population. Next, we obtained lung 
cancer treatment patterns from the National Cancer Database (NCDB) participant 
user file for 440,566 lung cancer cases diagnosed between years 2010 and 2014. The 
NCDB, established in 1989, is a nationwide, facility-based, comprehensive clinical 
surveillance resource oncology data set that currently captures 70% of all newly 
diagnosed malignancies in the United States annually from more than 1500 affiliated 
facilities. The NCDB is a joint project of the Commission on Cancer of the American 
College of Surgeons and the American Cancer Society. An analysis of individual-
level NCDB data was performed on site at the University of Michigan Medical School. 
Details of the analysis of the NCDB data, including case selection and data cleaning 
are provided as Supplementary Methods in the Supporting Information. In short, we 
obtained the sex-, age-, stage-, and histology-specific proportions of patients with 
lung cancer who received surgery, radiotherapy, chemotherapy, and any therapy as 
first-course treatment. Because treatment patterns among patients with lung cancer 
in the NCDB remained stable over time (see Supporting Fig. 1), the mean treatment 
proportions across years 2010-2014 were used in this study (see Supporting Table 1). 
For each scenario that we simulated, we then calculated the required lung cancer 
treatment capacity by multiplying the year-, sex-, age-, stage- and histology-specific 
Census-adjusted incidence from MISCAN-Lung with the mean sex-, age-, stage- and 
histology-specific treatment proportions from the NCDB. In the base-case analysis, 
the same treatment proportions were applied to screen-detected cases and clinically 
detected cases. Because screen-detected cases may have less comorbidity than 
clinically detected cases, a sensitivity analysis was also performed that used stage-
specific treatment proportions from the LDCT arm of the NLST for screen-detected 
cases (see Supporting Table 2).2
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Effect of adherence
On the basis of the results of an implementation study of lung cancer screening in 
the US Veterans Affairs Administration, we assumed a constant screening adherence 
of 50% for the base-case analysis.15 Another study in the Stanford Health Care system 
reported an adherence level of 60%.16 That study also reported national adherence 
rates of 69% for colorectal cancer screening, 79% for breast cancer screening, and 75% 
for cervical cancer screening in the United States. We assume that it is unlikely that 
adherence to lung cancer screening will surpass that of existing screening programs 
in the near future. Therefore, we assessed the effect of constant adherence levels of 
20%, 35%, 65%, and 80% in a sensitivity analysis. In a second sensitivity analysis, we 
assessed the effect of a linear buildup of screening adherence from 5% in 2018 to a 
plateau of 50% from 2027 onward. 
Statistical analysis
All analyses were performed with the MISCAN-Lung model and R software (version 
3.4.1).17
Results
Simulation of lung cancer incidence rates
In 2018, the projected number of screening eligible persons in the US population would 
be 11,816,790 for the USPSTF scenario, 11,258,937 for the CMS scenario, and 6,505,609 for 
the Ontario scenario (Supporting Fig. 2). By 2023, screening eligibility would decrease 
to 10,192,541 (USPSTF), 9,574,244 (CMS), and 5,548,430 (Ontario). By 2040, 4,710,017 persons 
would be eligible in the USPSTF scenario, 4,145,176 would be eligible in the CMS scenario, 
and 2,322,388 would be eligible according to the Ontario criteria.
In the absence of screening, annual Census-adjusted lung cancer incidence would 
increase to 215,392 cases by 2033 and would then gradually decrease (see Supporting Fig. 
3). The implementation in 2018 of a screening program with a constant 50% adherence 
would lead to an immediate peak in incidence in comparison with no screening. This 
peak would be highest for the USPSTF scenario (n=253,938), which would be followed 
by the CMS scenario (n=247,556) and the Ontario scenario (n=233,841). With a gradual 
buildup of adherence, this peak would be lower but last longer (Supporting Fig. 4).
Over the entire study period, the cumulative number of lung cancer cases would 
be 5,525,593 for the USPSTF scenario, 5,495,049 for the CMS scenario, 5,462,657 for the 
Ontario scenario, and 5,402,854 for the no screening scenario (Supporting Table 3).The 
proportions of screen-detected cases would be 16.8% (USPSTF), 14.3% (CMS), and 10.1% 
(Ontario). In the absence of screening,  22.2% of clinically detected cases would be 
diagnosed at stage I, 5.9% would be diagnosed at stage II, 25.5% would be diagnosed 
at stage III, and 46.3% would be diagnosed at stage IV (see Fig. 1A). Among screen-
detected cases in the USPSTF scenario, 65.6% would be diagnosed at stage I, 6.8% would 
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be diagnosed at stage II, 16.5% would be diagnosed at stage III, and 11.1% would be 
diagnosed at stage IV (see Fig. 1B). For both clinically detected and screen-detected 
cases, differences in stage distributions across scenarios were minimal. Overall,  the 
proportion of cases diagnosed at stage I would be 30.6% in the USPSTF scenario, 29.4% 
in the CMS scenario, 27.3% in the Ontario scenario, and 22.2% without screening (see 
Fig. 1C). Conversely, the proportion of cases diagnosed at stage IV would decrease 
because of screening: from 46.3% without screening to 38.9% (USPSTF), 40.0% (CMS), 
and 41.8% (Ontario).
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Figure 1. Distribution of stages at diagnosis for (A) clinically detected lung cancer cases, (B) 
screen-detected cases, and (C) all cases in the United States between 2015 and 2040 in the absence 
of low-dose computed tomography screening and for the 3 screening policies implemented in 
2018. All policies assumed a constant 50% adherence to screening. CMS indicates Centers for 
Medicare and Medicaid Services recommendations (annual screening of current smokers and 
former smokers who quit fewer than 15 years ago, aged 55-77 years, with a smoking history of 
at least 30 pack-years); Ontario, most cost-effective policy from a study for Cancer Care Ontario 
(annual screening of current smokers and former smokers who quit fewer than 10 years ago, 
aged 55-75 years, with a smoking history of at least 40 pack-years); USPSTF, US Preventive Services 
Task Force recommendations (annual screening of current smokers and former smokers who 
quit fewer than 15 years ago, aged 55-80 years, with a smoking history of at least 30 pack-years).
Treatment capacity requirements
Figure 2 shows the changes in lung cancer therapy due to the implementation of 
LDCT screening in 2018. The main change would be a large cumulative increase in 
the demand for lung cancer surgery. At the base-case adherence of 50%, the demand 
for lung cancer surgery would increase in comparison with no screening by 37.0% 
(USPSTF), 32.1% (CMS), and 22.8% (Ontario). However, the demand for radiotherapy 
would decrease by 2.2% (USPSTF), 2.6% (CMS), and 2.1% (Ontario). The demand for 
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chemotherapy would decrease by 5.4% (USPSTF), 5.1% (CMS), and 3.8% (Ontario). 
Finally, the number of patients who would receive any therapy would increase by 
5.7% (USPSTF), 4.5% (CMS), and 3.0% (Ontario).  If we assume that screen-detected 
cases would receive stage-specific treatment as reported in the NLST, the increase in 
surgery in comparison with no screening would be 55.3% (USPSTF), 46.3% (CMS), and 
32.3% (Ontario; Supporting Fig. 5). The demand for radiotherapy would decrease by 
7.4% (USPSTF), 6.8% (CMS), and 5.1% (Ontario). Chemotherapy demand would decrease 
by 4.3% (USPSTF), 4.7% (CMS), and 3.7% (Ontario). Finally, the demand for any therapy 
would increase by 7.6% (USPSTF), 5.9% (CMS), and 3.9% (Ontario).
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Figure 2. Cumulative changes in demand for lung cancer therapy in the United States be-
tween 2015 and 2040 with the implementation of low-dose computed tomography screening for 
lung cancer in 2018. The data are expressed as cumulative percentage changes in comparison 
with no screening. All policies assumed a constant 50% adherence to screening. CMS indicates 
Centers for Medicare and Medicaid Services recommendations (annual screening of current 
smokers and former smokers who quit fewer than 15 years ago, aged 55-77 years, with a smoking 
history of at least 30 pack-years); Ontario, most cost-effective policy from a study for Cancer 
Care Ontario (annual screening of current smokers and former smokers who quit fewer than 
10 years ago, aged 55-75 years, with a smoking history of at least 40 pack-years); USPSTF, US 
Preventive Services Task Force recommendations (annual screening of current smokers and 
former smokers who quit fewer than 15 years ago, aged 55-80 years, with a smoking history of 
at least 30 pack-years).
Figure 3 shows the absolute annual number of lung cancer treatments required 
between 2015 and 2040 for the base-case scenario. Supporting Table 4 additionally 
shows the percentage change in comparison with no screening in 2018, 2023, 2028, 
and 2040. In the absence of screening, the annual required number of lung cancer 
surgeries would remain relatively constant: 37,964 in 2018, 38,903 in 2023, 38,876 in 
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2028, and 34,021 in 2040. Implementing the USPSTF recommendations would increase 
demand for lung cancer surgery in comparison with no screening by 96.1% in 2018, 
46.0% in 2023, 38.3% in 2028, and 24.9% in 2040. In the CMS scenario, the increases in 
comparison with no screening would be 87.5% (2018), 41.2% (2023), 33.0% (2028), and 
19.7% (2040). Finally, implementing the Ontario recommendations would increase 
demand in comparison with no screening by 64.5% in 2018, 30.1% in 2023, 23.7% in 
2028, and 13.1% in 2040. 
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Figure 3. Absolute annual number of patients with lung cancer in the United States requiring 
(A) surgery, (B) radiotherapy, (C) chemotherapy, and (D) any therapy with the implementation 
of low-dose computed tomography screening for lung cancer in 2018. All policies assumed a 
constant 50% adherence to screening. CMS indicates Centers for Medicare and Medicaid Services 
recommendations (annual screening of current smokers and former smokers who quit fewer 
than 15 years ago, aged 55-77 years, with a smoking history of at least 30 pack-years); Ontario, 
most cost-effective policy from a study for Cancer Care Ontario (annual screening of current 
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smokers and former smokers who quit fewer than 10 years ago, aged 55-75 years, with a smoking 
history of at least 40 pack-years); USPSTF, US Preventive Services Task Force recommendations 
(annual screening of current smokers and former smokers who quit fewer than 15 years ago, 
aged 55-80 years, with a smoking history of at least 30 pack-years).
In the absence of screening, the annual number of patients with lung cancer requiring 
radiotherapy would increase from 81,802 in 2018 to 84,378 in 2023 and 85,242 in 2028, 
after which it would gradually decrease to 81,219 in 2040. Implementing the USPSTF 
recommendations would first increase demand for radiotherapy by 20.7% in 2018. 
However, demand would decrease in comparison with no screening shortly after 
that by 4.7% in 2023, 5.1% in 2028, and 3.3% in 2040. Results for the CMS and Ontario 
scenarios were similar, although differences in comparison with no screening were 
less pronounced.
We found a similar pattern for the number of cases that required chemotherapy. 
In the absence of screening, the demand for chemotherapy would be 83,221 in 2018, 
84,351 in 2023, 83,366 in 2028, and 72,586 in 2040. In the USPSTF scenario, demand would 
first increase by 18.7% in 2018, and this would be followed by relative decreases in 
comparison with to no screening of 9.0% in 2023 and 2028 and 6.2% in 2040. 
Finally, the number of lung cancer cases that would receive any therapy in the 
no screening scenario would increase from 141,751 in 2018 to 146,288 in 2023, and 147,815 
in 2028. Then, it would decrease to 137,607 in 2040. For each screening scenario, the 
number of cases receiving any therapy peaked in 2018: +36.5% (USPSTF), +32.7% (CMS), 
and +23.8% (Ontario) in comparison with no screening. The difference in comparison 
with no screening would then become smaller within the 5 years after implementation. 
For the USPSTF scenario, the increase in comparison with no screening would be 5.9% 
in 2023, 3.8% in 2028, and 2.1% in 2040. 
Effect of adherence
Figure 4 shows the effect of different levels of constant screening adherence on the 
number of patients requiring lung cancer surgery for the USPSTF scenario. In 2018, 
the required surgical capacity would be 52,619 (20% adherence), 63,623 (35%), 74,437 
(50%), 85,312 (65%), and 96,121 (80%). If we consider 20% adherence as the lower limit 
and 80% adherence as the upper limit, the number of surgeries would range from 
47,790 to 62,849 in 2023, from 46,213 to 58,752 in 2028, and from 38,259 to 45,172 in 2040. 
Results for the CMS and Ontario scenarios are shown in Supporting Figures 6 and 7, 
respectively. 
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Figure 4. Absolute annual number of patients with lung cancer in the United States requiring 
surgery with the implementation of low-dose computed tomography screening for lung cancer 
in 2018 using the US Preventive Services Task Force criteria at different constant screening 
adherence levels. USPSTF indicates US Preventive Services Task Force recommendations 
(annual screening of current smokers and former smokers who quit fewer than 15 years ago, 
aged 55-80 years, with a smoking history of at least 30 pack-years).
Figure 5 and Supporting Table 5 show the effect of a linear buildup of screening 
adherence from 5% in 2018 to a constant 50% from 2027 onward.  In 2018, the increases 
in surgical demand in comparison with no screening would be 9.6% (USPSTF), 8.7% 
(CMS), and 7.9% (Ontario). In 2023, the increases would be 38.3% (USPSTF), 34.2% (CMS), 
and 30.4% (Ontario). In 2028, the increases would be 42.0% (USPSTF), 36.1% (CMS), and 
31.6% (Ontario). Finally, in 2040, the increases would be 24.4% (USPSTF), 19.4% (CMS), 
and 16.1% (Ontario). For the USPSTF scenario, the demand for radiotherapy would 
change in comparison with no screening by +2.1% (in year 2018), +1.7% (2023), -2.9% 
(2028), and -3.4% (2024). Demand for chemotherapy would change by +1.9% (2018), -0.6% 
(2023), -6.8% (2028), and -6.2% (2040). Finally, demand for any therapy would change 
by +3.7% (2018), +9.3% (2023), +6.3% (2028), and +1.9% (2040). Changes in the demand for 
radiotherapy, chemotherapy, and any therapy for the CMS and Ontario scenarios 
were similar to the USPSTF scenario but less pronounced.
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Figure 5. Absolute annual number of patients with lung cancer in the United States requiring 
(A) surgery, (B) radiotherapy, (C) chemotherapy, and (D) any therapy with the implementation 
of low-dose computed tomography screening for lung cancer in 2018. All policies assume an 
adherence level of 5% in 2018 with an annual increase of 5 percentage points until a constant 
adherence of 50% is reached in 2027. CMS indicates Centers for Medicare and Medicaid Services 
recommendations (annual screening of current smokers and former smokers who quit fewer 
than 15 years ago, aged 55-77 years, with a smoking history of at least 30 pack-years); Ontario, 
most cost-effective policy from a study for Cancer Care Ontario (annual screening of current 
smokers and former smokers who quit fewer than 10 years ago, aged 55-75 years, with a smoking 
history of at least 40 pack-years); USPSTF, US Preventive Services Task Force recommendations 
(annual screening of current smokers and former smokers who quit fewer than 15 years ago, 
aged 55-80 years, with a smoking history of at least 30 pack-years).
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Discussion
The aim of this study was to quantify the expected treatment capacity required for 
the full-scale implementation of LDCT screening for lung cancer in the United States. 
Simulation of lung cancer incidence rates
The introduction of screening caused an immediate peak in lung cancer incidence. 
This initial peak can be explained by the lead time of screen-detected preclinical cas-
es, which would have otherwise been clinically detected later in time.
We found that screening caused a shift in the stage at diagnosis from stage IV 
to stage I. This stage shift was more pronounced for scenarios with less stringent 
eligibility criteria (i.e. stage shift for USPSTF > stage shift for CMS > stage shift for 
Ontario). This may be explained by the higher number (and proportion) of screen-
detected cases in those scenarios (see Supporting Table 3). In the NLST, which followed 
participants from 2002 to 2009, the proportion of stage I lung cancers in the LDCT arm 
was 50.0%.2 This is much higher than the 30.6% that we found in the USPSTF scenario. 
This difference may be explained by 3 factors. Most importantly, our simulation of 
the general population included all lung cancer cases, not just those detected in the 
screen-eligible population. Second, we conducted our model under assumptions 
of much lower (and perhaps more realistic) screening adherence (50%) than was 
achieved in the NLST (>90%).2 Third, our results were projected from 2015 to 2040 
and, therefore, included younger cohorts than the NLST. A previous MISCAN-Lung 
simulation of the 1950 cohort found that 48% of lung cancer cases were diagnosed at 
stage I or II when the USPSTF recommendations were implemented.5 In our current 
analysis, this proportion was only 36.9%. This may be explained by declining smoking 
trends for younger birth cohorts,8 which cause fewer individuals to be eligible for 
screening.7 These findings underline the necessity of modeling multiple birth cohorts 
when one is assessing lung cancer interventions over a time period. 
Treatment capacity requirements
We found that the implementation of lung cancer screening would lead to a 
substantial increase in the demand for lung cancer surgery. A previous study that 
investigated the radiological capacity requirements for implementing lung cancer 
screening in the United States defined capacity constraints as “a greater than 5% 
and (alternatively) greater than 25% projected increase in scans”.18 If we apply the 5% 
increase criterion to our base-case estimates, surgical capacity would be restrained 
in every year, for each scenario, and at each adherence level. If we apply the 25% 
increase criterion to our base-case estimates, capacity would be restrained for each 
scenario and adherence level in 2018. By 2023, capacity would be restrained for the 
USPSTF and CMS scenarios with ³35% adherence and for the Ontario scenarios with 
³50% adherence. Finally, by 2040, capacity would be restrained only for the USPSTF 
scenarios with ³65% adherence and for the CMS scenario with 80% adherence. With 
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the treatment proportions from the NLST for screen-detected cases, surgical capacity 
constraints would be even more pronounced. However, because the NLST was 
conducted under selective and controlled circumstances, these estimates should be 
considered an upper bound. Finally, if we applied the 5% criterion to the results of the 
sensitivity analysis with a gradual  buildup of adherence, surgical capacity would still 
be restrained in each year for each scenario. If we applied the 25% increase criterion 
to the same analysis, capacity would be not be restrained in 2018. However, capacity 
would still be restrained in 2023 and 2028 for each scenario.
Thoracic surgeons have lower operative and postoperative mortality rates for 
lung cancer surgery than general surgeons.19,20 Consequently, guidelines state that 
thoracic surgeons should be involved in treating screen-detected lung cancer.21,22 
However, earlier research projected that the future demand for thoracic surgeons 
would increase while the supply would decline.23 Without taking into account lung 
cancer screening, Moffatt-Bruce et al.24 reported that by 2035 the caseload per thoracic 
surgeon may increase by 121%. In addition, Edwards et al.25 reported that implementing 
LDCT lung cancer screening in Canada in 2014 could increase the number of operable 
(i.e., stage I and II) lung cancer cases per thoracic surgeon by 19.8% in 2030. However, 
our analysis of NCDB data indicates that many stage I and II NSCLC cases in fact do 
not receive surgery. Nevertheless, these studies provide indications that the current 
workforce of thoracic surgeons may not be able to cope with the additional demand 
caused by lung cancer screening. 
Residency training of additional thoracic surgeons takes on average 8.7 years.26 
However, the projected surgical demand peaked in the first 5 years after the 
implementation of screening. This peak would be more spread out over time with a 
gradual buildup of adherence. However, delaying the full-scale implementation of lung 
cancer screening may reduce the potential health benefits because smoking trends 
have been declining.7 Therefore, our data suggest that training of additional thoracic 
surgeons should start as soon as possible. In the meantime, a careful assessment 
and allocation of available capacity should be undertaken to ensure the maximum 
benefits of lung cancer screening. 
We found that the overall reduction in the demand for radiotherapy (-2.2%) 
and chemotherapy (-5.4%) was smaller than the overall increase in the demand 
for surgery (+37.0%). This is due to 3 factors. First, patients could receive multiple 
treatments. Second, radiotherapy and chemotherapy demand first increased because 
of the large incidence peak and then decreased. Third, the demand for surgery in 
the absence of screening was much lower than the demand for radiotherapy and 
chemotherapy. The initial peak in the demand for radiotherapy would exceed a 25% 
increase in comparison with no screening only by 2018 and only for the base-case 
USPSTF scenarios with 65% adherence and for the CMS scenario with 80% adherence. 
Similarly, the initial increase in the demand for chemotherapy in comparison with 
no screening would surpass the 25% mark only in 2018 for the base-case USPSTF and 
CMS scenarios with 80% adherence. Therefore, it is unlikely that the implementation 
of lung cancer screening will cause a major shortage of radiation oncology or 
chemotherapy services.
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Limitations
There are several potential limitations to the current study. First, earlier research has 
identified treatment disparities among US patients with lung cancer by race27 and 
insurance status.28 Although we implicitly account for these disparities by using the 
NCDB data, which cover 70% of incident cancer cases in the United States, MISCAN-
Lung currently does not explicitly model the effects of these variables. 
Second, our model is currently unable to estimate lung cancer incidence on a 
state level, whereas lung cancer incidence rates have been shown to vary by state.29 
This should be the subject of future research so that policy makers can plan treatment 
capacity on a local level. Policy makers should also note that simply increasing the 
number of trained thoracic surgeons may not be sufficient if patients at the highest 
risk for lung cancer are also encumbered by geographical (distance) or financial 
barriers (health insurance) to access.
Third, we have not modeled recurrent tumors. Also, the NCDB records only the 
first course of therapy, which is defined as all methods of treatment recorded in 
the treatment plan and administered to the patient before disease progression or 
recurrence. This might lead to an underestimation of the total number of treatments 
required for the implementation of lung cancer screening. 
Finally, because we projected demand in the future, there may be some future 
developments that could alter our estimates. For instance, we could not project 
the demand for targeted or immunotherapy agents because these are very recent 
developments. Furthermore, although current guidelines recommend stereotactic 
body radiotherapy only for patients with medically inoperable early-stage NSCLC,6 
there is an ongoing debate on its appropriateness in operable patients.30,31 Therefore, 
the proportion of early-stage cases that require radiotherapy could increase in 
the future. Two other developments that may possibly alter our estimates are the 
introduction of risk models to select individuals for screening and the use of nodule 
management strategies such as Lung-RADS. Finally, if future developments allow 
clinicians to distinguish indolent screen-detected cancers that would never cause 
symptoms from more aggressive cancers, overdiagnosis could decrease. In turn, this 
could decrease treatment demand.
In conclusion, we show that full-scale implementation of lung cancer screening 
in the United States will cause a major increase in the demand for lung cancer surgery, 
with a peak within the first 5 years. The current workforce of thoracic surgeons 
may not be able to cope with this increased demand. The question is whether this 
could jeopardize the benefits of screening. Although a gradual buildup of adherence 
could spread the peak in surgical demand over time, a delayed implementation of 
screening may reduce the potential health benefits. Therefore, implementation of 
lung cancer screening can be done only with a careful assessment and allocation of 
surgical capacity. 
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Analysis of National Cancer Database data
Data
Lung cancer treatment patterns were derived from the National Cancer Database 
(NCDB) Participant User File for lung cancer cases diagnosed in the United States 
between years 2010-2014. 
Case selection
We selected cases with International Classification of Diseases for Oncology 3rd edition 
lung cancer topography codes (C340 - C343, C348 and C349) and malignant behavior 
code.1 We included cases that were staged using the American Joint Committee on 
Cancer 7th edition Cancer Staging Manual, which was effective from 2010 through 
2017.2 Reasons for exclusion were: (1) stage 0, occult stage, unknown stage, or unknown 
stage subcategory (e.g. stage I rather than stage IA); (2) more than 4 months (122 
days) between date of diagnosis and onset of therapy; (3) patient did not receive any 
treatment at the reporting facility; (4) date of diagnosis before facility’s reference date 
(i.e. the date from which the facility guarantees the accuracy of data); (5) cases with 
a history of multiple primary tumors of which lung cancer wasn’t the first; (6) cases 
with unknown treatment; and (7) patients aged younger than 35 at diagnosis. This 
resulted in a final selection of 440,566 cases. 
Derivation of variables
In order to match NCDB data with the MISCAN-lung model,  we obtained gender, age, 
stage and histology specific proportions of patients receiving surgery, radiotherapy, 
chemotherapy, or no therapy as first course treatment. The derivation of these 
variables is detailed below.
Derivation of age
Age at diagnosis was used as a continuous variable for ages 35-89. However, the NCDB 
aggregates data for ages 90 and over. 
Derivation of stage
We used clinical stage at diagnosis, as defined by the American Joint Committee on 
Cancer 7th edition Cancer Staging manual.2 We did not include stage 0, occult, and 
unknown cancers because these do not have a clear standard treatment. Also, the 
MISCAN-lung model does not include these stages. We collapsed stage at diagnosis 
into the following categories to match MISCAN-lung output: IA, IB, II, IIIA, IIIB, IV.
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Derivation of histology
We classified International Classification of Diseases for Oncology 3rd Edition 
morphological codes into MISCAN-lung histology categories adenocarcinoma 
(including bronchioalveolar carcinoma and large cell carcinoma), squamous 
cell carcinoma, other non-small cell lung cancer and small cell lung cancer. This 
classification was based on an earlier publication.3
Derivation of treatment variables
The NCDB records the first course of treatment, defined as all methods of treatment 
recorded in the treatment plan and administered to the patient before disease 
progression or recurrence. The NCDB includes treatment modalities surgery, 
radiotherapy, chemotherapy, immunotherapy, hormone therapy, and other therapy. 
If a patient received any of these therapies, they were coded as having received any 
therapy. For this current study, we were not able to separately report on the use of 
hormone therapy immunotherapy, and other therapy because these were recorded 
very infrequently. Patients could receive multiple treatments. Hence, treatment 
proportions for surgery, radiotherapy, and chemotherapy do not add up to those for 
any therapy. We were not able to distinguish whether multiple therapies were given 
concurrently or sequentially.
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Supporting Figure 1: Time trends for therapy received by lung cancer patients in the United 
States. Figure based on analysis of 440,566 cases from the National Cancer Database diagnosed 
with lung cancer between 2010-2014.
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Supporting Figure 2: Number of persons in the United States that are eligible for Low-Dose 
Computed Tomography lung cancer screening in the United States between 2018-2040 for three 
screening policies. 
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Supporting Figure 3: Census-adjusted lung cancer incidence in the United States between 2015-
2040 in the absence of Low-Dose Computed Tomography screening and for three screening 
policies implemented in 2018. All policies assumed 50% adherence to screening. 
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Supporting Figure 4: Census-adjusted lung cancer incidence in the United States between 
2015-2040 in the absence of Low-Dose Computed Tomography screening and for three screen-
ing policies implemented in 2018. All policies assume an adherence level of 5% in 2018, with an 
annual 5 percentage point increase until a constant adherence of 50% is reached in 2027. 
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Supporting Figure 5: Cumulative change in demand for lung cancer therapy in the United 
States between 2015-2040 when implementing Low-Dose Computed Tomography screening for 
lung cancer in 2018, assuming that screen detected cases received stage-specific treatment as 
reported in the National Lung Screening Trial. Expressed as cumulative percentage change 
compared to no screening. All policies assumed constant 50% adherence to screening. 
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Supporting Figure 6: Absolute annual number of lung cancer patients in the United States 
requiring surgery when implementing Low-Dose Computed Tomography screening for lung 
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cancer in 2018 using the Centers for Medicare & Medicaid Services criteria at different constant 
screening adherence levels. 
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Supporting Figure 7: Absolute annual number of lung cancer patients in the United States 
requiring surgery when implementing Low-Dose Computed Tomography screening for lung 
cancer in 2018 using the Ontario criteria at different constant screening adherence levels. 
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Supporting Table 1: Lung cancer therapy observed in the National Cancer Database by lung 
cancer type and clinical stage at diagnosis.a
Clinical 
stage 
n Surgery 
(%)
Radiotherapy 
(%)
Chemotherapy 
(%)
Any therapy 
(%)
Non-small cell lung cancer
IA 60,876 43,920 (72.1) 13,689 (22.5) 5,476 (9.0) 56,210 (92.3)
IB 25,924 16,783 (64.7) 7,035 (27.1) 6,199 (23.9) 22,899 (88.3)
II 30,101 16,203 (53.8) 11,658 (38.7) 15,129 (50.3) 25,680 (85.3)
IIIA 48,808 10,538 (21.6) 31,196 (63.9) 32,757 (67.1) 39,803 (81.6)
IIIB 26,878 1,489 (5.5) 18,499 (68.8) 19,117 (71.1) 22,253 (82.8)
IV 182,056 5,224 (2.9) 82,756 (45.5) 91,641 (50.3) 124,814 (68.6)
Subtotal 374,643 94,157 (25.1) 164,833 (44.0) 170,319 (45.5) 291,659 (77.8)
Small cell lung cancer
IA 1,571 689 (43.9) 825 (52.5) 1,108 (70.5) 1,413 (89.9)
IB 934 199 (21.3) 565 (60.5) 683 (73.1) 795 (85.1)
II 2,456 250 (10.2) 1,747 (71.1) 2,002 (81.5) 2,141 (87.2)
IIIA 9,103 227 (2.5) 6,636 (72.9) 7,742 (85.0) 7,988 (87.8)
IIIB 7,139 59 (0.8) 5,084 (71.2) 6,168 (86.4) 6,340 (88.8)
IV 44,720 304 (0.7) 18,771 (42.0) 32,138 (71.9) 34,986 (78.2)
Subtotal 65,923 1,728 (2.6) 33,628 (51.0) 49,841 (75.6) 53,663 (81.4)
Total 440,566 95885 (21.8) 198,461 (45.0) 220,160 (50.0) 345,322 (78.4)
a Based on analysis of 440,566 cases from the National cancer Database diagnosed with lung can-
cer between 2010-2014. For the actual analysis in the main paper, treatment proportions were 
further stratified by gender, age, stage, and histology. Patients could receive multiple treat-
ments. Hence, treatment categories do not add up to 100%. 
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Supporting Table 2: Lung cancer therapy observed in the Low-Dose-Computed Tomography 
arm of the National Lung Screening Trial by stage at diagnosis.a
Stage n Surgery (%) Radiotherapy (%) Chemotherapy (%) Any therapy (%)
IA 415 388 (93.5) 26 (6.3) 28 (6.7) 407 (98.1)
IB 104 93 (89.4) 7 (6.7) 34 (32.7) 101 (97.1)
II 72 59 (81.9) 23 (31.9) 46 (63.9) 71 (98.6)
IIIA 98 37 (37.8) 71 (72.4) 77 (78.6) 95 (96.9)
IIIB 121 36 (29.8) 63 (52.1) 91 (75.2) 111 (91.7)
IV 220 23 (10.5) 72 (32.7) 149 (67.7) 180 (81.8)
a Proportions were calculated based on treatment frequencies reported in Table 3 in the 
Supplementary Appendix of Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality 
with low-dose computed tomographic screening. N. Engl. J. Med. 2011;365(5):395-409. 
Patients could receive multiple treatments. Hence, treatment categories do not add up to 100%.
Supporting Table 3: Cumulative number of lung cancer cases in the United States between 
2015-2040 and the proportion of screen detected and clinically detected cases in the absence 
of Low-Dose Computed Tomography screening and for three screening policies implemented 
in 2018.a
Policy n Clinically detected (%) Screen detected (%)
USPSTF 5,525,593 4,597,593 (83.3) 927,999 (16.8)
CMS 5,495,049 4,709,017 (85.7) 786,032 (14.3)
Ontario 5,462,657 4,908,971 (89.9) 553,686 (10.1)
No screening 5,402,854 5,402,854 (100) -
a All policies assumed constant 50% adherence to screening. 
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Supporting Table 4: Absolute annual number of lung cancer patients in the United States 
requiring surgery, radiotherapy, chemotherapy, and any therapy when implementing Low-
Dose Computed Tomography screening for lung cancer in 2018 (percentage change compared 
to no screening).a
Surgery
Scenario/ Year 2018 2023 2028 2040
No screening 37,964 38,903 38,876 34,021
USPSTF 74,437 (+96.1) 56,794 (+46.0) 53,781 (+38.3) 42,482 (+24.9)
CMS 71,188 (+87.5) 54,912 (+41.2) 51,710 (+33.0) 40,719 (+19.7)
Ontario 62,442 (+64.5) 50,632 (+30.1) 48,105 (+23.7) 38,463 (+13.1)
Radiotherapy
Scenario / Year 2018 2023 2028 2040
No screening 81,802 84,378 85,242 81,219
USPSTF 98,766 (+20.7) 80,426 (-4.7) 80,920 (-5.1) 78,554 (-3.3)
CMS 96,539 (+18.0) 80,246 (-4.9) 80,677 (-5.4) 78,409 (-3.5)
Ontario 92,377 (+12.9) 81,048 (-3.9) 81,830 (-4.0) 79,053 (-2.7)
Chemotherapy
Scenario / Year 2018 2023 2028 2040
No screening 83,221 84,351 83,366 72,586
USPSTF 98,776 (+18.7) 76,729 (-9.0) 75,831 (-9.0) 68,098 (-6.2)
CMS 97,483 (+17.1) 77,192 (-8.5) 76,263 (-8.5) 68,507 (-5.6)
Ontario 93,698 (+12.6) 78,889 (-6.5) 78,217 (-6.2) 69,603 (-4.1)
Any therapy
Scenario / Year 2018 2023 2028 2040
No screening 141,751 146,288 147,815 137,607
USPSTF 193,546 (+36.5) 154,914 (+5.9) 153,441 (+3.8) 140,452 (+2.1)
CMS 188,069 (+32.7) 153,346 (+4.8) 151,635 (+2.6) 138,978 (+1.0)
Ontario 175,527 (+23.8) 151,076 (+3.3) 150,401 (+1.7) 138,121 (+0.4)
a All policies assumed constant 50% adherence to screening. 
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Supporting Table 5: Absolute annual number of lung cancer patients in the United States 
requiring surgery, radiotherapy, chemotherapy, and any therapy when implementing Low-
Dose Computed Tomography screening for lung cancer in 2018 (percentage change compared 
to no screening).a
Surgery
Scenario/ Year 2018 2023 2028 2040
No screening 37,964 38,903 38,876 34,021
USPSTF 41,599 (+9.6) 53,811 (+38.3) 55,220 (+42.0) 42,334 (+24.4)
CMS 41,248 (+8.7) 52,213 (+34.2) 52,926 (+36.1) 40,612 (+19.4)
Ontario 40,966 (+7.9) 50,732 (+30.4) 51,160 (+31.6) 39,497 (+16.1)
Radiotherapy
Scenario / Year 2018 2023 2028 2040
No screening 81,802 84,378 85,242 81,219
USPSTF 83,538 (+2.1) 85,821 (+1.7) 82,811 (-2.9) 78,473 (-3.4)
CMS 83,293 (+1.8) 85,244 (+1.0) 82,499 (-3.2) 78,391 (-3.5)
Ontario 83,134 (+1.6) 84,862 (+0.6) 82,416 (-3.3) 78,590 (-3.2)
Chemotherapy
Scenario / Year 2018 2023 2028 2040
No screening 83,221 84,351 83,366 72,586
USPSTF 84,819 (+1.9) 83,872 (-0.6) 77,684 (-6.8) 68,058 (-6.2)
CMS 84,675 (+1.7) 83,797 (-0.7) 78,153 (-6.3) 68,503 (-5.6)
Ontario 84,560 (+1.6) 83,741 (-0.7) 78,506 (-5.8) 68,974 (-5.0)
Any therapy
Scenario / Year 2018 2023 2028 2040
No screening 141,751 146,288 147,815 137,607
USPSTF 146960 (+3.7) 159881 (+9.3) 157104 (+6.3) 140200 (+1.9)
CMS 146366 (+3.3) 157940 (+8.0) 155035 (+4.9) 138840 (+0.9)
Ontario 145931 (+2.9) 156304 (+6.8) 153622 (+3.9) 138295 (+0.5)
a All policies assume an adherence level of 5% in 2018, with an annual 5 percentage point in-
crease until a constant adherence of 50% is reached in 2027. 
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Abstract
Objectives
The degree of overdiagnosis due to lung cancer screening in the general US population 
remains unknown. Estimates may be influenced by the method used and by 
decreasing smoking trends, which reduce lung cancer risk and screening eligibility 
over time. Therefore, we aimed to estimate the degree of overdiagnosis due to lung 
cancer screening in the general US population, using three distinct methods.
Material and methods
The MISCAN-Lung model was used to project lung cancer incidence and overdiagnosis 
in the general US population between 2018-2040, assuming perfect adherence to the 
United States Preventive Task Force recommendations. MISCAN-Lung was calibrated 
to the NLST and PLCO trials and incorporates birth-cohort-specific smoking trends 
and life expectancies. We estimated overdiagnosis using the cumulative excess-
incidence approach, the annual excess-incidence approach, and the microsimulation 
approach.
Results
Using the cumulative excess-incidence approach, 10.5% of screen-detected cases were 
overdiagnosed in the 1950 birth-cohort compared to 5.9% in the 1990 birth-cohort. 
Incidence peaks and drops due to screening were larger for older birth-cohorts 
than younger birth-cohorts. In the general US population, these differing incidence 
peaks and drops across birth-cohorts overlap. Therefore, annual excess-incidence 
would be absent between 2029-2040, suggesting no overdiagnosis occurs. Using the 
microsimulation approach, overdiagnosis among screen-detected cases increased 
from 7.1%-9.5% between 2018-2040, while overdiagnosis among all lung cancer cases 
decreased from 3.7%-1.4%.
Conclusion
Overdiagnosis studies should use appropriate methods to account for trends in 
background risk and screening eligibility in the general population. Estimates 
from randomized trials, based on the cumulative excess-incidence approach, are 
not generalizable to the general population. The annual excess-incidence approach 
does not account for trends in background risk and screening eligibility, and falsely 
suggests no overdiagnosis occurs in the general population. Using the microsimulation 
approach, overdiagnosis was limited but not nil. Overdiagnosis increased among 
screen-detected cases, while overdiagnosis among all cases decreased. 
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Introduction
Overdiagnosis is considered to be one of the main harms of cancer screening, 
and is typically defined as a screen-detected cancer that would not have become 
symptomatic during an individual’s lifetime.1 There are two ways overdiagnosis can 
happen. First, a patient with a progressive screen-detected cancer may die of other 
causes before their cancer would have progressed to a point at which it would cause 
symptoms (i.e. before clinical presentation). This becomes more likely when the 
chances of dying from competing causes are higher, for example when screening 
elderly persons2 or those with many comorbidities. Second, some screen-detected 
cancers may not be progressive (i.e. indolent or regressing), and would thereby never 
reach a point at which they would cause symptoms. In both cases, it is impossible to 
determine whether an individual screen-detected case has been overdiagnosed. 
There are several methods for estimating overdiagnosis.3 A commonly used 
method is the cumulative excess-incidence approach, in which the difference in 
cumulative incidence between a screened group and a matched control group is 
attributed to overdiagnosis. Several studies used this approach to estimate the 
degree of overdiagnosis in low-dose computed tomography screening for lung cancer. 
Using data from the National Lung Screening Trial, Patz et al. reported that 18.5% 
of screen-detected lung cancers in the low-dose computed tomography arm were 
overdiagnosed at 7 years of follow-up.4 The Danish Lung Screening Trial reported that 
67.2% of screen-detected cancers were overdiagnosed at 11 years of follow-up.5 Finally, 
researchers from the ITALUNG trial reported no overdiagnosis at 9 years of follow-up.6 
The variation in overdiagnosis estimates between these randomized trials has 
been suggested to be due to several factors, including a different number of screening 
rounds and differences in baseline lung cancer risk.7 The number of screening rounds 
per participant would be much higher in a continuous population screening program. 
On the other hand, the background lung cancer risk (and screening eligibility) in 
the population has been shown to decrease over time, as younger birth-cohorts 
smoke less.8 Finally, while all randomized trial estimates used the cumulative excess-
incidence approach, this approach should not be used in a continuous screening 
program in the general population.9 Using other methods may also lead to different 
estimates.10 Consequently, it remains uncertain whether the published estimates of 
lung cancer overdiagnosis are generalizable to a continuous screening program in the 
general population. Therefore, we used three distinct methods to estimate the degree 
of lung cancer overdiagnosis in the general US population when fully implementing 
a continuous lung cancer screening program in 2018. 
Materials and methods
MISCAN-Lung model
Although the United States Preventive Task Force (USPSTF) has recommended 
lung cancer screening in the United States since 2013,11 current uptake is limited.12 
Consequently, comprehensive data on lung cancer incidence and overdiagnosis in 
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a continuous screening program are currently not available. Therefore, we used the 
MIcrosimulation SCreening ANalysis Lung (MISCAN-Lung) model to project future 
lung cancer incidence and overdiagnosis in the presence and absence of screening. 
MISCAN-Lung uses the National Cancer Institute’s Smoking History Generator8 
to generate sex and birth-cohort specific life histories, including smoking histories 
and non-lung cancer specific causes of death (corrected for smoking behavior). The 
generated smoking histories determine the chance of developing preclinical lung 
cancer. When preclinical lung cancer develops, it can progress to more advanced 
preclinical stages. At each of these stages, the preclinical cancer can be either 
clinically detected or screen-detected. For each individual, full life histories are 
generated in the presence and absence of screening. Key model parameters, such as 
the mean histology and sex-specific duration in each stage (i.e. the natural history), 
and the stage and histology-specific screening test sensitivity, have been calibrated to 
data from the National Lung Screening Trial and the Prostate, Lung, Colorectal and 
Ovarian Cancer Screening Trial. Details of model calibration have been described in 
previous publications.13,14 The model was previously used to inform the USPSTF on the 
lung cancer screening policy with the optimal ratio of benefits and harms.11,15
Projecting incidence
We used MISCAN-Lung to project lung cancer incidence in the US population in the 
absence and presence of screening. First, we simulated histology, stage, age, and sex-
specific lung cancer incidence rates for each individual birth-cohort from 1916 to 
2005 (i.e. persons aged 35-99 in years 2015-2040). Thereby, we account for different 
smoking trends and life-expectancies in the evaluated population. Next, we used the 
age and sex-specific Census population projections16 to convert the annual incidence 
rates for each birth-cohort to cohort-specific Census-adjusted annual incidence 
counts. Finally, we aggregated these Census-adjusted annual incidence counts across 
all cohorts, forming the Census-adjusted annual incidence count for the general US 
population. In the screening scenario, we assumed perfect adherence to the USPSTF 
recommendations between 2018-2040 (i.e. annual screening of those aged 55-80 with 
a smoking history of at least 30 pack-years, that currently smoke or quit less than 15 
years ago).
Estimating overdiagnosis
We used three distinct methods to estimate overdiagnosis: the cumulative excess-
incidence approach, the annual excess-incidence approach, and the microsimulation 
approach. The cumulative excess-incidence approach subtracts the cumulative 
incidence in the absence of screening after a certain period of follow-up from the 
cumulative incidence in the presence of screening, and attributes this difference to 
overdiagnosis. This approach provides an unbiased estimate of overdiagnosis in a 
closed cohort with a limited number of screens and sufficient follow-up.3,9 We assume 
that the effect of radiation exposure due to LDCT screening on lung cancer incidence 
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was negligible.15,17 Therefore, we used this approach to estimate overdiagnosis in several 
separate US birth-cohorts with a lifetime follow-up. As the number of individuals differs 
per birth-cohort, overdiagnosis using the cumulative excess-incidence approach was 
expressed as the rate of overdiagnosed cases per 100,000 persons in the cohort alive 
in 2015. Also, we expressed overdiagnosis as the lifetime percentage of screen-detected 
cases that would be overdiagnosed, calculated by dividing the rate of overdiagnosed 
cases by the rate of screen-detected cases. Finally, we expressed overdiagnosis as the 
lifetime percentage of all lung cancer cases that would be overdiagnosed, calculated 
by dividing the rate of overdiagnosed cases by the cumulative incidence rate in the 
presence of screening. 
In a continuous screening program in the general population, the annual excess-
incidence should be used instead of the cumulative excess-incidence.9 The underlying 
principle is that in a continuous screening program in the general population, new 
persons will receive their first screening at the end of a chosen follow-up period, 
which would bias the cumulative excess-incidence approach. In each calendar year, 
an increased incidence due to early detection is partly compensated by a drop in 
incidence among individuals that are no longer eligible. In the annual excess-incidence 
approach, incidence in the absence of screening is therefore subtracted from incidence 
in the presence of screening for each calendar year, and this difference is attributed 
to overdiagnosis. This approach should provide an unbiased overdiagnosis estimate 
after waiting until screening uptake stabilizes plus the longest preclinical duration.9,18 
A recent analysis suggests that the lead time of  screen-detected lung cancers in 
the National Lung Screening Trial can be as long as 9 years.19 Therefore, we used the 
annual excess-incidence approach to estimate the Census-adjusted annual number 
of overdiagnosed cases between 2027 (i.e. 2018 plus 9 years of lead time) and 2040 in the 
general US population. Overdiagnosis was also expressed as the annual percentage of 
screen-detected cases that would be overdiagnosed, calculated by dividing the Census-
adjusted excess-incidence count by the Census-adjusted number of screen-detected 
cases in each year. Finally, we expressed overdiagnosis as the annual percentage of 
all lung cancer cases that would be overdiagnosed, calculated by dividing the Census-
adjusted excess-incidence count by the Census-adjusted overall incidence count in 
the presence of screening in each year.
In the microsimulation approach, we used the identical individually simulated life 
histories in the presence and absence of screening to determine the Census-adjusted 
annual number of overdiagnosed cases in the general US population between 2018-
2040. The percentage of overdiagnosis among screen-detected cases was calculated by 
dividing the Census-adjusted number of overdiagnosed cases by the Census-adjusted 
number of screen-detected cases in each year. The percentage of overdiagnosis among 
all cases was calculated by dividing the Census-adjusted number of overdiagnosed 
cases by the Census-adjusted overall incidence count in the presence of screening in 
each year.
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Sensitivity analyses
A previous study found that the degree of lung cancer overdiagnosis varies across 
histologies.4 As the MISCAN-lung model incorporates sex and histology-specific 
natural history parameters, our estimates account for these differences. To provide 
insight into these differences, we stratified our lifetime cumulative excess-incidence 
estimates of the percentage of screen-detected cancers that are overdiagnosed for 
several separate birth-cohorts by histology and sex. 
Furthermore, smoking trends in the general population are different for men 
and women.8 Therefore, we also stratified our estimates of overdiagnosis in the general 
US population using the annual excess-incidence approach and the microsimulation 
approaches by sex.  
Results
Projecting incidence
For each separate birth-cohort, the Census-adjusted annual lung cancer incidence 
count would increase when individuals first become eligible for screening (see Fig. 
1). As individuals reach the upper age limit for screening eligibility, there would be a 
compensatory drop in incidence. Both these peaks and drops in the Census-adjusted 
annual incidence count would be higher for older birth-cohorts than for younger 
birth-cohorts. For example, the peak difference in the Census-adjusted annual 
incidence count between screening and no screening would be +5,389 cases for the 
1950 cohort compared to +374 cases for the 1990 cohort.
In the aggregated general US population, the full-scale (i.e. 100% adherence) 
introduction of lung cancer screening in 2018 would increase the Census-adjusted 
annual incidence count in that year from 197,348 to 309,327 (+ 56.7%). Subsequently, 
incidence in the presence of screening would gradually decrease (Fig. 2A). By 2028, the 
Census-adjusted annual incidence count in the presence of screening (212,810 cases 
in 2028) would approach incidence in the absence of screening (212,050 cases in 2028). 
Figure 2B shows that the projected Census-adjusted annual incidence count in the 
presence of screening would even be lower than in the absence of screening from 2029 
onwards (up to -1.0% in 2036).  
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Figure 1: Census-adjusted annual lung cancer incidence count between 2015–2060 for several 
US birth-cohorts when implementing lung cancer screening using the United States Preventive 
Task Force eligibility criteria in 2018. Results are presented through 2060 to show the lifetime 
effect of screening on incidence for several birth-cohorts.
Figure 2: A) Census-adjusted annual lung cancer incidence count in the general United States 
population between 2015–2040 when fully implementing lung cancer screening using the United 
States Preventive Task Force eligibility criteria in 2018. B) Detail of panel A for years 2026–2040.
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Overdiagnosis estimate using the cumulative excess-incidence approach
As shown in Table 1, the cumulative background incidence rate in the absence of 
screening would be higher in older birth-cohorts than in younger birth-cohorts (1950 
cohort: 6,206 per 100,000; 1990 cohort: 4,157 per 100,000). Also, the percentage of persons 
ever screened would be higher in older birth-cohorts (1950 cohort: 15.5%; 1990 cohort: 
2.9%). Consequently, the rate of screen-detected cases and the rate of overdiagnosed 
cases would also be lower in younger birth-cohorts (1950 cohort: 1,414 screen-detected 
cases and 148 overdiagnosed cases per 100,000; 1990 cohort: 287 screen-detected cases 
and 17 overdiagnosed cases per 100,000). With lifetime follow-up, 10.5% of screen-
detected cases would be overdiagnosed in the 1950 birth-cohort compared to 5.9% in 
the 1990 birth-cohort. Finally, 2.3% of all lung cancer cases would be overdiagnosed in 
the 1950 birth-cohort compared to 0.4% of the 1990 birth-cohort.
Table 1: Lung cancer incidence rates, screening eligibility, and overdiagnosis for several 
separate US birth-cohorts when fully implementing lung cancer screening in 2018 using the 
United States Preventive Task Force recommendations.
Birth-
cohort
Cumula-
tive 
incidence 
in the 
absence 
of 
screening a 
Percentage 
of the 
cohort 
ever 
screened b
Number 
of screen-
detected 
cases a
Cumula-
tive 
incidence 
in the 
presence 
of screen-
ing a
Number 
of over-
diagnosed 
cases a,c
Percentage
of screen-
detected 
cases that 
would be 
over- 
diagnosed d
Percentage 
of all cases 
that would 
be over-
diagnosed e
1950 6,206 15.5% 1,414 6,354 148 10.5% 2.3%
1960 5,791 13.8% 1,307 5,899 108 8.2% 1.8%
1970 4,665 7.1% 660 4,712 47 7.1% 1.0%
1980 4,635 5.1% 492 4,666 31 6.2% 0.7%
1990 4,157 2.9% 287 4,174 17 5.9% 0.4%
a Because the absolute size of each birth-cohort is different, numbers are expressed as rates  per 
100,000 persons of the cohort that were alive in 2015.
b For cohorts 1950 and 1960, it is assumed that individuals who would have been eligible before 
the implementation of screening in 2018 did not receive screening before 2018.
c Calculated by subtracting the cumulative incidence in the absence of screening from the 
cumulative incidence in the presence of screening.
d Calculated by dividing the rate of overdiagnosed cases by the rate of screen-detected cases.
e Calculated by dividing the rate of overdiagnosed cases by the cumulative incidence rate in the 
presence of screening.
Overdiagnosis estimate using the annual excess-incidence approach
In the general US population, the Census-adjusted annual excess-incidence count 
would be 2,579 cases in 2027 (4.3% of screen-detected cases and 1.2% of all lung cancer 
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cases). By 2028, the Census-adjusted annual excess-incidence count would have 
decreased to 760 cases (1.4% of screen-detected cases and 0.4% of all lung cancer 
cases). From 2029 onwards, incidence in the presence of screening would be lower 
than incidence in the absence of screening (see Fig. 2B). Therefore, there would be no 
annual excess-incidence from 2029 onwards, suggesting that no overdiagnosis would 
occur between 2029-2040.
Overdiagnosis using the microsimulation approach
Using the individually simulated life histories in the presence and absence of 
screening, the Census-adjusted annual number of overdiagnosed cases in the general 
US population in 2018 would be 11,429 (see Fig. 3A). After that, overdiagnosis would 
gradually decrease to 2,851 cases in 2040. Figure 3B shows the components necessary 
to express overdiagnosis as a percentage of screen-detected cases and as a percentage 
of all cases. Similar to the Census-adjusted annual number of overdiagnosed cases, 
the Census-adjusted annual number of screen-detected cases would also decrease, 
although at a faster rate (see Fig. 3B). Consequently, the proportion of screen-detected 
cases that are overdiagnosed would initially increase from 7.1% in 2018 to 9.5% in 2035 
(see Fig. 4). 
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Figure 3: A) Census-adjusted annual number of overdiagnosed lung cancer cases in the general 
US population between 2015–2040 when fully implementing screening using the United States 
Preventive Task Force recommendations in 2018. B) Census-adjusted annual lung cancer 
incidence count in the general US population between 2015–2040 when fully implementing 
screening using the United States Preventive Task Force recommendations in 2018, stratified by 
mode of detection, and the Census-adjusted annual number of overdiagnosed cases.
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In contrast to the decreasing Census-adjusted annual number of screen-detected 
cases, the Census-adjusted overall annual incidence count in the general population 
would remain relatively stable after the initial incidence peak. Combined with the 
declining Census-adjusted number of overdiagnosed cases, the percentage of all lung 
cancer cases that are overdiagnosed would decrease from 3.7% of all lung cancer cases 
in 2018 to 1.4% in 2040 (see Fig. 4).   
Figure 4: Annual percentage of overdiagnosed lung cancer cases in the United States between 
2018–2040 when fully implementing lung cancer screening using the United States Preventive 
Task Force eligibility criteria in 2018. The percentage of overdiagnosis among screen-detected 
cases was calculated by dividing the Census-adjusted number of overdiagnosed cases by the 
Census-adjusted number of screen-detected cases in each year. The percentage of overdiagnosis 
among all cases was calculated by dividing the Census-adjusted number of overdiagnosed cases 
by the Census-adjusted overall incidence count in the presence of screening in each year.
Sensitivity analyses
Using the cumulative excess-incidence approach, the percentage of screen-detected 
cancers that were overdiagnosed was higher for women (range: 5.7% in the 1990 
cohort to 11.2% in the 1950 cohort) than for men (range: 6.1% in the 1990 cohort to 
9.8% in the 1950 cohort) in each evaluated birth-cohort except the 1990 cohort (see 
Supplementary Fig. 1). This was also the case for the percentage of screen-detected 
adenocarcinomas that were overdiagnosed (range across women: 6.3% in the 1990 
cohort to 12.7% in the 1950 cohort; range across men: 6.8% in the 1990 cohort to 10.9% 
in the 1950 cohort). Across histologies, screen-detected adenocarcinomas were most 
likely to be overdiagnosed (range: 6.6% in the 1990 cohort to 11.9% in the 1950 cohort).
The proportion of screen-detected squamous cell carcinomas that were 
overdiagnosed was higher for men (range: 7.1% in the 1990 cohort to 10.4% in the 1950 
cohort) than for women (range: 6.4% in the 1990 cohort to 9.9% in the 1950 cohort). The 
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percentage of overdiagnosed screen-detected small cell lung cancers was low for both 
sexes (range: 1.7% in the 1990 cohort to 2.8% in the 1950 cohort). 
Using the annual excess-incidence approach, the Census-adjusted number of 
overdiagnosed cases would still approach zero in 2029 in both men and women (see 
Supplementary Fig. 2). Using the microsimulation approach, overdiagnosis among 
screen-detected cases and all cases was more common among women than men (see 
Supplementary Fig. 3). However, time trends were similar to the base-case analysis. 
Discussion
Modeling incidence
To our knowledge, we are the first to project the impact of continuous lung cancer 
screening on incidence and overdiagnosis for a multitude of US birth-cohorts as well 
as for the general US population, using three different methods. Stratified by birth-
cohort, incidence would increase once individuals reach the lower age threshold 
for screening (55 years). This increase is due to the early detection of prevalent and 
incident preclinical cases. As individuals within each cohort pass the upper age 
threshold for screening (80 years), there would be a compensatory drop in incidence. 
To fully account for this compensatory drop in incidence, the follow-up after screening 
stops should be at least as long as the longest lead-time.3 As we used lifetime follow-
up, we fulfill this criterion. We found that the effect of screening on lung cancer 
incidence (i.e. both the peak and drop) would be much larger for older cohorts than 
for younger cohorts. This can be explained by reductions in smoking trends,8 due to 
which younger birth-cohorts 1) have a lower background risk of getting lung cancer, 
and 2) are less often eligible for screening.20,21 
In the aggregated general US population, we projected a large incidence peak 
upon the implementation of screening in 2018, which occurs because several cohorts 
would become eligible for screening in that year (i.e. cohorts 1938-1963). In most other 
cancer screening programs, incidence with screening remains higher than incidence 
without screening.22 However, we found that as lung cancer screening in the general 
population stabilizes, annual incidence with screening would become lower than 
without screening. This happens because annual incidence in the general population 
consists of overlapping incidence peaks and drops from different birth-cohorts. 
Eventually, the larger incidence drops from older cohorts start to overlap with the 
smaller incidence peaks from younger birth-cohorts. 
Estimating overdiagnosis
Using the cumulative excess-incidence approach, we found that overdiagnosis was 
much more common in older birth-cohorts than in younger birth-cohorts. These 
differences are also driven by declining background lung cancer risk and screening 
eligibility. Due to these trends, cumulative excess-incidence estimates from closed 
cohorts are not generalizable to a broader population. Therefore, existing lung cancer 
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overdiagnosis estimates from randomized controlled trials are not representative for 
a continuous lung cancer screening program in the general US population. In the 
general US population, the lack of annual excess-incidence as a result of these declining 
smoking trends would suggest that no overdiagnosis occurs after 2029. However, we used 
the microsimulation modeling approach to show that overdiagnosis would be present 
in the general US population in each year since the implementation of screening. 
Using the microsimulation approach, the percentage of screen-detected lung 
cancers in the general US population that would be overdiagnosed increased between 
2018-2040, while the percentage of all lung cancer cases that would be overdiagnosed 
decreased in the same period. The increasing percentage of overdiagnosis among 
screen-detected cases can be explained by the average age of the pool of screening-
eligible individuals. Over time, this pool will increasingly consist of elderly individuals 
because fewer individuals from younger birth-cohorts become eligible for screening. 
As overdiagnosis is more common among elderly individuals (due to limited life 
expectancy), the Census-adjusted annual number of overdiagnosed cases decreases 
at a slower rate than the Census-adjusted annual number of screen-detected cases. 
Therefore, the percentage of screen-detected cases that is overdiagnosed will increase 
over time. In contrast, the total Census-adjusted annual incidence count will remain 
relatively constant over time due to growth and aging of the population. Therefore, 
the percentage of all lung cancer cases that is overdiagnosed will decrease. These 
findings confirm previous work stating that overdiagnosis estimates across different 
studies can only be compared when the same denominator is used (i.e. among screen-
detected cases or among all cases).23 We add that using different denominators can 
lead to different conclusions regarding possible time trends in overdiagnosis. 
Our sensitivity analyses show that overdiagnosis estimates differ by sex and 
histology. Overdiagnosis was generally most common among adenocarcinomas and 
among women. These findings may be explained by the preclinical duration of disease, 
which has been estimated to be longer for women and for adenocarcinomas.14 With a 
longer preclinical duration, the likelihood of overdiagnosis increases. Conversely, small 
cell carcinomas are known to progress quickly, which explains the lower likelihood 
of overdiagnosis. Among cases with squamous cell histology, overdiagnosis was more 
common in men than in women. This can be explained by the fact that while the 
preclinical duration is similar between men and women, the overall life expectancy 
for men is lower.14 The small differences between men and women in the 1990 cohort 
can be explained by the small numbers due to the low background risk of lung cancer. 
Differences in population smoking trends between men and women did not affect our 
conclusions regarding the appropriateness of the annual excess-incidence approach 
and regarding time trends in overdiagnosis using the microsimulation approach.
Considerations for other screening programs
Compared to other cancer screening programs, lung cancer screening is unique 
because the main risk factor for lung cancer (i.e. smoking) reduces over time, 
which affects not only the background risk, but also screening eligibility. In most 
other cancer screening programs, screening eligibility is only determined by age. 
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Nevertheless, screening participation rates can still vary over time. Also, background 
risk may change over time due to changes in behavioral, lifestyle, and medical 
factors. For example, the risk of breast cancer has been related to body mass index, 
reproductive behavior, and the use of hormone replacement therapy,24 all of which 
may change over time. An earlier theoretical study found that, if breast cancer risk 
and breast screening participation rates increase over time, the excess-incidence 
approach would overestimate overdiagnosis.25 Indeed, the background risk of breast 
cancer seems to increase over time.23 Therefore, previous studies that have applied 
the excess-incidence approach to a population setting may have overestimated breast 
cancer overdiagnosis.26
 
Strengths and limitations
A major strength of our study is the use of the MISCAN-Lung model, which allows 
for a comparison of identical full life histories in the absence and presence of 
screening. Also, our model can take smoking trends across birth-cohorts into 
account. Finally, microsimulation modeling can assess the effects of many different 
screening strategies. For example, Han et al. showed that lung cancer overdiagnosis 
estimates (within a fixed cohort) are sensitive to the eligibility criteria used, such as 
screening starting and stopping age, and different pack-years criteria.27 Nevertheless, 
using microsimulation modeling to estimate overdiagnosis can have limitations. 
Most importantly, constructing a model implies making underlying assumptions. 
Also, some parameters of microsimulation models, such as the natural history, 
must be calibrated. This should be done with great care, as different combinations 
of parameters can fit the same data.28 For MISCAN-Lung, details on calibration and 
validation have been published previously.13,14 
Conclusion
We conclude that it is crucial to use appropriate methods to account for trends in 
background cancer risk and screening eligibility when estimating overdiagnosis in 
the general population. Lung cancer overdiagnosis estimates from randomized trials, 
which are based on the cumulative excess-incidence approach in a closed cohort 
with a limited number of screens, are not generalizable to a screening program in the 
general population. Using the annual excess-incidence approach in the general US 
population suggests that no overdiagnosis will occur between 2029-2040. However, this 
estimate is biased as differences in background risk and screening eligibility across 
cohorts are not taken into account. Using the microsimulation method, we show 
that lung cancer overdiagnosis in the general US population between 2018-2040 will 
be limited but not nil. Due to trends in background risk and screening eligibility, 
overdiagnosis among screen-detected cases will increase between 2018-2040, while 
overdiagnosis among all cancer cases will decrease. 
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Supplementary Figure 1: Lifetime percentage of screen-detected cases that were overdiag-
nosed using the cumulative excess-incidence approach by histology, sex, and birth-cohort 
Abbreviations: NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer.
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For men:
For women:
Supplementary Figure 2: A) Census-adjusted annual lung cancer incidence count in the 
general United States population between 2015-2040 when fully implementing lung cancer 
screening using the United States Preventive Task Force eligibility criteria in 2018, by sex. B) 
Detail of panel A for  years 2026-2040.
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For men:             For women:
Supplementary Figure 3. Annual percentage of overdiagnosed lung cancer cases in the United 
States between 2018-2040 when fully implementing lung cancer screening using the United 
States Preventive Task Force eligibility criteria in 2018. The percentage of overdiagnosis among 
screen-detected cases was calculated by dividing the Census-adjusted number of overdiagnosed 
cases by the Census-adjusted number of screen-detected cases in each year. The percentage 
of overdiagnosis among all cases was calculated by dividing the Census-adjusted number of 
overdiagnosed cases by the Census-adjusted overall incidence count in the presence of screen-
ing in each year.
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Abstract
Background
Using appropriate health state utility values (HSUVs) is critical for economic evaluation 
of new lung cancer interventions, such as low-dose computed tomography screening 
and immunotherapy. Therefore, we provide a systematic review and meta-analysis of 
community and choice-based HSUVs for lung cancer. 
Methods
On March 6, 2017, we conducted a systematic search in Embase, Ovid Medline, Web 
of Science, Cochrane CENTRAL, Google Scholar, and the School of Health and Related 
Research Health Utility database. The search was updated on April 17, 2019. Studies 
reporting mean or median lung cancer specific HSUVs including a measure of variance 
were included, and assessed for relevance and validity. Studies with high relevance (i.e. 
community and choice-based) were further analyzed. Mean HSUVs were pooled using 
random effects models for all stages, stages I-II, and stages III-IV. For studies with a 
control group, we calculated the disutility due to lung cancer. A sensitivity analysis 
included only the methodologically most comparable studies (i.e. using the EQ-5D 
instrument and matching tariff). Subgroup analyses were conducted by time-to-
death, histology, sex, age, treatment modality, treatment line, and progression status.
Results
Twenty-seven high-relevance studies were identified and analyzed. The pooled HSUV 
was 0.68 (95%CI=0.61-0.75) for all stages, 0.78 (95%CI=0.70-0.86) for stages I-II, and 0.69 
(95%CI=0.65-0.73) for stages III-IV (p=.02 compared to stage I-II). Heterogeneity was 
present in each pooled analysis (p<.01;I2=92%-99%). Disutility due to lung cancer 
ranged from 0.11 (95%CI=0.05-0.17) to 0.27 (95%CI=0.18-0.36). In the sensitivity analysis 
with the methodologically most comparable studies, stage-specific HSUVs varied 
by country. Such studies were only identified for Canada, China, Spain, the United 
Kingdom, the United States, Denmark, Germany, and Thailand. In the subgroup 
analysis by time-to-death, HSUVs for metastatic non-small cell lung cancer ranged 
from 0.83 (95%CI=0.82-0.85) at ≥360 days from death to 0.56 (95%CI=0.46-0.66) at <30 days 
from death. Among patients with metastatic non-small cell lung cancer, HSUVs were 
lower for those receiving third or fourth line treatment and for those with progressed 
disease. Results of subgroup analyses by histology, sex, age, and treatment modality 
were ambiguous.
Conclusions
The presented evidence supports the use of stage and country-specific HSUVs. However, 
such HSUVs are unavailable for most countries. Therefore, our pooled HSUVs may 
provide the best available stage-specific HSUVs for most countries. For metastatic 
non-small cell lung cancer, adjusting for the decreased HSUVs in the last year of life 
may be considered, as well as further stratification of HSUVs by treatment line or 
progression status. If required, HSUVs for other health states may be identified using 
our comprehensive breakdown of study characteristics.
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Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide.1 New inter-
ventions, such as low-dose computed tomography screening2 and immunotherapy,3 
may reduce this burden.
For policy makers, it is important to weigh the balance between benefits and 
costs of such new interventions in an economic evaluation. Economic evaluations 
often express health benefits in terms of quality-adjusted life years. This measure 
adjusts the life-years gained by a new intervention (compared to current practice) 
for health-related quality of life (HRQoL) by using health state utility values (HSUVs). 
HSUVs are weights ranging from 0 to 1, with 0 representing death and 1 representing 
full health. In some cases, values below 0 are used to represent health states worse 
than death.
HSUVs can be elicited by a variety of methods. First, patients can be asked 
to directly value their own HRQoL. Valuation can be done using the choice-based 
time trade-off (TTO) or standard gamble (SG) methods, or the non-choice-based 
visual analogue scale (VAS). In simple terms, choice-based methods determine what 
respondents would be willing to give up or risk to avoid living in that health state. 
There are also indirect elicitation methods, such as asking patients to complete a 
generic (i.e. applicable across different diseases) multi-attribute instrument. Examples 
of such generic instruments are the EQ-5D, Short-Form Six Dimensions (SF-6D), and 
Assessment of Quality of Life (AQoL). Based on their answers, each patient is assigned 
a health state, which has been valued by members of the general public. These pre-
determined valuation sets are called the tariff. Another indirect elicitation method 
is drafting vignettes which describe a patient’s HRQoL, and then asking persons to 
value these vignettes. Finally, some studies have attempted to convert other HRQoL 
measures (such as the condition-specific European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire) to an existing generic multi-
attribute instrument without using a valuation method. This practice is called 
mapping.
Most international guidelines, including those from National Institute for Health 
and Care Excellence, prefer that the HRQoL of actual patients is valued by members of 
the general public (i.e. community-based), using choice-based methods.4-6 For reasons 
of comparability (e.g. across studies or diseases), the preferred instrument in most 
guidelines is the EQ-5D.5,6
Because of the broad variation in elicitation methods, HSUVs for lung cancer 
have been reported to vary drastically across the literature.7 Using different HSUVs 
can lead to different policies being ranked as cost-effective.8 Therefore, it is important 
to systematically identify appropriate and high-quality HSUVs for economic 
evaluations.9
Although earlier studies attempted to provide an overview of HSUVs for lung 
cancer, these only included metastatic non-small cell lung cancer cases,10  were 
not systematic reviews,7 did not include an overview of study characteristics nor a 
critical appraisal,7,10 and did not provide a pooled set of methodologically high-quality 
HSUVs.7,10 Therefore, we aimed to provide a current systematic review of HSUVs for 
all types of lung cancer, including an overview of study characteristics and a critical 
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appraisal, and a pooled set of community and choice-based HSUVs for use in economic 
evaluations.
Materials and methods
Study protocol
The protocol for this study was prospectively registered in the PROSPERO database 
under reference number CRD42018081495.11 This study was undertaken in concordance 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
statement,12 the Cochrane Handbook for Systematic Reviews,13 the good practices report 
by the International Society for Pharmacoeconomics and Outcomes Research entitled 
“Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models”,9 
a similar Technical Support Document developed for the National Institute for Health 
and Care Excellence,14 and recent guidance published in PharmacoEconomics.15
Search strategy
A broad and systematic search was conducted in the Embase, Ovid Medline, Web of 
Science, Cochrane CENTRAL, Google Scholar, and the School of Health and Related 
Research Health Utility Database (ScHARRHUD) databases on March 6, 2017, and 
updated on April 17, 2019. In short, synonyms for “lung cancer” were combined with 
synonyms for the following: “health state utility values”, ”quality of life”, different 
analyses, methods and instruments suitable for eliciting HSUVs, and different valuation 
techniques. Conference abstracts, letters, notes, commentaries and editorials were 
excluded. The complete syntax is provided in the Supplementary Methods. 
Study selection
We used Endnote X9 software to remove duplicates.16 The first and second authors 
screened titles and abstracts of all initial references according to a pre-specified 
algorithm, which was designed to broadly identify studies which may report lung 
cancer-specific HSUVs elicited using any technique (see the Supplementary Methods). 
In short, references were selected when the title or abstract indicated that (1) study 
results were likely lung cancer-specific; and (2) HSUVs were measured, or HRQoL 
was measured using an instrument suitable to elicit HSUVs, or HRQoL scores from 
another instrument were mapped onto a utility scale, or HRQoL was measured and 
the use of a valuation method was mentioned, or the study was a cost-utility analysis, 
or the study was a quality-adjusted survival study. Those references included by only 
one of both reviewers were discussed until reaching consensus. References added after 
the search update were only screened by the first author.
The full text of selected articles was subsequently screened by the first author 
according to a second pre-specified algorithm (see the Supplementary Methods) and 
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discussed with the second author. In short, studies were included for critical appraisal 
if the full text reported at least one original (i.e. not previously published) lung cancer 
specific mean or median HSUV including a measure of variance. Only studies written 
in English or Dutch language were considered. Conference abstracts were not con-
sidered because often only preliminary, incomplete, or non-peer-reviewed data are 
presented. Secondary literature (e.g. literature reviews and cost-utility analyses that 
sourced HSUVs from the literature) was excluded, but checked for cross-references. 
Articles selected for full text screening were also checked for cross-references.
Data extraction and critical appraisal
A digital data extraction form was developed in Microsoft Excel 2016, piloted on six 
studies, and subsequently refined. First, study characteristics were extracted for use 
in a critical appraisal. We developed a custom critical appraisal tool for assessing the 
relevance and validity of the selected studies, based on HSUV-relevant items from 
several established tools and good practices reports.9,14,17-19 In concordance with most 
international guidelines, study relevance was deemed high if HRQoL was measured 
in actual patients, while a choice-based method was used by members of the general 
public to value to HSUVs (i.e. elicitation was community and choice-based).6 Studies 
that scored insufficiently on any of these relevance items were excluded from 
subsequent analyses. This approach prioritizes consistency of the methodology across 
studies.9
For the remaining studies, all study characteristics that may affect HSUVs were 
extracted and summarized. If a single study (or multiple studies using the same data) 
applied different tariffs to the same HRQoL data, only the analysis that applied the 
matching tariff was extracted (i.e. the tariff matching the country of participants 
from whom HRQoL was measured). Similarly, if a single study applied multiple 
instruments to the same patients, only the most commonly preferred instrument 
was extracted. In accordance with several international guidelines, including those 
of the National Institute for Health and Care Excellence, the EQ-5D was preferred, 
followed by other generic preference-based instruments, and finally any remaining 
methods.5,6 Again, this approach prioritizes consistency of methodology across studies. 
Data extraction was done by the first author and subsequently discussed with the 
second author.
Meta-analysis and statistical methods
All studies remaining after critical appraisal were included in subsequent analyses, if 
appropriate. Mean or median HSUVs and standard errors were extracted. If standard 
errors were not available these were calculated using available information.13 In case 
median HSUVs were reported, standard deviations were estimated by dividing the 
interquartile range by 1.35.13 Then, the estimated standard deviation was used to 
calculate the standard error. For studies that reported HSUVs for a control group of 
the general population, we formally tested the disutility due to lung cancer using a 
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t-test, assuming unequal variances. For mapping studies, we extracted the observed 
HSUV data, if available.
If necessary, we first pooled mean HSUVs across strata within studies using a 
fixed effects model.20,21 For studies measuring HSUVs at multiple time-points in the 
same individuals, we only extracted and pooled the HSUV at the time point closest to 
baseline to avoid violating the assumption of independence of observations.22,23
As clinical and study characteristics were expected to vary across studies,7 HSUVs 
across the different studies were then pooled using a random effects model.20,24 To 
account for possible differences in HSUVs by stage,7,25 results were separately pooled 
for studies reporting HSUVs for all stages, for stages I-II, and for stage III-IV. Differences 
between the pooled HSUVs for stage I-II and stage III-IV were formally tested using a 
t-test, assuming unequal variances.
The study selection based on our critical appraisal accounts for several potential 
sources of heterogeneity, including the respondent type (i.e. only patients),7 the 
elicitation method (i.e. only indirect), the valuation method (i.e. only community 
and choice-based),7,25,26 and the upper bound of the utility scale (i.e. only perfect 
health).7 To account for further sources of heterogeneity, a sensitivity analysis pooled 
HSUVs only across those studies that explicitly used the EQ-5D-3L instrument. A 
second sensitivity analysis included only studies that used the EQ-5D instrument 
(regardless of the version), while also applying the tariff matching the country of 
HRQoL respondents.9,27,28 This second sensitivity analysis aimed to provide the 
methodologically most comparable HSUVs for each available country. We further 
conducted exploratory subgroup analyses by histology (non-small cell vs. small cell),7 
sex,27 age,27 treatment modality, treatment line, and progression status. Results of 
the second sensitivity analysis and the different subgroup analyses were not pooled 
because of the anticipated low numbers of studies within each group.
Meta-analysis was performed in R software version 3.6.129 using the meta30 and 
metafor31 packages. We did not assess the risk of publication bias in a funnel plot, 
which is recommended in the PRISMA checklist for systematic reviews,12 because this 
is not meaningful for continuous outcomes in a single group.
Results
Search strategy and study selection
After removing duplicates, our search included 5,828 studies. We further identified 13 
studies by cross-referencing. After screening the titles and abstracts of all identified 
studies, we assessed the full text of 458 studies. Of those, 407 studies were excluded for 
reasons outlined in Figure 1. Hence, 51 studies were included in the critical appraisal.
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Records identified through database searching (March 2017)
Embase (n = 2,896)
Medline Ovid (n = 2,777)
Web of Science (n =1,115)
Cochrane Central (n = 415)
Google Scholar (n = 200)
ScHARRHUD (n = 11)
Total (n = 7,414)
Records after removal of 
duplicates
(n = 4,388) 
Titles and abstracts screened
(n = 5,828) 
Additional records after 
search update (April 2019) 
(n = 1,440) 
Full text screened
(n = 458) 
Additional cross references 
Not in database search 
(n = 13)
In database search (n = 23) 
Records excluded 
(n = 5,406) 
Records excluded, with 
reasons 
Conference abstracts (n = 47)
Reviews (n = 7)
Study protocol (n = 2) 
Expert opinion (n = 3)
Non-English or Dutch language 
(n = 6)
HRQoL not measured (n = 2)
Economic evaluation without 
original HSUVs (n = 170)
No HSUV reported (n = 93)
Non-lung cancer specific 
HSUVs (n = 38)
Non-original data (n = 14)
No variance (n = 21)
Full text not available (n = 4)
Total (n = 407) 
Studies included for critical 
appraisal
(n = 51) 
Studies included in meta-
analysis (n = 27)
Analyses included across these 
studies (n = 28) 
Records excluded due to low 
relevance (not community and 
choice-based)
(n = 24) 
Figure 1: Flowchart of selection of studies reporting community and choice-based health state 
utility values for lung cancer. Abbreviations: HRQoL = health-related quality of life; HSUV = 
health state utility value; ScHARRHUD = School of Health and Related Research Health Utility 
Database.
Critical appraisal
The relevance of 27 out of 51 studies was high (see Supplementary Table 1).32-58 Of 
these, one study separately analyzed two datasets,36 which were treated as separate 
studies. The remaining 24 studies were excluded from subsequent analyses.59-82 
Among the excluded studies, 4 did not measure HRQoL in patients,72,77,81,82 9 did not use 
valuation by members of the general public,59,60,63,69,71,72,74,81,82 11 did not use a choice-based 
method for valuation,59,63,65,67-71,74,76,81 and 9 had missing data on one or more of these 
items.61,62,64,66,73,75,78-80
 Among included studies, the number of patients included for HSUV analysis 
ranged from 43 to 2396. Only 2 out of 27 studies clearly stated that missing HRQoL 
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data were imputed, or that HRQoL response was complete.37,47 Six studies performed 
multiple HRQoL measurements in the same participants. In 2 of those studies, which 
used time-to-death categories, loss-to-follow-up was not reported.57,58 These 2 studies 
were analyzed separately because the time since diagnosis could not be derived. The 
other 4 studies with repeated measures all reported loss to follow-up at each evaluated 
time-point.40,46,50,52
Study characteristics
Characteristics of the included studies are provided in Supplementary Tables 2a-2c. 
One study included only stage I and/or II cases,47 while 13 studies included only stage III 
and/or IV cases.35-39,44,45,48,49,51,52,57,58 However, 2 of these stage III-IV studies stratified HSUVs 
by time-to-death.57,58 These studies were analyzed in a separate subgroup analysis. 
Among 13 studies that included all stages, 5 stratified HSUVs by stage.33,34,40,42,46 Thus, 
the main analysis included 13 studies with HSUVs for all stages,32-34,40-43,46,50,53-56 6 studies 
with HSUVs for stages I-II,33,34,40,42,46,47 and 17 analyses across 16 studies with HSUVs for 
stage III-IV.33-40,42,44-46,48,49,51,52
Mean time since diagnosis was reported in 8 of the included studies,32,33,36,37,42,43,50,53 
and ranged from 27 days to 2.59 years. All included studies used the EQ-5D instrument, 
except 1 study which used the AQoL instrument40 and 2 studies which used the SF-6D 
instrument.43,54 Among EQ-5D studies, 6 did not specify which version was used,32,37,45,48,49,56 
1 used the new EQ-5D-5L version,55 and 14 used the EQ-5D-3L version.33-36,38,39,41,42,44,46,47,50,51,53 
The 14 studies that explicitly used the EQ-5D-3L version were separately pooled in a 
sensitivity analysis. All EQ-5D studies and the AQoL study used the TTO method for 
valuation, whereas the SF-6D studies used the SG method. Only 3 studies collected 
data through a personal interview.32,46,55 All studies reported mean HSUVs, except 1 
study which reported median HSUVs.40
Thirteen out of 27 studies applied the tariff that matched the country of origin 
of the HRQoL respondents.36,39-42,44-47,49,50,53,55 Out of these 13 studies, one did not use the 
EQ-5D instrument.40 The remaining 12 studies, which comprised 13 analyses, were 
included in a second sensitivity analysis of the methodologically most comparable 
HSUVs for each country.36,39,41,42,44-47,49,50,53,55
Twelve studies included only non-small cell lung cancer cases.33-38,41,47,49-52 The 
remaining studies included all lung cancer cases regardless of histology. Of these 
studies, 3 provided histology-specific HSUVs.46,48,53 However, 1 of these studies included 
only cases with stage IIIb-IV lung cancer.48 For reasons of comparability across studies, 
only the remaining 2 studies were included in a subgroup analysis by histology.46,53
The percentage of male patients ranged between 37 and 93. Five studies provided 
HSUVs stratified by sex.33,40,46,48,53 However, 1 of these studies only included stage IIIb-
IV lung cancer cases.48 Thus, the remaining 4 studies were included in a subgroup 
analysis of HSUVs by sex.33,40,46,53
Mean or median age of patients ranged between 51 and 70. Five studies stratified 
HSUVs by age.33,40,46,48,53 Two of those studies did not provide the number of patients in 
the different age groups.48,53 Of the remaining three studies, which included all stages 
of lung cancer, two used similar age categories. These two studies were included in a 
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subgroup analysis of HSUVs by age.40,46
Thirteen studies allowed the derivation of treatment-specific HSUVs, either 
by inclusion criteria or by HSUV stratification.33-39,44-47,49,53 However, only 7 of these 
studies allowed the derivation of HSUVs according to treatment modality (surgery, 
radiotherapy, chemotherapy, or a combination of those).33,37,39,44,46,47,49 Of these 7 studies, 
2 included all stages of lung cancer. Because the recommended treatment modality 
for lung cancer is mainly based on stage, a subgroup analysis of HSUVs by treatment 
modality was conducted using these 2 studies.33,46 Only 1 study was identified that 
reported HSUVs by treatment line.38 This study was included in a further subgroup 
analysis by treatment line.
We identified 2 studies reporting HSUVs by progression status.38,49 Both studies 
included only metastatic non-small cell lung cancer patients. These studies were 
included in a subgroup analysis by progression status.
Health state utility values
Figure 2 provides an overview of HSUVs across all included studies. The pooled HSUV 
for all stages was 0.68 (95%CI=0.61-0.75) across 5,100 persons. HSUVs for all stages 
ranged from 0.51 (95%CI=0.49-0.53)50 to 0.81 (95%CI=0.78-0.84),43 indicating the presence 
of significant heterogeneity (p<.01). Most heterogeneity could not be attributed to 
sampling error (I2=99%). For stages I-II, the pooled HSUV was 0.78 (95%CI=0.70-0.86) 
across 1,510 persons. There was significant heterogeneity across stage I-II studies 
(p<.01; I2=92%), as results ranged from 0.62 (95%CI=0.51-0.72)40 to 0.88 (95%CI=0.86-0.90).47 
The pooled HSUV for stage III-IV was 0.69 (95%CI=0.65-0.73) across 4,703 persons. The 
analysis of stage III-IV studies showed significant heterogeneity (p<.01; I2=98%), with 
study results ranging from 0.51 (95%CI=0.48-0.54)51 to 0.85 (95%CI=0.83-0.87).39 The 
difference between the pooled HSUV for stage I-II and stage III-IV was statistically 
significant (p=.02). In a sensitivity analysis, only studies that explicitly used the EQ-5D-
3L instrument were pooled (see Supplementary Figure 1). In this sensitivity analysis, 
the pooled HSUVs were similar to those in the main analysis.
Figures 3-5 show the results of the sensitivity analysis of the 12 methodologically 
most comparable studies, which excluded non-EQ-5D studies and studies which did 
not apply the matching tariff matching the country of HRQoL respondents. All of 
these studies used TTO for valuation. For all stages, mean HSUVs ranged from 0.51 
(95%CI=0.49-0.53) in Spain50 to 0.78 in the United States (95%CI=0.77-0.79)46 and Canada 
(95%CI=0.74-0.82)42 (see Figure 3). For stages I-II, results ranged from 0.78 (95%CI=0.74-
0.82) for Canada42 to 0.88 (95%CI=0.86-0.90) for Denmark47 (see Figure 4). For stage III-
IV, the range was 0.61 (95%CI=0.59-0.63) for a study in the United Kingdom36 to 0.85 
(95%CI=0.83-0.87) in Germany39 (see Figure 5).
Among the 2 studies reporting HSUVs for patients with metastatic non-small cell 
lung cancer by time-to-death,57,58 HSUVs decreased consistently throughout the last 
year of life (see Figure 6). HSUVs ranged from 0.83 (95%CI=0.82-0.85) at ≥ 360 days from 
death to 0.56 (95%CI=0.46-0.66) at <30 days from death. Both studies were U.S.-based 
and used the EQ-5D instrument with TTO valuation.
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Source
Stage = All   
Stage = I−II  
Stage = III−IV
Total
Total
Total
Heterogeneity: χ12
2  = 1082.29 (P  < .01), I2 = 99%
Heterogeneity: χ5
2 = 66.29 (P  < .01), I2 = 92%
Heterogeneity: χ16
2  = 682.41 (P  < .01), I2 = 98%
Kimman 2015 [32]
Grutters 2010 [33]
Jang 2010 [34]
Manser 2006 [40]
Khan 2016 [41]
Naik 2017 [42]
Shih 2006 [43]
Tramontano 2015 [46]
Maximiano 2018 [50]
O'Kane 2019 [53]
Rendas−Baum 2019 [54]
Su 2019 [55]
Sullivan 2011 [56]
Grutters 2010 [33]
Jang 2010 [34]
Manser 2006 [40]
Naik 2017 [42]
Tramontano 2015 [46]
Bendixen 2019 [47]
Grutters 2010 [33]
Jang 2010 [34]
Schuette 2012  [35]
Khan 2014 (a) [36]
Khan 2014 (b) [36]
van den Hout 2006 [37]
Chouaid 2013 [38]
Matter−Walstra 2014 [39]
Manser 2006 [40]
Naik 2017 [42]
Pickard 2007 [44]
Thongprasert 2015 [45]
Tramontano 2015 [46]
Erbaycu 2018 [48]
Limwattananon 2018 [49] 
Mendoza 2018 [51]
Meregaglia 2019 [52]
N
624
245
172
91
97
149
51
2396
495
519
43
104
114
144
50
44
89
982
201
101
122
231
670
130
297
255
154
45
60
50
150
1277
266
135
664
96
Mean utility (95% CI)
0.68 [0.61; 0.75]
0.78 [0.70; 0.86]
0.69 [0.65; 0.73]
0.61 [0.60; 0.62]
0.74 [0.71; 0.77]
0.76 [0.73; 0.79]
0.67 [0.61; 0.73]
0.52 [0.45; 0.58]
0.78 [0.74; 0.82]
0.81 [0.78; 0.84]
0.78 [0.77; 0.79]
0.51 [0.49; 0.53]
0.75 [0.74; 0.77]
0.58 [0.54; 0.62]
0.75 [0.70; 0.81]
0.56 [0.48; 0.64]
0.76 [0.72; 0.80]
0.80 [0.74; 0.85]
0.62 [0.51; 0.72]
0.78 [0.74; 0.82]
0.80 [0.79; 0.81]
0.88 [0.86; 0.90]
0.71 [0.65; 0.76]
0.75 [0.72; 0.78]
0.66 [0.63; 0.69]
0.61 [0.59; 0.63]
0.75 [0.71; 0.79]
0.57 [0.53; 0.61]
0.66 [0.62; 0.70]
0.85 [0.83; 0.87]
0.68 [0.61; 0.74]
0.77 [0.71; 0.83]
0.74 [0.70; 0.78]
0.67 [0.62; 0.72]
0.77 [0.76; 0.78]
0.66 [0.61; 0.70]
0.62 [0.58; 0.65]
0.51 [0.48; 0.54]
0.77 [0.73; 0.80]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Figure 2: Pooled results of studies reporting community and choice-based health state utility 
values for lung cancer by stage. The size of the symbol representing the effect size in each study 
is relative to the weight it had in random effects meta-analysis. Not all studies included both 
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stage I-II and stage III-IV cases. Not all studies that did include all stages stratified by stage. 
The total number of persons contributing to the pooled value for all stages was 5100; for stages 
I-II, the total number was 1510; and for stages III-IV, the total number was 4703. The difference 
between the pooled values for stages I-II and III-IV was statistically significant (p=.02). Arabic 
numerals between square brackets next to author names refer to the reference list.
Source
Tariff = Canada
Tariff = China 
Tariff = Spain 
Tariff = UK    
Tariff = US    
Naik 2017 [42]
O'Kane 2019 [53]
Su 2019 [55]
Maximiano 2018 [50]
Khan 2016 [41]
Tramontano 2015 [46]
N
149
519
104
495
97
2396
Mean utility (95% CI)
0.78 [0.74; 0.82]
0.75 [0.74; 0.77]
0.75 [0.70; 0.81]
0.51 [0.49; 0.53]
0.52 [0.45; 0.58]
0.78 [0.77; 0.79]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Figure 3: Results of sensitivity analysis including only the methodologically most comparable 
studies reporting community and choice-based health state utility values for all stages of lung 
cancer. Studies included in this sensitivity analysis used the EQ-5D instrument and applied the 
tariff matching the country of responding patients. Pooling results for this sensitivity analysis 
using a random effects model was not possible due to the small number of studies within 
subgroups. The size of the symbol representing the effect size in each study is relative to the 
weight it would have in fixed effects meta-analysis (i.e. relative to the inverse of its variance). 
Arabic numerals between square brackets next to author names refer to the reference list. 
Abbreviations: UK = United Kingdom; US = United States.
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Source
Tariff = Canada 
Tariff = Denmark
Tariff = US     
Naik 2017 [42]
Bendixen 2019 [47]
Tramontano 2015 [46]
N
89
201
982
Mean utility (95% CI)
0.78 [0.74; 0.82]
0.88 [0.86; 0.90]
0.80 [0.79; 0.81]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Figure 4: Results of sensitivity analysis including only the methodologically most comparable 
studies reporting community and choice-based health state utility values for stage I-II lung 
cancer. Studies included in this sensitivity analysis used the EQ-5D instrument and applied the 
tariff matching the country of responding patients. Pooling results for this sensitivity analysis 
using a random effects model was not possible due to the small number of studies within 
subgroups. The size of the symbol representing the effect size in each study is relative to the 
weight it would have in fixed effects meta-analysis (i.e. relative to the inverse of its variance). 
Arabic numerals between square brackets next to author names refer to the reference list. 
Abbreviations: US = United States.
Source
Tariff = Canada  
Tariff = Germany 
Tariff = Thailand
Tariff = UK      
Tariff = US      
Naik 2017 [42]
Matter−Walstra 2014 [39]
Thongprasert 2015 [45]
Limwattananon 2018 [49] 
Khan 2014 (a) [36]
Khan 2014 (b) [36]
Pickard 2007 [44]
Tramontano 2015 [46]
N
60
154
150
135
670
130
50
1277
Mean utility (95% CI)
0.77 [0.71; 0.83]
0.85 [0.83; 0.87]
0.67 [0.62; 0.72]
0.62 [0.58; 0.65]
0.61 [0.59; 0.63]
0.75 [0.71; 0.79]
0.74 [0.70; 0.78]
0.77 [0.76; 0.78]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Figure 5: Results of sensitivity analysis including only the methodologically most comparable 
studies reporting societal choice-based health state utility values for stage III-IV lung cancer. 
Studies included in this sensitivity analysis used the EQ-5D instrument and applied the tariff 
matching the country of responding patients. Pooling results for this sensitivity analysis using 
a random effects model was not possible due to the small number of studies within subgroups. 
The size of the symbol representing the effect size in each study is relative to the weight it would 
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have in fixed effects meta-analysis (i.e. relative to the inverse of its variance). Arabic numerals 
between square brackets next to author names refer to the reference list. Abbreviations: UK = 
United Kingdom; US = United States.
Source
TTD = >= 360 
TTD = 180−360
TTD = 30−180 
TTD = <30
Insinga 2018 [57]
Insinga 2019 [58]
Insinga 2018 [57]
Insinga 2019 [58]
Insinga 2018 [57]
Insinga 2019 [58]
Insinga 2018 [57]
Insinga 2019 [58]
N
184
86
94
79
167
142
32
39
Mean utility (95% CI)
0.83 [0.82; 0.85]
0.84 [0.82; 0.86]
0.76 [0.74; 0.79]
0.81 [0.80; 0.83]
0.71 [0.69; 0.73]
0.74 [0.72; 0.76]
0.56 [0.46; 0.66]
0.57 [0.48; 0.65]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Figure 6: Results of studies reporting community and choice-based health state utility values for 
lung cancer by time-to-death. Patients could contribute to multiple time-to-death categories. 
Therefore, an overall pooled result could not be provided. The size of the symbol representing 
the effect size in each study is relative to the weight it would have in fixed effects meta-analysis 
(i.e. relative to the inverse of its variance). Arabic numerals between square brackets next to 
author names refer to the reference list. Abbreviations: TTD= time-to-death, expressed in days.
Results for the subgroup analysis by histology are shown in Supplementary Figure 
2. The included studies both used the EQ-5D instrument with TTO valuation.46,53 
The HSUV for non-small cell lung cancer was similar in the U.S.-based study by 
Tramontano and colleagues and the Canadian study by O’Kane and colleagues. In 
the U.S.-based study, the HSUV for non-small cell lung cancer (0.78 (95%CI=0.77-0.79)) 
was marginally higher than the HSUV for small cell lung cancer (0.76 (95%CI=0.74-
0.78)). In the smaller Canadian study, there was a more substantial difference in HSUV 
between non-small cell lung cancer (0.77 (95%CI=0.76-0.79)) and the HSUV for small cell 
lung cancer (0.63 (95%CI=0.56-0.70)).
As shown in Supplementary Figure 3, HSUVs for men did not differ substantially 
across the four studies included in the subgroup analysis by sex.33,40,46,53 HSUVs for men 
ranged from 0.72 (95%CI=0.66-0.78) in the Australian study by Manser and colleagues, 
which applied the AQoL instrument with TTO valuation,40 to 0.78 (95%CI=0.77-0.79) 
in the U.S.-based study by Tramontano and colleagues, which applied the EQ-5D 
instrument with TTO valuation.46 In three of these studies, the HSUV for men was 
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similar to the HSUV for women, which ranged from 0.73 (95%CI=0.69-0.77) in the study 
by Grutters and colleagues, which applied the EQ-5D instrument to Dutch patients 
using the U.K. TTO valuation set,33 to 0.77 (95%CI=0.76-0.78) in the U.S.-based study 
by Tramontano and colleagues.46 However, the Australian study by Manser and 
colleagues40 reported substantially lower HSUV for women (0.52 (95%CI=0.44-0.60)).
Results for the subgroup analysis by age are shown in Supplementary Figure 4. 
In both age groups, HSUVs were higher in the U.S.-based study by Tramontano and 
colleagues, which applied the EQ-5D instrument with TTO valuation,46 compared with 
the Australian study by Manser and colleagues, which applied the AQoL instrument 
with TTO valuation.40 In both of the included studies, the HSUV for patients younger 
than 65 years was marginally lower than the HSUV for patients older than 65 years. 
For example, in the U.S. based study, the HSUV for those younger than 65 years was 0.76 
(95%CI=0.75-0.77), compared with 0.80 (95%CI=0.79-0.81) for those older than 65 years.46
Supplementary Figure 5 shows the results for the subgroup analysis by treatment 
modality. In the Dutch study by Grutters and colleagues,33 which used the EQ-5D 
instrument with the U.K. TTO valuation set, HSUVs ranged from 0.62 (95%CI=0.51-
0.73) among those receiving radiotherapy only to 0.86 (95%CI=0.76-0.96) among those 
receiving surgery with radiotherapy. In the U.S.-based study by Tramontano and 
colleagues, which also applied the EQ-5D instrument with TTO valuation, HSUVs 
ranged from 0.72 (95%CI=0.67-0.77) among those receiving surgery and radiotherapy to 
0.81 (95%CI=0.80-0.82) among those receiving surgery only.46
HSUVs by treatment line are shown in Supplementary Figure 6. Only 1 study was 
included in this subgroup analysis.38 This study applied the EQ-5D instrument to a 
multinational selection of patients with metastatic non-small cell lung cancer and 
applied the U.K. TTO tariff. The HSUV was 0.70 (95%CI=0.66-0.74) for the first treatment 
line, 0.73 (95%CI=0.67-0.78) for the second treatment line, and 0.57 (95%CI=0.47-0.66) for 
the third and fourth treatment lines.
Supplementary Figure 7 shows the results for the subgroup analysis of HSUVs by 
progression status.38,49 Both studies included patients with metastatic non-small cell 
lung cancer and used the EQ-5D instrument. The multinational study by Chouaid 
and colleagues applied the U.K. TTO tariff to all patients,38 whereas the Thai study by 
Limwattanon and colleagues applied the matching Thai TTO tariff.49 In both studies, 
the HSUV for the “progression free” health state was similar; 0.70 (95%CI=0.66-0.74) in 
the study by Chouaid and colleagues38 compared with 0.68 (95%CI=0.62-0.74) in the 
study by Limwattanon and colleagues.49. In the study by Chouaid and colleagues,38 the 
HSUV for the “progressive” health state (0.58 (95%CI=0.50-0.66)) was substantially lower 
than the HSUV for the “progression free” health state (0.70 (95%CI=0.66-0.74). This was 
also the case for the study by Limwattanon and colleagues,49 although the 95%CI for 
the “progressive disease” health state was wide.
Finally, Supplementary Table 3 shows the results for the 2 studies that included a 
control group of members of the general population.45,56 Both studies applied the EQ-
5D instrument with TTO valuation. The difference in HSUV between lung cancer cases 
and controls (i.e. disutility) was 0.11 (95%CI=0.05-0.17) in Thailand,45 and 0.27 (95%CI=0.18-
0.36) in the study applying the U.K. tariff to HRQoL data from U.S. patients.56 In both 
studies, the disutility due to lung cancer was statistically significant (p<0.01).
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Discussion
To our knowledge, we are the first to provide a systematic review and meta-analysis 
of community and choice-based HSUVs across all stages of lung cancer. Our pooled 
results show that the mean HSUV across the literature for stage I-II lung cancer (0.78; 
95%CI=0.70-0.86) is statistically significantly higher than the mean HSUV for stage III-
IV lung cancer (0.69; 95%CI=0.65-0.73). This makes sense, as stage I-II lung cancer can 
often be treated with curative intent, whereas metastatic disease (stage III-IV) often 
requires an ongoing palliative treatment with chemotherapy and/or radiotherapy.83 
The pooled HSUV for all stages (0.68; 95%CI=0.61-0.75) was close to that of stage III-IV, 
which can be explained by the fact that lung cancer is most often diagnosed at stage 
IV.84
While these pooled stage-specific HSUVs provide an overall mean HSUV across 
the literature, significant heterogeneity was present in all three stage groups, which 
could not be explained by sampling error. In our sensitivity analysis that included 
only the methodologically most comparable studies, the most important study 
characteristics were the same (i.e. respondent type, stage of disease, elicitation 
method, instrument, valuation method, valuation population, and upper bound 
of the utility scale). Furthermore, these studies applied the tariff that matches the 
country of responding patients, which further reduces potential heterogeneity. Among 
these studies, stage-specific HSUVs strongly differed by country (and thus by tariff). 
Such studies were only identified for 8 countries: Canada, China, Spain, the United 
Kingdom, the United States, Denmark, Germany, and Thailand. If stage-specific 
HSUVs provide sufficient granularity, authors of future economic evaluations of lung 
cancer interventions conducted in one of these 8 countries may consider using HSUVs 
from the corresponding study identified in this sensitivity analysis. For example, a 
study seeking to investigate the cost-effectiveness of lung cancer screening in the 
United States could use the stage-specific HSUVs from the study by Tramontano and 
colleagues.46 However, for most countries no such studies were identified. In addition, 
some authors may prioritize maximizing the use of available data over selecting one 
methodologically optimal study. In both cases, our pooled analysis may provide the 
best available stage-specific HSUVs.
For some economic evaluations, stage-specific HSUVs may not provide sufficient 
granularity. For example, further stratification of HSUVs for metastatic lung cancer 
may be sought by treatment line or progression status. Subgroup analyses indicated 
that HSUVs for patients with metastatic non-small cell lung cancer may indeed be 
lower among those with progressed disease and among those undergoing third or 
fourth line of treatment. Further exploratory subgroup analyses by histology, sex, 
age, and treatment modality did not provide unambiguous evidence for differences 
in HSUVs by these variables. For example, there were differences in HSUVs across 
treatment modalities within studies. However, the recommended and provided 
treatment modalities for lung cancer are mainly based on stage,85 which may partly 
explain these differences. In addition, results were inconsistent across studies. For 
example, receiving surgery with radiotherapy was associated with the lowest HSUV in 
one study, but with the highest HSUV in another study. In general, few studies were 
available with the required level of granularity for each of the conducted subgroup 
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analyses, reflecting the need for more high quality research. The lack of clear evidence 
regarding the effect of histology, sex, age, and treatment modality on HSUVs provides 
additional support for our suggestion to use stage-specific (and if available, country-
specific) HSUVs, if possible. Still, if authors of economic evaluations require HSUVs for 
other health states, Supplementary Tables 2a-2c provide a comprehensive breakdown 
of patient characteristics, methodological characteristics, and the stratification 
variables used in each of the included studies. These tables may be used to identify 
specific studies meeting the needs of such analyses.
We only identified two relevant studies that included a matched control group. 
In these studies, the disutility due to lung cancer was 0.11 (95%CI=0.05-0.17), and 0.27 
(95%CI=0.18-0.36), respectively. For comparison, the minimally important difference 
in EQ-5D HSUVs (defined as the smallest change that is perceived by patients as 
beneficial or that would result in a change in treatment) has been estimated to be 
0.06 for the U.S. and 0.08 for the U.K.44,86 It is important that more future HSUV studies 
include an adequately matched control group of members of the general population. 
Otherwise, the disutility due to lung cancer could be overestimated, as members of 
the general public do not have perfect health.27,56
Strengths and limitations
A major strength of our study is the inclusion of both non-small cell lung cancer 
and small cell lung cancer, regardless of stage, whereas a previous review included 
only advanced non-small cell lung cancer cases.10 Our search strategy, which was 
constructed in collaboration with an information specialist, was also a major 
strength. We screened almost 6000 abstracts and over 450 full text articles, identifying 
51 peer-reviewed studies reporting original HSUVs. Through this search strategy, we 
identified a broader range of relevant studies compared with two earlier reviews. The 
first, which was not a systematic review, screened 147 abstracts, yielding 22 studies 7. 
The second screened 1832 abstracts, yielding 34 inclusions, of which 16 appeared to be 
non-peer-reviewed conference abstracts (for some of these abstracts, we identified 
and included the full study). In addition, we included a thorough assessment of study 
characteristics, relevance, and validity, which allowed us to focus on comparable 
studies presenting the preferred community and choice-based HSUVs. In contrast, 
the two previous reviews included studies regardless of quality and methodology, 
including expert opinions.7,10
Due to the large number of identified studies and the assessment of study 
characteristics, we were able to select the methodologically most comparable 
community and choice-based HSUV studies. Therefore, we could control for the most 
important factors that may affect HSUVs without relying on meta-regression, which 
can be prone to false positive associations.87 Nevertheless, heterogeneity remained 
present across the identified studies. These differences may be due to additional 
factors that we were not able to fully control for.
First, the time of measurement relative to diagnosis or treatment may influence 
HSUVs.25,28 Unfortunately, we could not account for this possible effect in our main 
analysis. Many of the included studies in our meta-analysis did not report the mean 
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time between diagnosis and HSUV measurement. Also, while 4 out of 27 studies 
measured HSUVs at multiple time-points in the same patients, we could only 
include a single time-point in our main analysis to avoid violating the assumption of 
independent observations. For those studies, we included the observation closest to 
baseline to limit the variability of time-points across studies. Despite these limitations, 
the subgroup analysis by time-to-death showed that HSUVs for metastatic non-small 
cell lung cancer tend to decrease during the last year of life. In particular, HSUVs had 
decreased by approximately a third by the last month of life. A possible way to adjust 
for this effect in economic evaluations is to proportionally adjust the chosen HSUV for 
metastatic disease during the last phase of life.
Second, it can be difficult to disentangle the effects of some variables, even when 
comparing methodologically similar studies. For example, one of the studies in our 
meta-analysis reported HSUVs for two U.K.-based trials.36 Both trials measured HRQoL 
in stage III-IV non-small cell lung cancer patients using the EQ-5D instrument, and 
valued using the U.K. TTO tariff. However, the mean HSUV was 0.61 (95%CI:0.59-0.63) in 
the first trial and 0.75 (95%CI:0.71-0.79) in the second trial. The mean age of participants 
was 77 years in the first trial and 62 years in the second trial. Also, participants in the 
first trial received erlotinib or placebo, whereas patients in the second trial received 
radiotherapy and chemotherapy. Therefore, both age and treatment may have driven 
these markedly different HSUVs. Unfortunately, reporting and stratification of HSUVs 
was inconsistent across studies in our meta-analysis, which limited the ability to 
disentangle such effects.
Conclusions
The presented evidence supports the use of stage-specific HSUVs for lung cancer. In 
addition, it supports the use of country-specific HSUVs. However, stage-specific HSUVs 
were not available for many countries. Therefore, our pooled HSUVs may provide 
the best available stage-specific HSUVs for most countries. For metastatic non-small 
cell lung cancer, adjusting for the decreasing HSUVs in the last year of life may be 
considered. Based on a limited number of studies, further stratification of HSUVs for 
metastatic non-small cell lung cancer by treatment line or progression status may 
also be considered. There is currently little evidence supporting the use of histology, 
sex, age, or treatment modality-specific HSUVs. Still, if HSUVs for other health states 
are required, our comprehensive breakdown of study characteristics can help identify 
suitable studies.
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Search Query
Embase.com
(‘lung cancer’/de OR ‘lung carcinoma’/de OR (((lung OR pulmonar* ) NEAR/6 (cancer* 
OR carcino* OR neoplas*))):ab,ti) AND (‘quality of life’/exp/mj OR ‘quality of life 
assessment’/de/mj OR ‘cost utility analysis’/de OR ‘cost benefit analysis’/de OR ‘quality 
adjusted life year’/exp OR ‘vignette’/de OR ‘visual analog scale’/de OR ((qualit* NEAR/3 
life NEAR/6 (assess* OR measure*)) OR (utilit* NEAR/3 (cost OR Health OR value* OR 
scale*)) OR utilities OR qaly OR (cost NEAR/3 benefit*) OR eq-5d OR eq5d OR euroqol 
OR euro-qol OR hui OR ((sf or short-form) NEXT/1 (6 OR 12 OR 20 OR 36 OR thirtysix OR 
thirty-six OR twenty OR twelve OR six)) OR sf6* OR sf12* OR sf36* OR sf36* OR ((qualit*) 
NEAR/3 adjusted NEAR/3 (life-year* OR life-duration* OR life-expect* OR lifeyear*)) 
OR qaly* OR qald* OR qale* OR qtime* OR (qualit* NEAR/3 (well-being OR wellbeing)) 
OR qwb OR aqol OR 15d OR vignette* OR direct-elicitation* OR time-trade-off* OR 
time-tradeoff* OR tto OR standard-gamble* OR best-worst-scale* OR ‘visual analog* 
scale’ OR vas OR eortc-qlq-c30 OR fact-l OR hye OR hyes OR (health* NEAR/3 year* 
NEAR/3 equivalent*) OR (preference* NEAR/3 (state* OR score* OR value* OR valuat* 
OR weight)) OR hsuv OR hsuvs):ab,ti) NOT ([Conference Abstract]/lim OR [Letter]/lim 
OR [Note]/lim OR [Editorial]/lim)
Medline Ovid 
(exp “Lung Neoplasms”/ OR (((lung OR pulmonar* ) ADJ6 (cancer* OR carcino* OR 
neoplas*))).ab,ti,kf.) AND (*”Quality of Life”/ OR “Cost-Benefit Analysis”/  OR “Quality-
Adjusted Life Years”/ OR “Visual Analog Scale”/ OR ((qualit* ADJ3 life ADJ6 (assess* 
OR measure*)) OR (utilit* ADJ3 (cost OR Health OR value* OR scale*)) OR utilities 
OR qaly OR (cost ADJ3 benefit*) OR eq-5d OR eq5d OR euroqol OR euro-qol OR hui 
OR ((sf or short-form) ADJ (6 OR 12 OR 20 OR 36 OR thirtysix OR thirty-six OR twenty 
OR twelve OR six)) OR sf6* OR sf12* OR sf36* OR sf36* OR ((qualit*) ADJ3 adjusted 
ADJ3 (life-year* OR life-duration* OR life-expect* OR lifeyear*)) OR qaly* OR qald* 
OR qale* OR qtime* OR (qualit* ADJ3 (well-being OR wellbeing)) OR qwb OR aqol 
OR 15d OR vignette* OR direct-elicitation* OR time-trade-off* OR time-tradeoff* OR 
tto OR standard-gamble* OR best-worst-scale* OR “visual analog* scale” OR vas OR 
eortc-qlq-c30 OR fact-l OR hye OR hyes OR (health* ADJ3 year* ADJ3 equivalent*) 
OR (preference* ADJ3 (state* OR score* OR value* OR valuat* OR weight)) OR hsuv 
OR hsuvs).ab,ti,kf.) NOT (letter OR news OR comment OR editorial OR congresses OR 
abstracts).pt.
Cochrane CENTRAL 
((((lung OR pulmonar* ) NEAR/6 (cancer* OR carcino* OR neoplas*))):ab,ti) AND 
(((qualit* NEAR/3 life NEAR/6 (assess* OR measure*)) OR (utilit* NEAR/3 (cost OR 
Health OR value* OR scale*)) OR utilities OR qaly OR (cost NEAR/3 benefit*) OR eq 
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NEXT/1 5d OR eq5d OR euroqol OR euro NEXT/1 qol OR hui OR ((sf or short NEXT/1 form) 
NEXT/1 (6 OR 12 OR 20 OR 36 OR thirtysix OR thirty NEXT/1 six OR twenty OR twelve 
OR six)) OR sf6* OR sf12* OR sf36* OR sf36* OR ((qualit*) NEAR/3 adjusted NEAR/3 
(life NEXT/1 year* OR life NEXT/1 duration* OR life NEXT/1 expect* OR lifeyear*)) 
OR qaly* OR qald* OR qale* OR qtime* OR (qualit* NEAR/3 (well NEXT/1 being OR 
wellbeing)) OR qwb OR aqol OR 15d OR vignette* OR direct NEXT/1 elicitation* OR 
time NEXT/1 trade NEXT/1 off* OR time NEXT/1 tradeoff* OR tto OR standard NEXT/1 
gamble* OR best NEXT/1 worst NEXT/1 scale* OR ‘visual analog* scale’ OR vas OR 
eortc NEXT/1 qlq NEXT/1 c30 OR fact NEXT/1 l OR hye OR hyes OR (health* NEAR/3 
year* NEAR/3 equivalent*) OR (preference* NEAR/3 (state* OR score* OR value* OR 
valuat* OR weight)) OR hsuv OR hsuvs):ab,ti) 
Web of science  
TS=(((((lung OR pulmonar* ) NEAR/5 (cancer* OR carcino* OR neoplas*)))) AND 
(((qualit* NEAR/2 life NEAR/5 (assess* OR measure*)) OR (utilit* NEAR/2 (cost OR 
Health OR value* OR scale*)) OR (cost NEAR/2 benefit*) OR ((qualit*) NEAR/2 adjusted 
NEAR/2 (“life-year*” OR “life-duration*” OR “life-expect*” OR lifeyear*))  OR vignette* 
OR “direct-elicitation*” OR “time-trade-off*” OR “time-tradeoff*” OR “standard-
gamble*” OR “best-worst-scale*” OR “visual analog* scale” OR (health* NEAR/2 year* 
NEAR/2 equivalent*) OR (preference* NEAR/2 (state* OR score* OR value* OR valuat* 
OR weight)))) ) AND DT=(article) 
Google scholar
“lung|pulmonary cancer|carcinoma|neoplasms” “quality*life 
assessment|measurement”|”cost|Health utility”|utilities|”quality adjusted 
life|lifeyear|lifeyears”
The School of Health and Related Research Health Utility Database 
(ScHARRHUD)
Lung cancer
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Inclusion criteria for title/abstract screening
1a. Title/abstract reports the study includes specifically lung cancer patients 
OR
1b. Title/abstract reports that results were stratified by cancer type AND (these cancer 
types include lung cancer OR keywords include “lung cancer”)
AND one of the following 
2a. Title/abstract reports health state utility values (HSUVs) (on a 0-1 scale) were 
measured or reported as an outcome
OR 
2b. Title/abstract reports health-related quality of life (HRQoL) was measured AND 
the instrument used was reported AND the instrument used is suitable for the elic-
itation of HSUVs:
• EQ-5D (EuroQol five dimensions) 
• SF-6D (Short-Form-6D) OR SF-12 OR SF-36
• HUI (Health utility Index; version 1,2 or 3)
• QWB (Quality of Well-Being)
• AQoL (Assessment of Quality of Life)
• 15D
• Vignettes
• Direct elicitation
OR
2c. Title/abstract reports HRQoL was measured (not including pain, nausea, or other 
symptoms) AND the use of a “valuation method” suitable for the elicitation of HSUVs 
was mentioned: 
• Time trade-off (TTO)
• Standard gamble (SG)
• Best Worst Scale (BWS)
• Visual analogue scale (VAS)
OR
2d. Title/abstract reports the study type is a cost-utility analysis (thus using quali-
ty-adjusted life years (QALYs) and not only life years (LYs)) 
OR 
2e. Title/abstract reports the study type is a quality adjusted-survival study (some-
times referred to as Q-TWiST)
OR
2f. Title/abstract reports HSUVs were mapped from an instrument not mentioned 
under item 2b (for example from a disease-specific measure, such as the EO-
RTC-QLQ-C30), onto a utility scale (0-1) 
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Exclusion criteria for title/abstract screening:
• Animal studies
• Conference abstracts 
• Editorials/commentaries/letters
• Reviews (systematic reviews/meta-analyses/overview articles)
• Study protocol
• Expert opinion (expert opinion was used without any instrument and/or 
valuation method)
• Guidelines
• Non-English or Dutch language
• Mesothelioma studies
• HRQoL not measured
• Studies with HRQoL measured as endpoint, but used instrument or valuation not 
mentioned in title/abstract OR used instrument or valuation mentioned, but 
other than listed under 2b and 2c.
• HRQoL values were mapped from one instrument to another AND HSUVs are not 
mentioned in title or abstract
• Economic evaluation without original HSUVs (for example, cost-effectiveness 
analysis not using quality adjusted life years (QALYs) but only life years (LYs), OR 
cost-utility analysis with non-original HSUVs)
• Non lung cancer specific HSUVs (non-lung cancer specific study AND no 
stratification by cancer type)
• Non-original data (previously published HSUVs reported)
Inclusion criteria for full text screening
Reports original, lung cancer specific mean or median HSUVs, including a measure of 
variance (e.g., sample size + variance, standard deviation, standard error, interquartile 
range), elicited using one of the following methods:
• EQ-5D (EuroQol Five Dimensions Questionnaire) 
• SF-6D (Short-Form-6D) 
• HUI (Health Utility Index; 1,2 or 3)
• QWB (Quality of Well-Being)
• AQoL (Assessment of Quality of Life)
• 15D
• Vignettes
• Direct elicitation
• Mapping of HRQOL measures from another instrument (e.g. FACT-L); HSUVs are 
reported in the manuscript. If utilities were mapped from an instrument listed 
above, include only the original HSUVs.
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Exclusion criteria for full text screening:
• Animal studies
• Conference abstracts
• Editorials/commentaries/letters
• Reviews (systematic reviews/meta-analyses/overview articles)
• Study protocol
• Expert opinion (expert opinion was used without any instrument and/or 
valuation method)
• Guidelines
• Non-English or Dutch language
• Mesothelioma studies
• HRQoL not measured
• Economic evaluation without original HSUVs (for example, cost-effectiveness 
analysis not using quality adjusted life years (QALYs) but only life years (LYs), OR 
cost-utility analysis with non-original HSUVs)
• No HSUV (no numerical mean or median HSUVs reported). 
• Non lung cancer specific HSUVs (non-lung cancer specific study AND no stratifi-
cation by cancer type)
• Non-original data (previously published HSUVs reported OR another study used 
the same underlying data to derive HSUVs with higher-quality methodology, e.g. 
matching tariff)
• No measure of variance reported with HUVs (and no data to estimate variance)
• Full text not available
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Supplementary Table 1: Critical appraisal of studies reporting mean or median health state 
utility values for lung cancer.
Relevance Validity
Source Res-
pon-
dents a
Valuati-
on popu-
lation b
Valuati-
on me-
thod c
Sample 
size d
HRQoL 
respon-
se e
Handling 
missing 
data f
Loss 
to fol-
low-up g
Kimman 2015 1 + + + 624 624 NR NAP
Yabroff 2007 2 + - - 439 NR NR NAP
Lee 2011 3 + - + 241 220 - NAP
Grutters 2010 4 + + + 374 245 - NAP
Trippoli 2001 5 + NR NR 95 92 - NAP
Iyer 2013 6 + NR NR 837 832 - NAP
Jang 2010 7 + + + 172 172 NR NAP
Chouaid 1998 8 + - - 10 10 NR NAP
Blackhall 2014 9 + NR NR 347 313 - NAP
Rauma 2015 10 + + - 276 230 - NAP
Geerse 2017 11 + NR NR 223 191 - NAP
Schuette 2012 12 + + + 542 231 - NAP
Khan 2014 (a) 13 + + + 670 670 NR NAP
Khan 2014 (b) 13 + + + 130 130 NR NAP
Lamers 2007 14 + + - 210 131 - NR
van den Hout 2006 
15
+ + + 297 297 + NAP
Verduyn 2012 16 + + - 261 251 - NAP
Burfeind 2010 17 + - - 113 113 - +
Huang 2017 (1) 18 + + ± NR NR - NR
Chouaid 2013 19 + + + 319 255 - NAP
Matter-Walstra 
2014 20
+ + + 154 154 - NAP
Manser 2006 21 + + + 116 91 - +
Papatheofanis 
2000 22
+ - - 134 23 - NAP
Khan 2016 23 + + + 100 97 NR NAP
Naik 2017 24 + + + NR 149 - NAP
Shih 2006 25 + + + NR 51 - NAP
Kennedy 1995 26 - - + 9 9 NR NAP
Ilonen 2007 27 + + NR 98 31 - NAP
Pickard 2007 28 + + + 50 50 NR NAP
Ko 2003 29 + - - 54 54 NR NAP
Thongprasert 2015 30 + + + 150 150 NR NAP
Galetta 2015 31 + NR NR 118 118 + NAP
Tramontano 2015 32 + + + 5015 2396 - +
Bendixen 2019 33 + + + 201 201 + NAP
Erbaycu 2018 34 + + + 266 266 - NAP
Huang 2017 (2) 35 + + ± NR NR - NR
table continues
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Relevance Validity
Source Res-
pon-
dents a
Valuati-
on popu-
lation b
Valuati-
on me-
thod c
Sample 
size d
HRQoL 
respon-
se e
Handling 
missing 
data f
Loss 
to fol-
low-up g
Insinga 2018 36 + + + NR NR - NR
Insinga 2019 37 + + + NR NR - NR
Kim 2018 38 - + + 515 515 - NAP
Limwattananon 
2018 39
+ + + 135 135 NR NAP
Maximiano 2018 40 + + + 760 495 - +
Mendoza 2018 41 + + + 664 664 - NAP
Meregaglia 2019 42 + + + 96 96 - +
O'Kane 2019 43 + + + 519 519 NR NAP
Reck 2018 (1) 44 + NR NR 582 419 - NAP
Reck 2018 (2) 45 + NR NR 272 186 - NAP
Rendas-Baum 2019 
46
+ + + 43 43 NR NAP
Su 2019 47 + + + 104 104 - NAP
Wood 2019 48 + NR NR 1030 1030 NR NAP
Goodwin 1988 49 - - - 21 21 NR NAP
Cykert 2000 50 - - + 64 64 NR NAP
Sullivan 2011 51 + + + 114 114 - NAP
Abbreviations: NR = not reported; NAP = not applicable; HRQoL = health-related quality of life; 
HSUV = health state utility value.
Studies with low relevance (i.e., that score a “-” sign or “NR” for any of the relevance criteria) 
were not included for subsequent analyses because they are not community- and choice-based. 
Superscript Arabic numerals refer to the list of references at the end of this appendix.
a What was the respondent type? 
Plus sign indicates patients 
Minus sign indicates all others
b What population was used to valuate HRQoL (scores or vignettes) to HSUVs? 
Plus sign indicates the general population. 
Minus sign indicates all others (e.g., patients, caregivers, experts). 
For mapping studies, consider the valuation method of the instrument to which HRQoL 
scores were mapped (observed data).
c  What method was used to valuate HRQOL scores to HSUVs? 
Plus sign indicates a choice-based method (i.e. time trade-off or standard gamble). 
Plus/minus sign indicates that multiple methods were used according to the country of 
origin of respondents; at least one of these methods was choice-based.
Minus sign indicates visual analogue scale or other non-choice based methods.
For mapping studies, consider the valuation method of the instrument to which HRQoL
scores were mapped (observed data).
d How many persons  met the inclusion criteria, and, if applicable, signed informed consent 
and/or were randomized? 
In case of multiple disease sites: only for the lung cancer stratum
In case of multiple analyses, only for the HRQoL analysis
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In the case of a time series, only the baseline N for this item
e How many participants were included in the HRQoL analysis? 
In case of multiple disease sites: only for the lung cancer stratum
In case of multiple disease sites: only for the lung cancer stratum
In the case of a time series, only consider the baseline N 
f What was the method of handling missing HRQoL data?
Plus sign indicates that missing HRQoL data were mentioned and quantified in the study, 
and missing data were imputed; or it was explicitly stated that there were no missing data 
(and completeness of data was not an eligibility criterion). 
Minus sign indicates that missing HRQoL data were mentioned in the study, and cases with 
missing data were dismissed (complete case analysis).
g Was loss to follow-up reported? 
Plus sign indicates that loss to follow-up was reported for each time-point. 
Plus/minus sign indicates that loss to follow-up was reported, but not for each time-point.
Minus sign indicates that cases that were lost to follow-up were excluded.
Not applicable to non-longitudinal studies (In case of multiple HRQoL measurements in the 
same individuals only; if results for multiple time points were based on cross-sectional samples 
of different patients, do not consider loss to follow-up; also, if study design was longitudinal but 
numerical HSUVs are only reported for a single time-point, consider the study non-longitudi-
nal).
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Supplementary Table 2a: Scope of studies reporting community and choice-based health 
state utility values for lung cancer.
Source QoL 
res-
pon-
se  a
Inclusion 
years b
Lung 
cancer 
type c
Stage d Treatment e Per-
cent 
male 
f
Age, 
mean 
years 
(range) g
Time of 
measure-
ment, 
mean 
(range) h
Kimman 
2015 1 
624 2012-2013 All All NR 37 * 51.8 
(18-100) *
27 d 
(<12 w) *
Grutters 
2010 4
245 2004-2007 NSCLC All Any 67 68 (40-90) 2.59 y
(0.82-4.76 
y)
Jang 2010 7 172 NR-NR NSCLC All Any 46.5 66 
(32-65) § 
NR
Schuette 
2012 12
231 2007-2009 NSCLC III-IV Post-first 
line
69.7 66.3 
(39-86)
NR
Khan 2014 
(a) 13
670 NR-NR NSCLC IIIB-IV Erlotinib or 
placebo
NR 77 § (<12m)
Khan 2014 
(b) 13
130 NR-NR NSCLC IIIA-IIIB Radio-
therapy or 
chemo-radi-
otherapy
NR 62 §  NR
van den 
Hout 2006 15 
297 1999-2002 NSCLC III-IV Radiothe-
rapy
80 § 69 (48-85) 
§**
1m (0-88 
m) §**
Chouaid 
2013 19
255 2010-2011 NSCLC IIIB-IV Any 61.2 64.8 
(32.9-99.6)
NR
Matter-Wal-
stra 2014 20
154 2011-2012 All Advan-
ced
Post-first 
line chemo-
therapy
59 * 62.1 
(40-77)
NR
Manser 
2006 21 
91 NR-NR All All Any 68.5 67 NR
Khan 2016 23 97 2014-2015 NSCLC All Any 44 69 
(39-86) §
NR
Naik 2017 24 149 2012-2014 All All Any 47 * 59 (18-100) 
§*
22 m §*
Shih 2006 25 51 NR-NR All All Any 47 § 51 §* 101 d
Pickard 
2007 28
50 NR-NR All Advan-
ced
Chemo-
therapy
41 62 NR
Thongpra-
sert 2015 30
150 NR-NR All III-IV Chemo-
therapy or 
radio-
therapy
52 60.9 NR
Tramontano 
2015 32
2396 2003-2005 All All Any 52 NR NR
Bendixen 
2019 33 
201 2008-2014 NSCLC I Surgery 50 
**
66 § ** NR
table continues
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Source QoL 
res-
pon-
se  a
Inclusion 
years b
Lung 
cancer 
type c
Stage d Treatment e Per-
cent 
male 
f
Age, 
mean 
years 
(range) g
Time of 
measure-
ment, 
mean 
(range) h
Erbaycu 
2018 34 
266 2010-2013 All IIIB-IV Chemo-
therapy and/
or radio-
therapy
93.2 61.35 
(35-86)
NR
Insinga 2018 
36  
NR NR-NR NSCLC IV Pembrolizu-
mab and/or 
chemo-
therapy
NR 63 NR
Insinga 
2019 37 
NR NR-NR NSCLC IV Pembrolizu-
mab and/or 
chemo-
therapy
NR 65 NR
Limwat-
tananon 
2018 39
135 2017-2017 NSCLC Ad-
van-ced
Chemo-
therapy or 
erlotinib
NR NR NR
Maximiano 
2018 40
495 2011-2012 NSCLC All Any 79 63.3 
(33-86)
8.1 m 
(0-84 m)
Mendoza 
2018 41 
664 NR-NR NSCLC Ad-
van-ced
NR 70 60.8 NR
Meregaglia 
2019 42
96 2011-2014 NSCLC III-IV Any 68.7 61.1 
(36-85)
NR
O'Kane 2019 
43 
519 2014-2016 All All Any 45 64 
(29-96)
11 m 
(0-200 m)
Rendas-
Baum 2019 46
43 2008-2012 All All NR 46.5 67.4 NR
Su 2019 47 104 2017-2017 All All Any 56 * 63.67 * 2 y *
Sullivan 
2011 51 
114 2000-2003 All All NR 48 * 69.6 NR
Abbreviations: d = days; w = weeks; m = months; y = years; NR = not reported; NSCLC = non-small 
cell lung cancer; SCLC = small cell lung cancer. 
Superscript Arabic numerals refer to the list of references at the end of this appendix.
§ Median was reported instead of mean
* Baseline characteristics included also non-lung cancer patients
** Baseline characteristics were stratified by study arm, data from the (first) intervention 
group is reported here
a How many participants were included in the health-related quality of life (HRQoL) analysis? 
In case of multiple disease sites: only for the lung cancer stratum
In case of multiple disease sites: only for the lung cancer stratum
In the case of a time series, only consider the baseline N 
b Between which years were participants recruited, or from which years were data sampled?
c What lung cancer type was included? 
d What is the stage of diagnosis of included patients? 
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e Did patients receive treatment at the time of measurement of health state utility values 
(HSUVs)? If so, which treatments?
f What percentage of included participants was male at baseline? 
g What is the mean age of included participants at baseline? 
h What was the mean time since diagnosis? 
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b What method was used to valuate health-related quality of life (HRQOL) scores to HSUVs? 
c From what country were HRQoL respondents recruited?
d What tariff was applied for valuation of HRQoL?
e Was a matching tariff applied? 
Plus sign indicates that the tariff was used of the same country or region as the participants 
were recruited from. In case participants were from multiple countries, the correct tariff 
was applied to each patient.
Plus/minus sign indicates the use of a single value set while participants were recruited 
from more than one country. 
Minus sign indicates that a different tariff was used than the county of origin of respon
dents. 
Not applicable to vignette studies, mapping,  or direct elicitation of patient’s own health.
f What was the mode of administration? (Self-administered; personal interview; or telephone 
interview)
g Are HSUVs reported for multiple time points? 
If yes, code as either “individual” (multiple time points measured in individual patients) or 
“cross-sectional” (multiple time-points assessed based on stratification of cross-sectional sam-
ple of different patients). 
If measured at multiple time points but numerical values only reported at a single time-point, 
code as no. 
h Were HSUVs reported as mean or median?
i This study also applied direct rating to patients (VAS), and general population tariffs from 
France, the United Kingdom, and the European union to HRQoL data from the same sample of 
German patients. We included only the matching German tariff in the meta-analysis.
j This study also performed crosswalking of EQ-5D-3L HSUVs to the EQ-5D-5L instrument. We 
included the original EQ-5D-3L values for analysis.
k This study also applied the United Kingdom and United States general population tariffs to 
HRQoL data from the same sample of Canadian patients. We included only the matching Ca-
nadian tariff in the meta-analysis.
l This study also applied the United Kingdom tariff to HRQoL data from the same group of US-
based patients. We included only the US-based tariff in the meta-analysis.
m This study also used the SF-6D instrument. We only include the EQ-5D HSUVs because that 
instrument is preferred by the National Institute for Clinical Excellence.
n  This study applied tariffs from the United Kingdom and the Netherlands to HRQoL data from 
a combined sample of Polish and Hungarian patients. We included only the United Kingdom 
tariff in the meta-analysis because that tariff was applied more frequently across other studies, 
hence improving comparability of results.
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Supplementary Table 2c: Stratification variables used in studies reporting community and 
choice-based health state utility values for lung cancer.
Source Stratification variables a
Kimman 2015 1 Overall
Grutters 2010 4 Age; gender; initial treatment; stage; survival time; recurrence; 
adverse events
Jang 2010 7 Overall; stage; recurrence status + treatment status
Schuette 2012 12 Overall
Khan 2014 (a) 13 Overall
Khan 2014 (b) 13 Overall
van den Hout 2006 15 Treatment (radiotherapy regimen)
Chouaid 2013 19 Overall; progression status; progression status + treatment (line)
Matter-Walstra 2014 20 Overall
Manser 2006 21 Time since diagnosis + the following: overall; age; gender; 
employment; language; education; marital status; resectability; 
stage; histology; ECOG grade; comorbidities
Khan 2016 23 Overall
Naik 2017 24 Overall; stage
Shih 2006 25 Overall
Pickard 2007 28 Overall; ECOG grade
Thongprasert 2015 30 Overall
Tramontano 2015 32 Time since diagnosis + the following: overall; gender; race/
ethnicity; age; stage; histology; treatment (surgery; chemo; 
radiotherapy combinations); comorbidity 
Bendixen 2019 33 Time since surgery + treatment (type of surgery)
Erbaycu 2018 34 Gender; marital status; occupation; smoking status; graduation; 
comorbidity; age; histology; stage
Insinga 2018 36  Time to death
Insinga 2019 37 Time to death
Limwattananon 2018 39 Treatment (systemic regimen); progression status
Maximiano 2018 40 Time since baseline
Mendoza 2018 41 Overall
Meregaglia 2019 42 Time since baseline
O'Kane 2019 43 Age; gender; histology; brain metastasis status; smoking 
status; treatment (number of previous lines of chemotherapy 
treatment; radiotherapy; surgery); brain metastasis status
Rendas-Baum 2019 46 Overall
Su 2019 47 Overall
Sullivan 2011 51 Overall
Superscript Arabic numerals refer to the list of references at the end of this appendix.
a By what variables are utilities stratified? 
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Supplementary Table 3: Results of studies reporting community and choice-based health 
state utility values for lung cancer as well as for a control group of members of the general 
population.
Source a Stage III-IV All stages Controls Disutility
n mean 
(SD)
n mean 
(SD)
n mean 
(SD)
Difference 
cases-controls 
(95% CI)
Thongprasert 2015 30 b 150 0.67 (0.30) - - 150 0.78 (0.17) 0.11 (0.05-0.17) *
Sullivan 2011 51 c - - 114 0.56 (0.46) 79522 0.83 (0.42) 0.27 (0.18-0.36) *
Abbreviations: SD= standard deviation; 95%CI = 95% confidence interval.
Superscript Arabic numerals refer to the list of references at the end of this appendix.
a Both studies used the EQ-5D instrument, applying a time-trade-off tariff.  
b This study applied the Thai tariff to EQ-5D data from Thai persons. Controls were younger 
than the patient sample (mean age 44.4 years compared to 60.9 years for the patient sample).
c This study applied the United Kingdom tariff to EQ-5D data from persons from the United 
States. Controls were younger than the patient sample (mean age 42.8 years compared to 69.6 
years for the patient sample).
* p<.001.
Supplementary Tables and Figures
185
Source
Stage = All   
Stage = I−II  
Stage = III−IV
Total
Total
Total
Heterogeneity: χ6
2 = 714.59 (P  < .01), I2 = 99%
Heterogeneity: χ4
2 = 52.45 (P  < .01), I2 = 92%
Heterogeneity: χ10
2  = 579.94 (P  < .01), I2 = 98%
Grutters 2010 [4]
Jang 2010 [7]
Khan 2016 [23]
Naik 2017 [24]
Tramontano 2015 [32]
Maximiano 2018 [40]
O'Kane 2019 [43]
Grutters 2010 [4]
Jang 2010 [7]
Naik 2017 [24]
Tramontano 2015 [32]
Bendixen 2019 [33]
Grutters 2010 [4]
Jang 2010 [7]
Schuette 2012  [12]
Khan 2014 (a) [13]
Khan 2014 (b) [13]
Chouaid 2013 [19]
Matter−Walstra 2014 [20]
Naik 2017 [24]
Pickard 2007 [28]
Tramontano 2015 [32]
Mendoza 2018 [41]
N
245
172
97
149
2396
495
519
144
50
89
982
201
101
122
231
670
130
255
154
60
50
1277
664
Mean utility (95% CI)
0.69 [0.58; 0.81]
0.80 [0.75; 0.86]
0.71 [0.64; 0.77]
0.74 [0.71; 0.77]
0.76 [0.73; 0.79]
0.52 [0.45; 0.58]
0.78 [0.74; 0.82]
0.78 [0.77; 0.79]
0.51 [0.49; 0.53]
0.75 [0.74; 0.77]
0.76 [0.72; 0.80]
0.80 [0.74; 0.85]
0.78 [0.74; 0.82]
0.80 [0.79; 0.81]
0.88 [0.86; 0.90]
0.71 [0.65; 0.76]
0.75 [0.72; 0.78]
0.66 [0.63; 0.69]
0.61 [0.59; 0.63]
0.75 [0.71; 0.79]
0.66 [0.62; 0.70]
0.85 [0.83; 0.87]
0.77 [0.71; 0.83]
0.74 [0.70; 0.78]
0.77 [0.76; 0.78]
0.51 [0.48; 0.54]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Supplementary Figure 1: Pooled results of studies reporting community and choice-based 
health state utility values for lung cancer, explicitly elicited using the EQ-5D-3L instrument, by 
stage. The size of the symbol representing the effect size in each study is relative to the weight 
it had in random effects meta-analysis. Not all studies included both stage I-II and stage III-IV 
cases. Not all studies that did include all stages stratified by stage. Arabic numerals between 
square brackets refer to the reference list in this appendix.
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Source
Histology = NSCLC
Histology = SCLC 
Tramontano 2015 [32]
O'Kane 2019 [43]
Tramontano 2015 [32]
O'Kane 2019 [43]
N
2025
483
264
36
Mean utility (95% CI)
0.78 [0.77; 0.79]
0.77 [0.76; 0.79]
0.76 [0.74; 0.78]
0.63 [0.56; 0.70]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Supplementary Figure 2: Subgroup analysis of community and choice-based health state 
utility values for lung cancer by histology. Arabic numerals between square brackets refer to 
the reference list in this appendix. Abbreviations:  NSCLC = non-small cell lung cancer; SCLC = 
small cell lung cancer.
Source
Sex = Male  
Sex = Female
Grutters 2010 [4]
Manser 2006 [21]
Tramontano 2015 [32]
O'Kane 2019 [43]
Grutters 2010 [4]
Manser 2006 [21]
Tramontano 2015 [32]
O'Kane 2019 [43]
N
164
62
1242
233
181
29
1154
286
Mean utility (95% CI)
0.75 [0.71; 0.79]
0.72 [0.66; 0.78]
0.78 [0.77; 0.79]
0.75 [0.73; 0.77]
0.73 [0.69; 0.77]
0.52 [0.44; 0.60]
0.77 [0.76; 0.78]
0.76 [0.74; 0.78]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Supplementary Figure 3: Subgroup analysis of community and choice-based health state 
utility values for lung cancer by sex. Arabic numerals between square brackets refer to the 
reference list in this appendix.
Source
Age = Under 65
Age = Over 65 
Manser 2006 [21]
Tramontano 2015 [32]
Manser 2006 [21]
Tramontano 2015 [32]
N
39
1017
52
1379
Mean utility (95% CI)
0.62 [0.50; 0.74]
0.76 [0.75; 0.77]
0.68 [0.62; 0.74]
0.80 [0.79; 0.81]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Supplementary Figure 4: Subgroup analysis of community and choice-based health state 
utility values for lung cancer by age. Please note that in Tramontano 2015, age 65 was included 
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in the “over 65” category. In Manser 2006, age 65 was included in the “under 65” category. Arabic 
numerals between square brackets refer to the reference list in this appendix.
Source
Treatment = Surgery only                  
Treatment = Chemotherapy only             
Treatment = Radiotherapy only             
Treatment = Surgery with chemotherapy     
Treatment = Surgery with radiotherapy     
Treatment = Surgery with chemoradiotherapy
Treatment = Chemoradiotherapy             
Treatment = No treatment                  
Grutters 2010 [4]
Tramontano 2015 [32]
Grutters 2010 [4]
Tramontano 2015 [32]
Grutters 2010 [4]
Tramontano 2015 [32]
Grutters 2010 [4]
Tramontano 2015 [32]
Grutters 2010 [4]
Tramontano 2015 [32]
Grutters 2010 [4]
Tramontano 2015 [32]
Grutters 2010 [4]
Tramontano 2015 [32]
Grutters 2010 [4]
Tramontano 2015 [32]
N
111
563
.
360
18
126
26
271
6
63
19
207
63
679
.
127
Mean utility (95% CI)
0.77 [0.72; 0.82]
0.81 [0.80; 0.82]
0.79 [0.77; 0.81]
0.62 [0.51; 0.73]
0.75 [0.72; 0.78]
0.81 [0.72; 0.90]
0.79 [0.77; 0.81]
0.86 [0.76; 0.96]
0.72 [0.67; 0.77]
0.72 [0.62; 0.82]
0.76 [0.73; 0.79]
0.69 [0.61; 0.77]
0.77 [0.76; 0.78]
0.79 [0.76; 0.82]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Supplementary Figure 5: Subgroup analysis of community and choice-based health state util-
ity values for lung cancer by treatment modality. Manser 2006 did not report health state uti-
lity values for those receiving no treatment. In addition, Manser 2006 only included 2 patients 
in the stratum that received chemotherapy only. Those 2 patients had a perfect health state 
utility value, but no standard deviation was given. Therefore, these 2 patients were omitted 
from the current analysis. Arabic numerals between square brackets refer to the reference list 
in this appendix.
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Source
Treatment line = First          
Treatment line = Second         
Treatment line = Third or fourth
Chouaid 2013 [19]
Chouaid 2013 [19]
Chouaid 2013 [19]
N
137
61
45
Mean utility (95% CI)
0.70 [0.66; 0.74]
0.73 [0.67; 0.78]
0.57 [0.47; 0.66]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Supplementary Figure 6: Subgroup analysis of community and choice-based health state util-
ity values for lung cancer by treatment line. Arabic numerals between square brackets refer to 
the reference list in this appendix.
Source
Progression = Progression free
Progression = Progressive     
Chouaid 2013 [19]
Limwattananon 2018 [39] 
Chouaid 2013 [19]
Limwattananon 2018 [39] 
N
182
28
64
25
Mean utility (95% CI)
0.70 [0.66; 0.74]
0.68 [0.62; 0.74]
0.58 [0.50; 0.66]
0.32 [0.08; 0.56]
0 0.2 0.4 0.6 0.8 1
Mean utility (95% CI)
Supplementary Figure 7: Subgroup analysis of community and choice-based health state util-
ity values for lung cancer by progression status. Both studies included metastatic non-small 
cell lung cancer cases and used the EQ-5D instrument. Arabic numerals between square brac-
kets refer to the reference list in this appendix.
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This thesis investigates the interplay of early detection, treatment, and quality of life 
in lung cancer screening. As outlined in the introduction, this thesis focuses on two 
main research questions. Part I (“Lung cancer treatment”) aims to answer the research 
question: “How does the implementation of lung cancer screening affect the demand 
for different treatment modalities?”. Part II (“Benefits and harms of population-based 
screening programs”) subsequently aims to answer the research question: “What 
are the benefits and harms of population-based lung cancer screening programs?”. 
Each part is divided into three chapters, which cover different aspects relating to 
the two main research questions. This general discussion provides a summary and 
interpretation of the main findings of each chapter, and uses those to synthesize an 
answer to the main research questions. Subsequently, methodological considerations 
of the studies included in this thesis are discussed, followed by recommendations 
for future research and policies. Finally, a point-by-point summary of the overall 
conclusions and recommendations is provided.
Summary and interpretation of main findings
Part I: Lung cancer treatment
Chapter 1
Chapter 1 used the U.S. National Cancer Database (NCDB) to investigate which 
treatments lung cancer patients in the United States currently receive,1 and whether 
these treatments are in concordance with clinical guidelines.2,3 Guideline-concordant 
treatment was defined as the minimal treatments recommended by the guidelines. 
Non-surgical treatment options for potentially inoperable patients were included as 
part of the recommended treatments. 
Among 441,812 U.S. lung cancer patients diagnosed between 2010-2014, only 
62.1% received the minimally recommended treatments. In addition, 16.3% received 
treatment that was not guideline-concordant, and 21.6% received no treatment. 
The percentage receiving guideline-concordant treatment varied across clinical 
subgroups, defined by stage and histology, and was highest among early-stage non-
small cell lung cancer (NSCLC) (76.2%) and lowest among advanced NSCLC (50.4%). 
For each clinical subgroup, as well as for the entire sample, multivariable logistic 
regression models were used to identify groups of patients that are less likely to 
receive guideline-concordant treatment. 
After adjusting for potentially confounding patient, tumor, and health care 
provider characteristics, including comorbidity, age was the factor most strongly 
associated with the likelihood of receiving guideline-concordant treatment (e.g. age 
≥80 years compared with <50 years: adjusted odds ratio = 0.12). In addition, black 
patients were less likely to receive guideline-concordant treatment than white 
patients (adjusted odds ratio = 0.78). Patterns of care among those receiving non-
guideline-concordant treatment indicated possibilities for an increased uptake of 
certain treatments, such as stereotactic body radiation therapy (SBRT) for potentially 
inoperable patients with early-stage NSCLC. 
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Knowing which patients are at risk of receiving suboptimal treatment may be an 
important first step towards the development and testing of targeted interventions 
to improve lung cancer care.4,5 In addition, awareness of this issue among individual 
medical doctors may increase the chance of identifying any unjustified concerns or 
inappropriate beliefs their patients may have regarding their treatment options.6 
Ensuring that all groups of lung cancer patients receive optimal treatment is especially 
important because the success of lung cancer screening will depend on the optimal 
treatment of cases detected at early stage. To address the disparities identified in 
chapter 1, more research should be conducted to identify the underlying reasons.7 In 
addition, future lung cancer screening studies should account for existing treatment 
disparities. This is further elaborated on in the section “Incorporate racial disparities 
in lung cancer (screening) research” under the heading “Directions for future research 
and policy” below.
Chapter 2
Using the same NCDB, chapter 2 further investigated the uptake of SBRT among 
patients with early-stage NSCLC, as well as the uptake of minimally invasive surgery 
(MIS) and the rate of conversions from MIS to open surgery. We found that, between 
2010-2014, the uptake of SBRT as the radiation modality increased substantially. 
Among those with stage IA NSCLC, SBRT uptake increased from 53.4% in 2010 to 73.0% 
in 2014. During the same period, the uptake of MIS as the surgical modality among 
stage IA cases increased from 28.7% to 48.6%, while the rate of conversions to open 
surgery decreased from 17.0% to 9.1%. For other early stages (i.e. stages IB-IIB), uptake 
of SBRT and MIS was lower, but time trends were similar. 
These findings implicate that, although the uptake of SBRT and MIS are increasing, 
there is still room for improvement. Lung cancer screening guidelines state that 
optimal treatment of lung cancer cases detected at an early stage is essential.8,9 This 
includes the use of SBRT and MIS.8 Therefore, we anticipate that the uptake of SBRT 
and MIS will continue to increase along with the continuing implementation of lung 
cancer screening.
Chapter 3
Chapter 3 aimed to quantify how currently observed lung cancer treatment patterns 
will change due to the continued implementation of population-based lung cancer 
screening in the United States. The main underlying mechanism behind screening 
is a shift towards early stages, for which better treatment options are available. In 
addition, lung cancer screening may be more effective among women than among 
men,10-12 at least in part because screening may more effectively identify certain 
histological subtypes of lung cancer that are more common among women, such as 
adenocarcinoma.10 Therefore, the MISCAN-Lung model13,14 was used to project how the 
gender, stage, histology, and age-specific incidence of lung cancer in the general U.S. 
population will change between 2015-2040 due to the implementation of screening in 
2018. Then, the gender, stage, histology, and age-specific treatment patterns from the 
National Cancer Database were used to project the corresponding change in demand 
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for the different treatment modalities used in lung cancer care. By using real-world 
treatment data, this analysis acknowledges the fact that some patients do not receive 
the recommended treatments (for example due to patient preferences).
Assuming a 50% adherence to screening, implementing the 2014 United States 
Preventive Task Force (USPSTF) policy would increase the demand for lung cancer 
surgery by 37.0%, with a peak in the first years. Overall, radiotherapy use would 
decrease by 2.2%, and overall, chemotherapy use would decrease by 5.4%. Results were 
highly sensitive to screening adherence. A gradual buildup of screening uptake may 
spread the initial peak in surgical demand over time. 
Currently, the median time between lung cancer diagnosis and onset of treatment 
in the United States ranges between 15-57 days (across 12 studies).15 If, at some point 
in time, the capacity for lung cancer surgery would be insufficient, this delay could 
potentially increase. Therefore, to avoid unnecessary increases in waiting times for 
lung cancer surgery, surgical capacity planning should be an important part of the 
continuing implementation of lung cancer screening in the United States.
Answer to first main research question
Together, chapters 1-3 answer the first main research question (“How does the 
implementation of lung cancer screening affect the demand for different treatment 
modalities?”):
To ensure that lung cancer screening is effective, it is crucial that optimal 
treatment is available and provided, particularly for those diagnosed with early-
stage lung cancer. Continuing the implementation of lung cancer screening in 
the United States will result in an overall increase in demand for lung cancer 
surgery, with a peak in the initial years. The magnitude of this peak will depend 
on the degree of screening uptake. If, at some point, surgical capacity would 
become constrained, a gradual buildup of screening uptake could be a strategy 
to avoid increases in waiting times for lung cancer surgery. Changes in demand 
for radiotherapy and chemotherapy due to screening will likely not cause 
any capacity issues. Addressing treatment disparities by age and race, which 
persist after adjusting for relevant patient, tumor, and health care provider 
characteristics, should be an important focus of future research and policy. The 
increasing uptake of SBRT and MIS as treatment modalities for early-stage NSCLC 
is expected to continue with the implementation of lung cancer screening.
Part II: Benefits and harms of population-based screening programs
Chapter 4
In a population-based screening program, screening takes places far beyond the 1-5 
screening rounds offered in the randomized controlled trials. 16-23 In addition, new 
persons become eligible for screening each year, whereas others become ineligible due 
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to age. In other words, screening takes place in a dynamic population. It is unclear how 
the decreasing smoking prevalence in the general U.S. population24 affects the benefits 
and harms of lung cancer screening in such a dynamic population. Overdiagnosis 
is considered one of the main harms of cancer screening. Previous assessments 
of lung cancer overdiagnosis were based on modeling of a single birth cohort,25 or 
on randomized controlled trials with an insufficient period of follow-up.26 Chapter 
4 provides a population-based estimate of lung cancer overdiagnosis,27 accounting 
for the decreasing smoking prevalence in the general U.S. population.24 In addition, 
Chapter 4 provides methodological guidance for future overdiagnosis studies. 
The MISCAN-Lung model was used to project lung cancer incidence with and 
without screening in the general U.S. population between 2018-2040. The model was 
updated to account for changes in smoking behavior (and thus background lung 
cancer risk and screening eligibility) across the many birth cohorts that comprise 
the evaluated population. Three distinct methods were used to estimate the degree 
of overdiagnosis. 
For several separate birth cohorts from the general U.S. population, the 
cumulative excess-incidence approach was used to show that overdiagnosis is less 
likely among younger birth cohorts than among older birth cohorts. For example, 
5.9% of screen-detected cases were overdiagnosed in the 1990 birth-cohort, compared 
with 10.5% in the 1950 birth-cohort. This was associated with a lower background risk 
of lung cancer among younger cohorts, as well as a decreased screening eligibility 
(due to decreasing smoking trends). To assess the annual rate of overdiagnosis in the 
entire general U.S. population, two approaches were used: the annual excess-incidence 
approach and the microsimulation approach. Using the annual excess-incidence 
approach, overdiagnosis appeared absent between years 2029 and 2040. This occurred 
because the annual excess-incidence approach does not account for the decreasing 
background lung cancer risk and screening eligibility across birth cohorts. The 
microsimulation approach, which uses the underlying full individual life histories in 
the presence and absence of screening, showed that overdiagnosis was present in each 
year that screening occurred. Overdiagnosis increased from 7.1% to 9.5% of screen-
detected cases between 2018–2040. During the same period, overdiagnosis decreased 
from 3.7% to 1.4% of all lung cancer cases.
To conclude, the cumulative excess-incidence approach may only be used 
to assess overdiagnosis in separate closed cohorts. Therefore, results from this 
commonly used approach are not representative for the entire general population. In 
addition, the annual excess-incidence approach does not account for smoking trends 
in the general population, and consequently provides biased overdiagnosis estimates. 
Given a carefully calibrated model, the microsimulation approach may be used to 
provide an estimate of the annual rate of overdiagnosis in the general population, 
accounting for trends in background risk and screening eligibility. These conclusions 
have implications for policy, because an assessment of overdiagnosis is often part of 
the decision to implement a particular screening program or not.28 
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Chapter 5
The main benefits of lung cancer screening are the number of averted lung cancer 
deaths, and the corresponding number of life-years gained. When assessing the 
number of life-years gained by screening, it is important to include an adjustment 
for the generally lower quality of life after receiving a diagnosis of lung cancer. 
Adjustment of life-years gained for quality of life takes place using health state utility 
values (HSUVs), and yields quality-adjusted life years (QALYs). Economic evaluations 
often use HSUVs from previous studies without assessing the relevance and validity 
of those HSUVs. Therefore, in chapter 5, the literature was systematically reviewed for 
published HSUVs for lung cancer. 
After screening almost 6000 titles and abstracts, and more than 450 full text 
articles, 51 studies reporting mean or median lung cancer-specific HSUVs and a 
measure of variance were identified. Twenty-seven of these studies used community 
and choice-based methods to elicit HSUVs, as recommended by most international 
guidelines.29 These studies were further analyzed. The pooled HSUV across the studies 
that included all stages of lung cancer was 0.68. Among stage I-II lung cancer, the 
pooled HSUV was 0.78. Finally, the pooled HSUV among stage III-IV lung cancer was 
0.69. In a sensitivity analysis, only the methodologically most comparable studies 
were included, which used the EQ-5D instrument and applied the tariff matching the 
country of quality of life respondents. In that sensitivity analysis, stage-specific HSUVs 
varied substantially by the country in which the study was conducted. However, 
studies providing such stage-and country-specific HSUVs were only identified for 8 
countries. Therefore, pooling of stage-and country-specific HSUVs was not possible. 
A subgroup analysis concluded that the HSUVs for metastatic NSCLC decreased 
significantly during the last year of life, ranging from 0.83 at ≥360 days from death 
to 0.56 at <30 days from death. Based on a limited number of studies, other subgroup 
analyses indicated that for patients with metastatic NSCLC, HSUVs may decrease 
during the third or fourth treatment line and when disease progresses.
Therefore, chapter 5 concluded that, for most countries, the pooled stage-
specific HSUVs across the literature may provide the best available evidence. For 
those countries with available high-quality studies with stage and country-specific 
HSUVs, those HSUVs may be used instead. In addition, (proportionally) adjusting for 
the decreased HSUVs in the last year of life may be appropriate, particularly for those 
with metastatic NSCLC. If required, further stratification of HSUVs for metastatic 
NSCLC by treatment line or progression status may be considered. By providing the 
state-of-the-art in lung cancer HSUVs, chapter 5 will enhance the reliability and 
validity of future economic evaluations. This is topical because in the near future, 
many such economic evaluations will be conducted regarding lung cancer screening 
and new immunotherapy agents.
Chapter 6
In chapter 4, the main harm of lung cancer screening, overdiagnosis, was assessed for 
the entire general U.S. population, which includes non-screening eligible individuals. 
This perspective is often appropriate when making policy decisions. However, 
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for shared decision making in clinical practice, it is more important to know the 
expected benefits and harms of screening among eligible individuals. Although 
decision aids with such estimates have been previously developed, these were based 
on the 3 screening scans offered in the National Lung Screening Trial (NLST).30-32 
However, in practice, eligible individuals are asked to consider up to 25 screening 
scans. In addition, existing decision aids do not account for potential differences in 
screening effect by age and gender. Therefore, chapter 6 assessed the benefits and 
harms of participating in population-based lung cancer screening for 55, 60, 65, 70, 
and 75-year-old men and women meeting the USPSTF eligibility criteria in 2020. The 
QALYs gained by screening were adjusted using the HSUVs identified in chapter 5. 
The key benefit of screening, the number of lung cancer deaths averted, was 
projected to be 41 per 1000 eligible 55-year-old men in 2020 (M55), compared with 
25 per 1000 eligible 75-year-old men in 2020 (M75), 49 per 1000 eligible 55-year-old 
women in 2020 (W55), and 30 per 1000 eligible 75-year-old women in 2020 (W75). Per 
lung cancer death averted, the projected number of life-years gained was 13.5 (M55), 
7.1 (M75), 13.7 (W55), and 7.7 (W75). Thus, screening those eligible at older ages from 
2020 would result in fewer lifetime benefits than screening those eligible at younger 
ages from 2020 (also accounting for birth-cohort-specific smoking trends and life-
expectancy). In addition, women would experience more benefits from screening, 
compared with similarly-aged men.
When adjusting for quality of life, the number of QALYs gained per lung cancer 
death averted was approximately a quarter to a third lower than the number of 
life-years gained per averted lung cancer death (depending on age and sex). For 
example, 10.0 QALYs would be gained per averted lung cancer death (M55) when using 
the pooled stage-specific HSUVs from chapter 5, compared with 13.5 life-years (M55). 
Using the HSUVs from the most high-validity U.S.-based study identified in chapter 
5 resulted in similar QALYs gained per averted lung cancer death. For example, 10.4 
QALYs would be gained per averted lung cancer death (M55) when using HSUVs from 
the most high-validity study, compared with 10.0 (M55) when using the pooled HSUVs.
The key harm of screening, the lifetime percentage of screen-detected cases that 
would be overdiagnosed, ranged from 6.7% (M55) to 13.9% (W75). Overdiagnosis was 
more likely among older eligible individuals (regardless of sex) and among women 
(compared with similarly aged men). The key adverse event, the number of biopsies 
or bronchoscopies for screening findings that are ultimately not lung cancer, was 
projected to range from 21 (M75 and W75) to 72 (W55). Adverse events were less likely 
among older eligible individuals, but more likely among women.
To conclude, screening older eligible individuals from 2020 leads to fewer benefits, 
fewer adverse events, but more overdiagnosis, compared with screening 55-year-
old eligible individuals from 2020. In addition, compared with similarly-aged men, 
women experience more benefits, more adverse events, and more overdiagnosis. Per 
lung cancer death averted, the number of QALYs gained is approximately a quarter 
to a third lower than the number of life-years gained. The QALYs gained were fairly 
robust to the choice of HSUVs. The findings presented in Chapter 6 indicate the need 
to personalize the information discussed in shared decision making by age and sex. 
Personalized shared decision making conversations may be facilitated by using the 
presented graphical decision aids.
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Answer to second main research question
Together, chapters 4-6 answer the second main research question (“What are the 
benefits and harms of population-based lung cancer screening programs?”):
The main harm of lung cancer screening is overdiagnosis. When screening 
all U.S. individuals meeting the USPSTF eligibility criteria from 2018-2040, 
overdiagnosis among screen-detected cases will increase from 7.1% to 9.5%, 
whereas overdiagnosis among all lung cancer cases will decrease from 3.7% to 1.4%. 
This is due to decreasing smoking trends across birth cohorts, which reduces the 
background lung cancer risk and screening eligibility over time in the general 
U.S. population. It is important to use appropriate methods to account for these 
trends. For shared decision making in clinical practice, the benefits and harms 
of lung cancer screening were assessed among men and women eligible for 
screening in the calendar year 2020. Using that perspective, the expected lifetime 
benefits of screening and the number of adverse events decrease with advancing 
age (accounting for smoking trends across birth cohorts), whereas overdiagnosis 
increases. In addition, compared with similarly-aged men, women experience 
more benefits, more adverse events, and more overdiagnosis. The number of 
QALYs gained per lung cancer death averted is approximately a quarter to a 
third lower than the number of life-years gained, regardless of the choice of 
HSUVs. Shared decision making discussions prior to lung cancer screening should 
preferably be personalized by age and sex. This may be facilitated by using the 
age and sex-specific graphical decision aids presented in this thesis.
Methodological considerations
Causal inference and observational data
In chapter 1, logistic regression models were used to investigate which groups of patients 
are less likely to receive guideline-concordant treatment. These multivariable models 
were corrected for potential confounding factors identified in previous studies. The 
NCDB comprises up to 70% of incident cancer cases in the United States, and chapter 
1 included all clinical subgroups of lung cancer. Therefore, these findings are more 
generalizable than earlier studies. Nevertheless, it is important to realize that the 
NCDB data are observational. Therefore, the findings in chapter 1 do not allow for firm 
conclusions regarding causality. In chapter 1, this is reflected by using language such 
as “associated with”, instead of “caused”. 
Recently, some investigators have argued that causal inference using 
observational data may still be possible when using specific methods.33 In short, 
these investigators argue that there are 2 main types of observational studies: those 
that aim to predict the value of an outcome, and those that aim to make causal 
inferences.33 When causal inference is the aim, investigators could draw “directed 
acyclic graphs”.34 In such graphs, the relations between all factors that are related to 
either the exposure variable or outcome variable should be indicated by a directed 
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arrow, based on previous literature. Then, statistical models should only control for 
those variables that are identified as a “confounder”, strictly defined as a variable that 
has a unidirectional causal effect on both the exposure and outcome variable. 
Although these efforts to improve causal inference based on observational data 
are important developments, it is worth mentioning several additional considerations. 
First, studies using observational data are not limited to prediction modeling and 
causal inference.35 Often, the most appropriate aim is to identify associations, while 
correcting for potential confounding factors. Second, the proposed criteria for 
identifying confounders are very strict. As was the case in chapter 1, there is often 
insufficient evidence to determine all the interrelations of potentially influential 
variables in “directed acyclic graphs”. In particular, the directions of previously 
identified associations are often unknown. In that case, imposing a strict statistical 
model structure based on assumed interrelations may actually introduce bias.36 In 
chapter 1, a more pragmatic definition of a confounder was used instead: a variable 
that is associated with the exposure of interest, and that also plausibly affects the 
outcome of interest.37
Perhaps more important than to prove the causality of the associations identified 
in chapter 1, is attempting to identify the underlying reasons.7 This is further 
elaborated on in the section “Incorporate racial disparities in lung cancer (screening) 
research” under the heading “Directions for future research and policy” below.
Differences in treatment of screen-detected and clinically detected 
cancer
In chapter 3, it was assumed that screen-detected and non-screen detected lung 
cancers receive the same treatment, given similar stage, histology, age, and gender. 
However, in practice, persons participating in screening programs may be healthier 
than average (i.e. the so-called “healthy volunteer effect”).38 Therefore, persons with a 
screen-detected lung cancer may receive surgery relatively more often than persons 
with clinically detected lung cancer. Indeed, lung cancer surgery was more prevalent 
among cases in the low-dose computed tomography screening (LDCT) arm of the NLST 
than among cases in the NCDB with a similar stage.39,40 Therefore, Chapter 3 included 
a sensitivity analysis, in which stage-specific treatment patterns from the LDCT arm 
of the NLST were applied to screen-detected cases instead of treatment patterns from 
the NCDB. Using these alternative treatment patterns for screen-detected cases, the 
increase in surgical demand due to screening was more pronounced. However, it 
should be noted that the NLST was conducted in a highly controlled environment. 
Therefore, surgical use in the LDCT arm of the NLST may be an upper bound. Early 
detection of lung cancer by screening will only be effective if treatment is optimal. 
Therefore, it is important that, as more representative data become available, future 
studies monitor whether surgical use differs between screen-detected cancers and 
non-screen detected cancers.
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Modeling assumptions
The assessments of benefits and harms of population-based lung cancer screening 
in this thesis were based on analyses conducted using the MISCAN-Lung model. As 
with any statistical model, the validity of the estimates depends on the validity of the 
model structure and calibration. Hence, the commonly used aphorism “all models are 
wrong, but some are useful”. The structure of the MISCAN-Lung model was discussed 
in several chapters in this thesis.27,39 In addition, the model structure and calibration 
of key parameters was more elaborately described in previous publications.13,14 In 
short, key assumptions regarding unobservable parameters, such as the preclinical 
duration of disease, were carefully calibrated to data of the NLST and Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening (PLCO) trials.13,14 At this point, MISCAN-Lung 
is considered a well-established and validated model, which has been used to inform 
the USPSTF recommendations for lung cancer screening.25,28 
Nevertheless, it is worth discussing the potential effect of two model assumptions 
on the findings presented in this thesis. First, the MISCAN-Lung model, which uses 
the U.S. National Cancer Institute’s Smoking History Generator,24 accounts for 
changes in smoking behavior across birth cohorts. However, the model assumes that 
these smoking patterns are unaffected by screening. In reality, however, current lung 
cancer screening recommendations emphasize that lung cancer screening should 
be complemented with smoking cessation interventions.28,41-43 Recently, Cancer 
Intervention and Surveillance Modeling Network (CISNET) investigators assessed the 
potential impact of adding smoking cessation counseling to lung cancer screening, 
under varying hypothetical rates of screening uptake and smoking quitting 
probabilities.44 The CISNET investigators found that complementing lung cancer 
screening (with a 30% adherence to screening) with a hypothetical smoking cessation 
intervention with a moderate 10% quitting probability would increase the number 
of averted lung cancer deaths by 14%, and the number of life-years gained by 81%. 
This effect could be even greater with a higher screening uptake and quit probability. 
Therefore, the projected benefits due to screening presented in this thesis may be 
even larger if successful smoking cessation strategies are implemented concurrently. 
Nevertheless, the actual magnitude of the effect of joint screening and smoking 
cessation counseling in clinical practice is currently unknown, and the optimal 
cessation intervention is unclear.45 In addition, it has been suggested that a negative 
screening result may provide some screenees with a false sense of reassurance, thus 
potentially lowering the smoking quit rates.46 However, this effect was not present in 
the Netherlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial.47 More 
research is needed to assess the interplay of lung cancer screening and smoking 
cessation interventions in a population setting.
Second, rates of adverse events in MISCAN-Lung were modeled using data from 
the NLST. However, currently other nodule follow-up algorithms are recommended, 
such as Lung-RADS.41 Such new nodule management algorithms generally use 
volumetric nodule assessment, and indeterminate nodule categories for which 
follow-up screening is a safe approach. Therefore, Lung-RADS may greatly reduce 
the number of false-positive screening results.48 Therefore, rates of adverse events 
projected by MISCAN-Lung may in practice turn out to be less frequent. However, 
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Lung-RADS may misidentify some lung cancers as benign, thereby decreasing the 
screening sensitivity, and ultimately the benefits due to screening.48 Unfortunately, 
there is currently insufficient real-world data to correctly include Lung-RADS in the 
MISCAN-Lung model. 
Directions for future research and policy
Optimizing current lung cancer screening programs
The second part of this thesis focused on the benefits and harms of population-based 
lung cancer screening. These chapters were based on lung cancer screening programs 
using the 2014 USPSTF eligibility criteria, which are based on age, the number of 
accumulated pack-years, and the time since quitting smoking.28 Although smoking 
history and age are the most important risk factors for lung cancer, there are additional 
risk factors. These include chronic obstructive pulmonary disease,49,50 a positive family 
history for lung cancer,51  and exposure to occupational or environmental factors 
such as air pollution,52,53 industrial chemicals,52 asbestos,52,54 and radon.52,55 Therefore, 
several multivariable models have been developed to predict an individual’s risk of 
lung cancer or lung cancer death.56-58 
In a retrospective analysis of the NLST and PLCO data, these models had superior 
sensitivity and specificity for predicting 6-year lung cancer incidence (>79.8% and 
>62.3%, respectively), compared with the NLST criteria (71.4% and 62.2%, respectively).59 
A subsequent study investigated the benefits and harms of lung cancer screening 
programs that use these risk models to select individuals for screening.60 Compared 
with the current USPSTF criteria, selection of eligible individuals using risk models 
averted more lung cancer deaths, but yielded only modestly more life-years, while 
overdiagnosis increased (given a similar number of screening examinations). These 
findings could mostly be explained by the fact that risk-based criteria selected 
older individuals for screening than the current pack-year based USPSTF criteria. 
This happens because lung cancer risk continues to increase with age, whereas the 
current pack-year based criteria stop screening after 15 years of smoking cessation. 
Excluding individuals with a life expectancy less than 5 years from screening reduced 
overdiagnosis by 65.1–67.3%, while retaining the life-years gained. However, in practice, 
it is difficult to accurately predict an individual’s life expectancy. These studies show 
that selection of individuals for screening by using risk models may increase the 
benefits of screening, but may also increase the harms. 
The 2014 USPSTF recommendations have been found to be cost-effective, given 
a willingness-to-pay threshold of $100,000 per QALY gained.61 As risk-based strategies 
avert more lung cancer deaths (given a similar number of screens), cost-effectiveness 
may be more favorable. However, the moderate effect on the life-years gained could 
mitigate the cost-effectiveness of risk-based screening strategies. In addition, the 
increased selection of elderly individuals for screening could increase treatment costs, 
as more chronic treatment for inoperable elderly patients may be required. However, 
the cost-effectiveness of a screening strategy can be influenced by the interplay of 
many factors. Thus, the cost-effectiveness of risk-based screening strategies should 
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be investigated in future modeling studies. To limit the influence of specific model 
assumptions on the outcomes, these studies should preferably include and compare 
projections from several independently developed models.
In the NELSON trial, the individual risk of developing lung cancer was dependent 
on earlier screening results.62 A recently updated version of one of the previously 
assessed lung cancer risk prediction models incorporates information on previous 
screening results.63 Including previous screening results significantly improved model 
discrimination for lung cancer incidence (area under the curve: 0.761 compared 
with 0.687). The authors suggest that the screening interval could be tailored to the 
individual’s personal lung cancer risk and previous screening findings, but acknowledge 
that further validation of such approaches in prospective studies is necessary. An 
important multicenter European implementation trial, named 4-IN-THE-LUNG-RUN, 
will prospectively investigate the effect of one such approach: tailoring an individual’s 
screening interval to the baseline screening results.64 
More research is necessary to identify the optimal approach to tailor screening 
intervals to individual persons. Possibly, less intensive screening may be appropriate 
for those with an initial negative screening result. Furthermore, the screening 
interval could possibly be further tailored as a person undergoes subsequent screens. 
In addition, the net benefit of lung cancer screening among certain eligible persons 
(e.g. those with a low annual lung cancer risk) is preference-sensitive.65 Possibly, 
patient preferences may also help identify eligible individuals for whom less intensive 
screening (or not screening) is an appropriate option. Such approaches can be 
investigated by carefully conducted modeling studies.
Prioritizing efforts to increase the uptake of screening
Although lung cancer screening has been recommended in the United States since 
2013, only a limited portion of eligible individuals are actually screened.66,67 In the 
United States, potential screenees need to be assessed for eligibility and counseled 
on the benefits and harms by clinicians.42 In the typical mandatory shared decision 
making appointment, the time spent discussing lung cancer screening is typically 
only a minute.68 These findings point to time constraints among clinicians. Also, 
physician’s knowledge on current lung cancer screening guidelines appears to show 
gaps.69 Although new risk-based approaches may increase the benefits of screening, 
they are more complex than current screening guidelines. Data on more variables 
needs to be collected to assess eligibility (and possibly the screening interval), which 
could increase time constraints. Furthermore, some primary care providers feel that 
they lack proper understanding of risk models, and believe that risk-based screening 
may unnecessarily confuse potential screenees.70 These factors may hinder an increase 
in screening uptake.
Therefore, it could be worthwhile to initially focus efforts on increasing the 
uptake of the current recommendations, even if these are imperfect. Sometimes, less 
(complexity) is more.71 Increasing the uptake of screening on the short term is especially 
important because the number of screening eligible individuals in the United States 
is expected to decrease in coming years due to decreasing smoking trends.39,72 In other 
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words, if screening uptake remains low, an important window of opportunity could 
be missed, thus potentially mitigating the additional long-term benefits of risk-
based screening programs. A first step towards increasing screening uptake could be 
to use qualitative methods to identify physician’s informational needs and barriers 
to recommend and implement screening. Then, effective educational material could 
be developed to increase physician’s knowledge on lung cancer screening, and even 
more importantly, their acceptance and recommendation of lung cancer screening 
policies. Additionally, these educational materials could be used to train navigators, 
whom may alleviate physician’s time constraints. The combined training and use of 
primary care physicians and navigators may particularly increase the uptake of lung 
cancer screening.73 
     
Incorporate racial disparities in lung cancer (screening) research
In chapter 1, racial disparities were identified in the use of guideline-concordant 
treatment for lung cancer.1 A recent study by CISNET investigators showed that, 
given a similar lung cancer risk, current USPSTF eligibility criteria select relatively 
fewer black persons than white persons for screening.74 In addition, a recent study 
showed that, compared with white lung cancer patients, black lung cancer patients 
are less likely to be eligible for lung cancer screening according to the current USPSTF 
recommendations (56% compared with 32%).75 This was mostly due to the lower 
median number of pack-years among black lung cancer patients compared with 
white lung cancer patients (25.8 compared with 48.0, respectively). In other words, a 
substantial proportion of black lung cancer patients did not meet the minimum 30 
pack-years criterion. The authors suggest that lowering the pack-years criterion to 20 
pack-years may be appropriate for black persons. This statement is supported by the 
finding in an older study that black smokers have a significantly higher lung cancer 
risk than smokers of other races, given a similar number of cigarettes smoked per 
day.76 Another possible approach would be to use lung cancer risk prediction models 
that include race to select individuals for screening. 
These studies show that, given current practice, black persons with a high risk of 
lung cancer are less likely to be selected for lung cancer screening, and additionally, 
if lung cancer is detected, black patients are less likely to receive optimal treatment. 
It is important that future research investigates ways to address these disparities. 
An important first step would be to conduct (qualitative) studies to identify the 
underlying reasons for the identified disparities. Also, future lung cancer screening 
and treatment modeling efforts could explicitly incorporate race. Using such race-
specific models, different strategies to mitigate racial disparities could be assessed. 
For example, the comparative effectiveness of the two suggested methods to tailor 
screening eligibility to race could be assessed.
General discussion
236
Assess the joint impact of immunotherapy and screening
Chapter 1 showed that between 2010-2014, rates of lung cancer surgery, radiotherapy, 
and chemotherapy remained stable. Chapter 2 considered more granular treatment 
patterns among early-stage NSCLC, and showed that the uptake of MIS and SBRT as 
treatment modalities increased during the same period. As outlined in the introduction 
of this thesis, new therapies have more recently been introduced: targeted therapy 
and immunotherapy. Targeted therapies act on specific molecular features expressed 
by some, but not all, lung cancers. These therapies include epidermal growth factor 
receptor (EGFR) inhibitors (e.g. erlotinib, afatinib and gefitinib)77-79 and anaplastic 
lymphoma kinase (ALK) inhibitors (e.g. crizotinib and ceritinib).80,81 Immunotherapy 
agents help the immune system to identify and target lung cancer cells, or the blood 
supply they need to grow. In lung cancer care, these include vascular endothelial 
growth factor (VEGF) inhibitors (e.g. bevacizumab),82 protein programmed cell death 
1 (PD-1) inhibitors (e.g. pembrolizumab and nivolumab),83,84 protein programmed 
cell death-ligand 1 (PD-L1) inhibitors (e.g. atezolizumab),85 and ROS1 inhibitors (e.g. 
crizotinib and entrectinib).86
The use of these agents outside of clinical trials is still very recent; the first 
immunotherapy agent to be approved by the U.S. Food and Drug Administration for 
the first-line treatment of certain advanced lung cancer cases was pembrolizumab, 
in October 2016. Important lung cancer treatment databases, such as the NCDB 
used in this thesis, usually lag several years. Therefore, the use of targeted and 
immunotherapy agents could not be assessed in this thesis. Nevertheless, this is, and 
will remain a very active area of research. At first, the recommendation of targeted and 
immunotherapy agents was limited to the palliative treatment of specific advanced 
NSCLC patients (depending on the expression of EGFR, ALK, and PD-L1). However, the 
use of some of these agents has already shifted from second-line treatment to first-
line treatment. In addition, current studies are investigating the effect of adjuvant or 
neoadjuvant treatment with targeted and immunotherapy agents for operable early-
stage and locally advanced NSCLC, and as consolidation therapy after concurrent 
chemoradiation for inoperable locally advanced NSCLC.87,88 
These developments may complement and interact with lung cancer screening 
efforts. As the uptake of lung cancer screening in the United States will continue 
to increase, there will be a shift towards diagnosis at earlier stages (see chapter 3 
in this thesis).39 Targeted and immunotherapy agents are currently provided 
mainly to patients with advanced NSCLC, potentially prolonging their survival. 
Because these agents are very expensive, their increased use may increase the 
cost-effectiveness of lung cancer screening. However, if the (neo)adjuvant use of 
targeted and immunotherapies in early-stage NSCLC indeed proves effective, this 
effect may be mitigated. It is important that future (modeling) studies assess the 
relative contributions of new therapeutics and the continuing uptake of lung cancer 
screening in reducing the lung cancer burden. Also, the cost-effectiveness and budget 
impact of each of these developments alone and combined should be assessed. Such 
studies can help policy makers make important decisions, for example regarding 
reimbursements and prioritization.
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Initiate a high-quality international study of health state utility values
By providing the state-of-the-art in HSUVs for lung cancer, chapter 5 will enhance 
the validity of future health economics modeling efforts. Nevertheless, chapter 5 also 
identified important areas where additional research is needed. Most importantly, 
although a large number of studies was identified, many studies were found to be of 
insufficient quality. In many of the included studies, HSUVs were not the primary 
endpoint. Therefore, reporting of the methodology of HSUV elicitation was often 
limited. In addition, there was substantial variation in stratification variables, coding, 
and reporting across the identified studies. Therefore, we could not pool results by 
other variables than stage, while age, sex, treatment, and time since diagnosis could 
be factors influencing HSUVs. Some authors have used meta-regression in an attempt 
to pool HSUVs from markedly different patients, elicited using different methods, 
but this approach can lead to false positive associations.89 Only two of the studies 
identified in Chapter 5 included a matched control group of the general population. 
Including a matched control group is important because members of the general 
population do not have a perfect health.90 Finally, many identified studies did not 
apply the choice-based tariff of the country in which patient’s quality of life scores 
were collected. This important because applying a different tariff to quality of life 
scores from the same patients can leads to large variations in HSUVs.91
An important step towards overcoming these issues would be to conduct a study 
(or series of studies) across multiple countries, in which health-related quality of 
life is measured in nationally representative samples of lung cancer patients (e.g. 
by age, stage, sex and histology), and in which societal preferences are elicited using 
the EQ-5D instrument with the choice-based tariff that matches the country of the 
responding patients. This study should collect data on the treatment received, and 
measure HSUVs at the moment of diagnosis, and at subsequent fixed time intervals. 
Because a choice-based EQ-5D tariff is not available for many countries, this study 
should be preceded by the elicitation of such a tariff from a matched (at least by age 
and sex) sample of members of the general population. This sample could then also 
be asked to rate their own health-related quality of life, thus serving as a control 
group to the lung cancer patients. It would be important that the entire resulting 
dataset would be made available in open access. That way, investigators of future 
health economic evaluations can tailor the data to the needs of their model, instead 
of relying on selected findings presented in a published manuscript.  
Assess the benefits and harms of lung cancer screening in the Netherlands
The research in this thesis was focused on the United States, where lung cancer 
screening has been recommended since 2013.28 In Europe, discussions regarding a 
possible implementation of lung cancer screening have been ongoing for several 
years.92 In recent years, the European position has been to start planning for a 
possible implementation, but to await the results of the NELSON trial before making 
a final decision.92 Now that the final mortality results the NELSON have been 
published, showing a significant 24% lung cancer mortality reduction compared 
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with no screening,11 European countries will likely face important implementation 
questions. Many studies have been conducted regarding the optimal lung cancer 
screening policy in the United States. However, the results from those studies do not 
necessarily translate directly to other countries. First, demographics and smoking 
rates vary across countries.93 Second, as detailed elsewhere in this discussion, there 
are some important differences between the performance of the NELSON trial and 
the NLST trial, on which most U.S.-based work was based. Third, treatment patterns 
may differ across countries. Therefore, an important step would be to recalibrate the 
MISCAN-Lung model to individual-level data from the NELSON trial, and to use Dutch 
smoking and treatment data as input. Then, the optimal lung cancer screening policy 
for the Netherlands can be determined, as well as the treatment capacity required for 
a successful implementation.
Overall conclusions and recommendations
The results of the different chapters in this thesis lead to the following conclusions:
- In the United States, lung cancer treatment disparities by race and age persist, 
despite adjusting for important patient, tumor, and healthcare provider 
characteristics. Addressing these disparities is topical because the success of lung 
cancer screening depends on optimal treatment of cases detected at an early 
stage.
- Between 2010-2014, the uptake of stereotactic body radiation therapy and 
minimally invasive surgery in the United States increased substantially, while 
the rate of conversions to open surgery decreased. These trends are expected to 
continue with the increasing uptake of lung cancer screening.
- The continued implementation of lung cancer screening in the United States 
will substantially increase the demand for lung cancer surgery, especially in the 
first years. A gradual buildup of screening uptake can spread this peak over time, 
thus potentially avoiding unnecessary increases in waiting times for lung cancer 
treatment.
- Future rates of overdiagnosis due to lung cancer screening in the general U.S. 
population will be affected by the reducing smoking behavior, which affects 
the background risk of lung cancer and screening eligibility. Using appropriate 
methods to account for these trends is crucial.
- Future comparative effectiveness studies of lung cancer screening and treatment 
should use methodologically appropriate health state utility values to calculate 
the quality-adjusted life-years gained by the intervention. 
- The mandatory shared decision making conversation prior to lung cancer 
screening should preferably include the use of age and sex-specific graphical 
decision aids.
Based on the research conducted in this thesis, the following suggestions for future 
research and policy are suggested:
- Prioritizing the identification of ways to increase the low uptake of the current 
lung cancer screening recommendations in the United States.
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- Optimization of current lung cancer screening policies, for example by risk 
stratification.
- Exploring potential strategies to address racial disparities in lung cancer screening 
eligibility and treatment.
- Assessing the relative contributions of new lung cancer therapeutics and 
screening on reducing the lung cancer burden. 
- Initiating a high-quality international study of health state utility values for 
lung cancer to address gaps in the current literature.
- Quantifying the benefits and harms of implementing lung cancer screening in 
the Netherlands, and identifying the optimal policy.
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General introduction
Smoking is the main risk factor for lung cancer. Therefore, primary prevention 
(smoking cessation) is potentially the most effective method of preventing lung 
cancer. However, despite the successes of tobacco control policies since the 1960s, lung 
cancer is still the leading cause of cancer deaths worldwide. When patients present 
with symptoms, their lung cancer has often metastasized to distant sites. Currently, 
there are no curative treatment options for metastasized lung cancer. The goal of 
secondary prevention (screening) is to identify lung cancer before it presents with 
symptoms, in which case the disease is presumably in an earlier stage, thus enabling 
better treatment options. In 2011, the U.S. National Lung Screening Trial showed that 
three annual low-dose computed tomography screens, among high-risk current and 
former smokers, can reduce lung cancer mortality by 20%. The benefit of lung cancer 
screening was recently confirmed by the Dutch-Belgian randomized lung cancer 
screening trial, which found a 24% lung cancer mortality reduction. In the United 
States, annual lung cancer screening has been recommended since 2013, for persons 
aged 55-80 with a smoking history of at least 30 pack-years, that currently smoke or 
quit less than 15 years ago. Despite this recommendation, the uptake of lung cancer 
screening in the United States remains low. In Europe and the United Kingdom, many 
countries have been debating a possible implementation of lung cancer screening. In 
the meantime, many topics of debate remain.
This thesis deals with two of these topics. The first part of this thesis (Chapters 
1-3) investigates which treatments lung cancer patients in the United States received 
before the implementation of screening, and how these treatment patterns change 
as a result of the implementation of lung cancer screening. In the second part of 
this thesis (Chapters 4-6), the benefits and harms of population-based lung cancer 
screening in the United States are investigated from different perspectives.
Part I: Lung cancer treatment
Chapter 1
Using the U.S. National Cancer Database, Chapter 1 assessed treatment patterns 
among 441,812 U.S. individuals diagnosed with lung cancer between 2010-2014. Overall, 
21.6% of cases did not receive any first course treatment. Only 62.1% of cases received 
guideline-concordant treatment. Black patients and elderly patients were less likely 
to receive guideline-concordant treatment, despite adjustment for relevant patient, 
tumor, and healthcare provider characteristics. The remaining 16.3% of cases received 
less intensive treatment than recommended. Treatment patterns among these 
cases suggested possibilities for an increased uptake of certain treatments, such as 
stereotactic body radiation therapy (SBRT) for potentially inoperable patients with 
early-stage non-small cell lung cancer (NSCLC). 
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Chapter 2
Chapter 2 used the NCDB to assess the uptake of SBRT as the radiation modality among 
early-stage NSCLC cases in the United States. Among those with stage IA NSCLC, the 
use of SBRT as the radiation modality increased from 53.4% in 2010 to 73.0% in 2014. 
Uptake of SBRT was lower among stages IB-IIB, although time trends were similar 
to those among stage IA. Chapter 2 also assessed the uptake of minimally invasive 
surgery (MIS) among surgically treated patients with early-stage NSCLC. Between 
2010-2014, the uptake of MIS among cases with stage IA NSCLC increased from 28.7% 
to 48.6%. During the same period, the rate of conversions from MIS to open surgery 
decreased from 17.0% to 9.1%. The uptake of MIS was lower among stages IB-IIB than 
among stage IA, while the rate of conversions was higher. 
Chapter 3
Chapter 3 extended the MISCAN-Lung microsimulation model with gender, stage, 
histology, and age-specific lung cancer treatment patterns from the NCDB. The 
extended model was used to assess the change in demand for the different lung 
cancer treatment modalities due to the implementation of lung cancer screening 
in the United States. Under the base-case assumption of 50% adherence to the 
current United States Preventive Task Force recommendations between 2018-2040, 
the implementation of lung cancer screening would increase the demand for lung 
cancer surgery by 37.0%. There would be a large initial peak in demand for lung cancer 
surgery in the first years, which could be mitigated by a gradual build-up of screening 
uptake. Overall, radiotherapy use and chemotherapy use would slightly decrease. 
Part II: Benefits and harms of population-based screening 
programs
Chapter 4
Chapter 4 used three different methods to estimate the degree of overdiagnosis due 
to lung cancer screening in the United States. Using the cumulative excess-incidence 
approach, the lifetime percentage of screen-detected cases that was overdiagnosed 
ranged from 10.5% in the 1950 birth-cohort to 5.9% in the 1990 birth-cohort. The 
microsimulation approach was used to project the annual rate of overdiagnosis in 
the entire general U.S. population between 2018-2040. This population is composed 
of many different birth cohorts. Using this approach, overdiagnosis increased from 
7.1% of screen-detected cases in 2018 to 9.5% of screen-detected cases in 2040. During 
the same period, the percentage of all lung cancer cases (both clinically and screen-
detected cases) that was overdiagnosed decreased from 3.7% to 1.4%. These changes 
in overdiagnosis across birth cohorts and over time are due to decreasing smoking 
trends, which reduce the background risk of lung cancer and the percentage of 
screening-eligible individuals over time. We showed that the third method, the 
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annual excess-incidence approach, does not correctly account for these trends, thus 
producing biased overdiagnosis estimates.  
Chapter 5
Chapter 5 reviewed the literature for lung cancer specific health state utility values 
(HSUVs), which are used to calculate the number of quality-adjusted life years 
(QALYs) gained by screening. The literature review focused on HSUVs elicited using 
community and choice-based methods. Twenty-seven of these studies were identified. 
The pooled HSUV was 0.68 for all stages, 0.78 for stages I-II, and 0.69 for stages III-IV. 
A sensitivity analysis included only the methodologically most comparable studies, 
which calculated HSUVs using the tariff matching the country of origin of responding 
patients. Such studies were identified for 8 countries, and HSUVs varied by stage and 
country. A subgroup analysis showed that HSUVs for metastatic NSCLC decreased 
significantly throughout the last year of life. Finally, subgroup analyses indicated that 
HSUVs for metastatic NSCLC may differ by treatment line and progression status.
Chapter 6
Chapter 6 assessed the benefits and harms of participating in population-based lung 
cancer screening among those eligible according to the United States Preventive Task 
Force criteria in 2020. Using the pooled HSUVs from chapter 5 resulted in similar 
QALYs gained compared with using the HSUVs from the most high-validity U.S. based 
study. Compared with screening 55-year-old eligible individuals from 2020, screening 
older eligible individuals from 2020 leads to fewer benefits, fewer adverse events, 
but more overdiagnosis. Furthermore, compared with similarly-aged men, women 
experience more benefits, more adverse events, and more overdiagnosis. These 
findings indicate the need to tailor the information discussed in the mandatory 
shared decision making visit by age and sex. Therefore, chapter 6 provided age and 
sex-specific graphical decision aids.
General discussion
The general discussion of this thesis provides an overview of the overall conclusions 
that can be derived from these chapters. First, lung cancer treatment disparities by 
race and age persist, despite adjusting for important patient, tumor, and healthcare 
provider characteristics. Second, the uptake of SBRT and VATS in the United States 
increased substantially between 2010-2014, while the rate of conversions to open 
surgery decreased. Addressing disparities by race and age, as well as continuing 
the increasing uptake of new treatment modalities, will contribute to a successful 
implementation of lung cancer screening. Third, the implementation of lung cancer 
screening in the United States will substantially increase the demand for lung cancer 
surgery, especially in the first years. A gradual buildup of screening uptake can spread 
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this peak over time. Fourth, it is important to use appropriate methods to adjust 
overdiagnosis estimates for reducing smoking trends in the general population. Fifth, 
it is important to use methodologically appropriate HSUVs to calculate the quality-
adjusted life-years gained by  lung cancer screening. Finally, shared decision making 
prior to lung cancer screening should preferably take place using age and sex-specific 
graphical decision aids. 
The general discussion of this thesis also provides recommendations for future 
research. First, the identification of ways to increase the currently low uptake of lung 
cancer screening in the United States should take priority. Second, efforts to optimize 
eligibility criteria and screening intervals should be continued. Third, strategies 
to overcome racial disparities in lung cancer screening eligibility and subsequent 
treatment should be explored. Fourth, the relative contributions of new lung cancer 
therapeutics (immunotherapy) and lung cancer screening to the reduction of lung 
cancer burden should be assessed. Fifth, an international study on lung cancer 
specific HSUVs should be initiated, addressing current gaps in knowledge. Finally, a 
modeling study should assess the lung cancer screening strategy with the optimal 
balance between benefits and harms in the Netherlands.
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Algemene inleiding
Roken is de belangrijkste risicofactor voor longkanker. Daarom is primaire preventie 
(stoppen met roken) in potentie de belangrijkste manier om longkanker te voorkomen. 
Sinds de jaren ’60 is veel voortgang geboekt met anti-rookbeleid. Desondanks blijft 
longkanker wereldwijd de belangrijkste oorzaak van kankersterfte. Op het moment dat 
patiënten klachten krijgen en een arts bezoeken, is de longkanker vaak al uitgezaaid. 
Momenteel zijn er geen curatieve behandelingsmogelijkheden voor uitgezaaide 
longkanker. Het doel van secundaire preventie (screening) is om longkanker op te 
sporen voordat het klachten veroorzaakt. In dat geval is de ziekte vaak minder ver 
gevorderd, waardoor er betere behandelingsopties zijn. In 2011 toonde de Amerikaanse 
National Lung Screening Trial aan dat de sterfte aan longkanker met 20% kan worden 
teruggebracht door huidige en voormalige rokers met een hoog risico drie screenings 
te laten ondergaan middels low-dose computed tomography scans. Onlangs werden 
deze bevindingen ruimschoots bevestigd door het Nederlands-Leuvens Longkanker 
ScreeningsONderzoek (NELSON). In de Verenigde Staten wordt sinds 2013 jaarlijkse 
longkankerscreening aanbevolen voor 55 tot 80-jarige personen, die minstens 30 
pakjaren hebben gerookt en niet langer dan 15 jaar geleden gestopt zijn met roken. 
Ondanks deze aanbeveling wordt in de Amerikaanse praktijk slechts een beperkt deel 
van deze doelgroep daadwerkelijk gescreend. In Europa en het Verenigd Koninkrijk 
wordt de invoering van een structureel longkankerscreeningsprogramma al een 
aantal jaar overwogen. Intussen zijn er nog veel longkankerscreenings-gerelateerde 
onderwerpen waarover het laatste woord nog niet is gesproken.
In dit proefschrift werden twee van deze onderwerpen behandeld. In het eerste 
deel (hoofdstukken 1-3) werd onderzocht welke behandelingen longkankerpatiënten 
in de Verenigde Staten momenteel krijgen. Vervolgens werd onderzocht hoe deze 
behandelingspatronen veranderen door de invoering van longkankerscreening. In 
het tweede deel van dit proefschrift werden de gunstige en schadelijke effecten van 
een longkankerscreeningsprogramma in de Verenigde Staten onderzocht vanuit 
verschillende perspectieven.
Deel I: Behandeling van longkanker
Hoofdstuk 1
In hoofdstuk 1 werd de initiële behandeling van 441812 longkankerpatiënten uit de 
Amerikaanse National Cancer Database onderzocht. Deze personen werden tussen 
2010 en 2014 gediagnosticeerd. Een aanzienlijk deel (21.6%) van deze patiënten kreeg 
geen initiële behandeling. Slechts 62.1% kreeg de behandeling die door de richtlijnen 
wordt aanbevolen. Ondanks een correctie voor relevante patiënt-, tumor-, en behan-
delaarsgebonden factoren, hadden Afro-Amerikaanse patiënten en ouderen minder 
kans om de aanbevolen behandeling te krijgen. De resterende 16.3% van de patiënten 
kreeg wel een behandeling, maar deze was minder intensief dan aanbevolen door 
de richtlijnen. De behandelingspatronen binnen deze laatste groep suggereerden 
dat sommige behandelingen vaker gegeven zouden kunnen worden, zoals stereotac-
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tische radiotherapie (SBRT) voor patiënten met een niet-kleincellig longcarcinoom 
(NSCLC) in een vroeg stadium die niet in aanmerking komen voor een operatie.
Hoofdstuk 2
In hoofdstuk 2 werd wederom de Amerikaanse National Cancer Database gebruikt 
om specifieker te kijken naar de behandelingen van patiënten die tussen 2010-2014 
gediagnosticeerd werden met een vroeg stadium (stadium I-II) NSCLC. Onder patiënten 
met een stadium IA NSCLC, die behandeld werd met radiotherapie, nam het gebruik 
van stereotactische bestraling (stereotactic body radiation therapy - SBRT) toe van 
53.4% in 2010 naar 73.0% in 2014. Deze percentages waren lager onder patiënten met 
een stadium IB-IIB NSCLC, maar de relatieve toename over de tijd was vergelijkbaar. 
In hoofdstuk 2 werd daarnaast onderzocht welk deel van de operaties onder patiënten 
met een vroeg stadium NSCLC gebeurde middels een minimaal invasieve operatie (een 
kijkoperatie of een robot-geassisteerde operatie). Onder patiënten met een stadium 
IA NSCLC nam dit percentage tussen 2010 en 2014 toe van 28.7% naar 48.6%, terwijl het 
aantal minimaal invasieve operaties dat uiteindelijk toch werd afgemaakt als een 
open operatie (conversies) binnen dezelfde periode afnam van 17.0% naar 9.1%. Het 
aandeel minimaal invasieve operaties was lager onder patiënten met een stadium 
IB-IIB NSCLC, maar het aantal conversies was hoger.
Hoofdstuk 3
In hoofdstuk 3 werd het MISCAN-Long microsimulatiemodel uitgebreid met geslachts-, 
stadium-, histologie-, en leeftijdsspecifieke behandelingsgegevens uit de Amerikaanse 
National Cancer Database. Het model werd vervolgens gebruikt om te voorspellen 
hoe de vraag naar verschillende longkankerbehandelingen zal veranderen door de 
invoering van longkankerscreening in de Verenigde Staten. Als 50% van de personen 
die tussen 2018 en 2040 voor longkankerscreening in aanmerking komen (volgens 
de criteria van de United States Preventive Task Force (USPSTF)) ook daadwerkelijk 
gescreend wordt, zal de vraag naar longkankeroperaties met 37% toenemen. Het 
grootste deel van deze toegenomen vraag zal in de eerste jaren plaatsvinden. Deze piek 
in vraag naar longkankerchirurgie kan verlicht worden door het aantal gescreende 
personen in de eerste jaren gelijkmatig op te bouwen. Het gebruik van radiotherapie 
en chemotherapie zal door longkankerscreening iets afnemen.
Deel II: Gunstige en schadelijke effecten van een longkan-
kerscreeningsprogramma
Hoofdstuk 4
In hoofdstuk 4 werden drie methoden vergeleken om overdiagnose door 
longkankerscreening in de Verenigde Staten te kwantificeren. De cumulative excess 
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incidence methode werd gebruikt om het percentage door screening gevonden 
longkankers dat overgediagnosticeerd was te schatten binnen enkele losse 
geboortecohorten. Binnen het cohort dat in 1950 werd geboren was dat percentage 
10.5% en binnen het cohort dat in 1990 werd geboren was dat percentage 5.9%. De 
microsimulatie-methode werd gebruikt om het jaarlijkse percentage overdiagnose 
tussen 2018 en 2040 te schatten onder de algemene Amerikaanse bevolking. Deze 
algemene bevolking is opgebouwd uit een groot aantal verschillende geboortecohorten. 
Middels de microsimulatie-methode bleek dat het percentage door screening 
gevonden longkankers dat overgediagnosticeerd was toenam van 7.1% in 2018 tot 9.5% 
in 2040. Tijdens dezelfde periode nam het percentage van alle longkankers (zowel 
door screening als klinisch gevonden) dat overgediagnosticeerd was af van 3.7% naar 
1.4%. De verschillen in overdiagnose tussen de geboortecohorten en over de tijd 
konden verklaard worden doordat rookgedrag afneemt. Daardoor wordt het risico 
op longkanker steeds kleiner. Ook komen er steeds minder mensen in aanmerking 
voor longkankerscreening. Ten slotte toont hoofdstuk 4 aan dat de derde methode, 
de annual excess-incidence methode, niet corrigeert voor deze trends. Daarom is deze 
methode niet geschikt om overdiagnose in de algemene bevolking te kwantificeren.
Hoofdstuk 5
In hoofdstuk 5 werd de literatuur over longkanker-specifieke health state utility values 
(HSUVs) op een rij gezet. HSUVs worden gebruikt om het aantal quality-adjusted life 
years (QALYs) te berekenen dat door screening wordt gewonnen. De literatuurreview 
richtte zich specifiek op HSUVs die berekend zijn vanuit een maatschappelijk 
perspectief, met behulp van op keuzen gebaseerde methoden. Er werden 27 van 
dit soort studies gevonden. De gepoolde HSUV voor alle longkankerstadia was 0.68. 
Voor stadium I-II was de gepoolde HSUV 0.78 en voor stadium III-IV 0.69. In een 
sensitiviteitsanalyse werden alleen de methodologisch meest vergelijkbare studies 
meegenomen. Deze studies gebruikten het EQ-5D instrument om HSUVs te berekenen. 
Daarbij pasten zij het tarief van het juiste land toe. Dergelijke studies werden voor 
slechts 8 landen gevonden. Binnen deze studies varieerden HSUVs per stadium en 
land. Een subgroepanalyse toonde aan dat HSUVs voor gemetastatseerd NSCLC lager 
werden gedurende het laatste levensjaar. Ten slotte suggereerde subgroepanalyses dat 
HSUVs voor gemetastaseerd NSCLC mogelijk verschillen naar lijn van behandeling en 
progressiestatus.
Hoofdstuk 6
In hoofdstuk 6 werden de gunstige en schadelijke effecten berekend van deelname 
aan het door de USPSTF aanbevolen longkankerscreeningsprogramma. Dit werd apart 
berekend voor mannen en vrouwen van verschillende leeftijden, die in het jaar 2020 
voor screening in aanmerking kwamen. Zowel de gepoolde HSUVs uit hoofdstuk 6 als 
de HSUVs van de meest valide Amerikaanse studie werden gebruikt om het aantal 
gewonnen QALYs te berekenen. Beide HSUVs leverden vergelijkbare resultaten op. 
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Vergeleken met 55-jarige personen die in 2020 in aanmerking komen voor screening, 
ondervinden oudere personen die in 2020 in aanmerking komen voor screening 
minder voordelen van deelname aan screening. Tevens ondervinden zij minder 
nadelige gevolgen. De kans op overdiagnose is onder oudere personen echter groter. 
Vergeleken met mannen met dezelfde leeftijd, ondervinden vrouwen meer voordelen 
van screening. Tevens ondervinden zij vaker nadelige gevolgen en is de kans op 
overdiagnose groter. Deze bevindingen wijzen erop dat de informatie die voorafgaand 
aan het screenen – tijdens shared decision making – met patiënten wordt besproken, 
bij voorkeur gepersonaliseerd moet zijn naar leeftijd en geslacht. Daarom werden in 
hoofdstuk 6 leeftijds- en geslachtsspecifieke (grafische) beslishulpen gepresenteerd.
Algemene discussie
De algemene discussie van dit proefschrift geeft een overzicht van de belangrijkste 
conclusies die op basis van de verschillende hoofdstukken getrokken kunnen 
worden. Ten eerste krijgen Afro-Amerikaanse patiënten met longkanker en ouderen 
geen optimale behandeling, ondanks correctie voor relevante patiënt-, tumor-, en 
behandelaarsgebonden factoren. Ten tweede nam het gebruik van SBRT en minimaal 
invasieve chirurgie in de Verenigde Staten substantieel toe tussen 2010 en 2014, terwijl 
het aantal conversies naar open chirurgie gedurende dezelfde periode afnam. Het 
aanpakken van de geobserveerde ongelijkheden in longkankerbehandeling en het 
toenemende gebruik van SBRT en minimaal invasieve chirurgie, zullen bijdragen 
aan een succesvolle voortzetting van de invoering van longkankerscreening in de 
Verenigde Staten. Ten derde zal de voortgezette invoering van longkankerscreening 
in de Verenigde Staten zorgen voor een substantiële toename in de vraag naar 
longkankerchirurgie, met een uitgesproken piek in de eerste jaren. Deze piek in vraag 
naar longkankerchirurgie kan verlicht worden door het aantal gescreende personen 
in de eerste jaren gelijkmatig op te bouwen. Ten vierde is het belangrijk om de juiste 
methoden toe te passen om de hoeveelheid overdiagnose door longkankerscreening 
in de algemene bevolking te kwantificeren, omdat gecorrigeerd moet worden voor 
afnemend rookgedrag. Ten vijfde is het belangrijk om methodologisch juiste HSUVs te 
gebruiken om de gezondheidswinst door longkankerscreening uit te kunnen drukken 
in quality-adjusted life years. Ten slotte is het aan te bevelen om bij shared decision 
making voorafgaand aan longkankerscreening een leeftijds- en geslachtsspecifieke 
beslishulp te gebruiken.
In de algemene discussie van dit proefschrift worden tevens aanbevelingen 
gedaan voor vervolgonderzoek. Ten eerste is het belangrijk dat er manieren worden 
gevonden om het aantal voor screening in aanmerking komende personen in de 
Verenigde Staten dat daadwerkelijk wordt gescreend te vergroten. Ten tweede moet 
er meer onderzoek worden gedaan naar de optimale criteria om personen voor 
screening te selecteren en naar het optimale screeningsinterval. Ten derde moeten 
er strategieën ontwikkeld en getest worden om rassenongelijkheid in de selectie van 
personen voor longkankerscreening en in de behandeling van longkanker tegen te 
gaan. Ten vierde wordt het aanbevolen om te onderzoeken wat de relatieve bijdragen 
van nieuwe behandelingen (immunotherapie) en longkankerscreening zijn aan het 
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verminderen van de ziektelast door longkanker. Ten vijfde wordt het aanbevolen om 
een internationaal onderzoek op te starten, waarin de huidige hiaten in de kennis 
over longkanker-specifieke HSUVs worden opgevuld. Ten slotte wordt het aanbevolen 
om middels een modelleerstudie te onderzoeken welke longkankerscreeningsstrategie 
de beste balans tussen gunstige en schadelijke effecten zal geven in Nederland.
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